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"These simple tenets have become the sine qua non of
modern science. A man who believes that he can empty the
jar of the universe and discover all of its secrets is
insufficiently humble to engage in modern science. On the
other hand, a man who remains unconvinced of the
uniqueness and value of his own experience will lack the
ego of a scientist."
Charles A Whitney. The Discovery of our Galaxy. Angus &
Robertson 1972 London
PREFACE
This thesis gives an account of original research work
carried out between January 1984 and July 1987 in the
Neuropathology laboratory of the Department of Pathology
in the University of Leeds. Sections of the work presented
have been published as substantive or abstracted papers
included in the list of references at the end of the work.
Chapter 2. In vitro studies of glial tumours - Franks and
Burrow, 1986
Chapter 3. Tissue plasminogen activator activity in human
gliomas - Franks and Ellis, 1989
Chapter 4. MHC class II antigen expression in gliomas -
Franks and Bird, 1986a
ACKNOWLEDGEMENTS
For technical assistance with the tissue culture section
of this work I am grateful to Heather Burrow, and for
technical assistance at various times with the
immunohistochemistry I thank Eve Ellis (Chapters 2, 3 and
4), Barbara Ozols (Chapter 2), Lynn MacPherson (Chapter 2)
and Ian Grigor (Chapter 4). Steve Toms printed the
illustrations from original transparencies. Many
colleagues offered helpful advice and criticism of the
work presented and I am especially grateful to Dr Keith
Bradbury, Dr Judith Bulmer and Dr James Ironside for their
help and discussion and to Professor Colin Bird for his
support while the work was being carried out.
I thank Dr Alex Gordon, who has acted as adviser for this
thesis, for the quality of the advice he has offered and
for the willingness with which he has undertaken the task.
The assistance of the members of the neurosurgery
departments at Leeds General Infirmary, Hull Royal
Infirmary and Pinderfields General Hospital, Wakefield in
supplying tissue for study is gratefully acknowledged, as
is the assistance of Philip Bogue and his staff in the
Neuropathology laboratory who maintained and administered
the tumour bank on which this work drew heavily.
I am grateful to Dr M Waterfield and Dr G Hodges (Imperial
Cancer Research Fund, London) and Dr M Steel (MRC
iv
Cytogenetics Unit, Edinburgh) for the kind gift of
antibodies against Epithelial Growth Factor Receptor,
Fibronectin, and MHC class II antigens respectively.
The work was in part supported by a generous grant from
the Special Trustees fund of the General Infirmary at
Leeds.
My family, as always, have had to bear the greater burden
during the carrying out, and writing up, of the research




I, Antony John Franks, declare that, with the exception of
the technical assistance acknowledged above, the work
described in this thesis is entirely my own and the thesis
has been composed by myself.
vi
ABSTRACT
The phenomenon of heterogeneity in neoplasia and its
implications for tumour growth and behaviour are
considered, firstly for tumours in general and then for
tumours of astrocytes in particular. Attention is drawn to
the nature of cellular interactions that may occur within
tumours between populations of neoplastic cells whose
differences may impose an interdependence that will
determine and control growth. Such differences will also
influence the degree to which isolated cells and the
properties they display in vitro will be representative of
the populations of cells that comprise the tumour in vivo.
An account is given of in vitro studies of a series of
human astroglial neoplasms with the description of two
main cells types derived during such studies: one which
appeared to be glial in origin, was process-forming and
expressed Glial Fibrillary Acidic Protein, and the other,
of uncertain origin, was flattened and adherent in
configuration and expressed surface fibronectin. The
factors determining the isolation of these two cell types
are considered and the conclusion is reached that
technique of culture is a more significant determinant of
the predominant cell type isolated than is the degree of
malignancy of the original tumour. The evidence for and
against a glial or mesenchymal origin for the
fibronectin-expressing cells is considered.
Studies are then described of the distribution in vivo of
a range of phenotypic markers characterising the cells
vii
isolated in vitro. On the evidence provided by this work
the fibronectin-expressing cells seem more likely to have
originated from vascular, or vascular-associated
structures, but may have been influenced by tumour-derived
products in such a way that their behaviour in vitro
suggests a transformed nature.
To examine other influences on the vascular and glial
elements in astroglial tumours studies of immune cell
infiltration, growth factor receptor expression and tumour
cell growth were undertaken. These indicated that there
are qualitative similarities, but quantitative differences
between high and low grade tumours that might explain the
relative uniformity of the in vitro behaviour of
vascular-derived elements.
The hypothesis is advanced that the process of
carcinogenesis in astroglial tumours differs from that in
many epithelial tissues by virtue of the exposure of
vascular elements to any putative carcinogen. Thus
vascular components in astrocytic tumours may already have
suffered damage that, whilst insufficient to result in
neoplastic change, affects their behaviour in vivo and in
vitro. In vitro this results in the isolation of cells
that appear to be transformed but are not of glial origin,
and in vivo in an degree of vascular proliferation unusual
in other sites and an increased incidence of sarcoma
development.
In vitro studies of human gliomas would be of potential
value for examining the interactions between neoplastic
viii
parenchymal cells, mesenchymal elements and cells of the
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CHAPTER 1. HETEROGENEITY IN TUMOURS
INTRODUCTION
Heterogeneity is observed in tumours of most types. This
chapter examines the phenomenon as it occurs in tumours in
general and, specifically, in the subset of gliomas
derived from astrocytes. Tumours have three main
components, or elements, namely: the neoplastic cell
comprising the tumour parenchyma; the mesenchymal tissues
that form the tumour stroma; and the mixture of
lymphocytes and macrophages that result from the immune
response to the abnormal tissue formed by the tumour. All
of these elements show heterogeneity and will be
considered in the work presented in this thesis.
The nature and possible basis of tumour heterogeneity.
One consequence of biological variation and the essential
nature of neoplastic transformation in mammalian cells is
that two tumours which are histologically similar will
rarely be biologically identical. The cells that comprise
individual tumours have been recognised to be
heterogeneous in terms of morphology (Foulds, 1954;
Shapiro et al, 1981), chromosome content and cell kinetics
(Shapiro, 1986; Dexter et al, 1982; Friedlander et al,
1984), antigenic expression (Greiner, 1986; Heppner et al,
1983; Sainsbury et al, 1987), capacity to form tumours
from single cells (Franks, 1983; Simnett, 1981),
metastatic potential (Aulenbacher et al, 1984; Franks et
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al, 1975; Layton et al, 1984), chemosensitivity (Shapiro
et al, 1985; Yung et al, 1982) and the influence of
population cell density on cell growth (Westermark, 1973).
The concept of a tumour being a mass of tissue composed of
a homogeneous population of cells, each individual being
autonomous and independent is therefore too simplistic to
be of value; yet this is a tacit assumption which often
underlies techniques where cells isolated in-vitro are
used to test the potential of therapeutic agents (Kimmel
et al, 1987; Morgan et al, 1983; Rosenblum et al, 1982).
It is apparent that tumours will consist of a mixture of
cells demonstrating a range of properties. These may
reflect either varying degrees of damage sustained as a
result of exposure to an exogenous carcinogen or further
changes in genotype as a consequence of the genetic
instability that is known to be a feature of the
transformed state (Kendal et al, 1987; Nowell, 1986). The
picture is further complicated by the inclusion of normal
tissue elements (or their derivatives) in the form either
of a supporting stroma or residual normal cells surrounded
by invading neoplastic cells.
A polyclonal origin has been demonstrated for some
experimental tumours (Reddy et al, 1980) and the
multifocal nature of some human skin and urothelial
tumours suggests such a derivation. Nevertheless the
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current consensus remains that tumours arise by neoplastic
transformation of a single cell (Nowell, 1986) with the
subsequent emergence of a heterogeneous population,
although this ignores the possibility that other cells may
be damaged by carcinogenic agents without developing
recognisably neoplastic properties.
The mechanisms whereby heterogeneous populations of cells
develop in tumours are ill-understood. There is evidence
of intrinsic genetic instability manifest as an enhanced
mutation rate (Cifone et al, 1981; Kendal et al, 1987;
Loeb et al, 1974), possibly mediated by proto-oncogene
amplification (Lancet, 1987); it has also been proposed
that fusion of tumour cells with reactive cells of the
monocyte / macrophage series may occur (Munzarova et al,
1987) thereby conferring properties of invasion and
metastasis. Cells whose new properties, however acquired,
are not disadvantageous, would be expected to survive,
while those with properties which constituted a positive
advantage might be expected to form an increasing
population within a tumour. A reduced dependence on
exogenous factors, or a reduced sensitivity to controlling
influences would both confer a major advantage;
consequently, with time, cells might be expected to emerge
which demonstrated a higher rate of proliferation or
greater capacity for survival in areas separate from the
tumour mass (i.e. to metastasise). The sequential
acquisition of properties, such as invasion or metastasis,
is observed in many tumours and is referred to as
- 7 -
progression. It is believed to underly the well-recognised
transitions from benign colonic adenoma to invasive
adenocarcinoma (Morson, 1974), and from low grade
astrocytoma to malignant glioblastoma (Cairncross, 1988).
The fact that the chromosomal abnormalities found in low
grade astrocytomas resemble in pattern, if not frequency,
those of malignant astrocytomas (Rey et al, 1987, 1987a)
is strong evidence that such progression does occur.
Another basis for heterogeneity may be the retention and
exhibition by tumour stem cells of a potential for
differentiation. Thus, hypothetically, some of the
structural variation observed in tumours may reflect the
various stages of maturation which, in turn, indicate a
persistent responsiveness of neoplastic cells to those
factors that control the differentiation of the normal
cell (Sachs, 1984) . An example of this phenomenon is the
development of quite complex differentiated structures
such as keratin "pearls" in human squamous carcinomas.
Factors have been described which induce differentiation
in neoplastic myeloid cells and reduce their sensitivity
to growth factors (Fibach et al, 1972). Glial Maturation
Factor (so named for its effect on normal embryonic glial
cells) has been shown to enhance contact inhibition, and
specialised intermediate filament expression, in
neoplastic glial cells in vivo and in vitro (Lim et
al, 1986) . The maturation of a neuroblastoma into a
ganglioneuroblastoma and ultimately into a benign
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ganglioneuroma (Willis, 1958) reflects the natural pattern
of maturation of neuroblasts. An extreme example of the
capacity of stem cells to produce diversity through
differentiation is seen in teratomas where a single
neoplastic cell is capable of producing a wide range of
cell types many of which are fully differentiated
(Kleinsmith et al, 1964).
The significance of tumour heterogeneity in the growth of
tumours
Research over many decades into the nature of the
neoplastic process has seen an increasing realisation that
the behaviour of the cells in both natural and
experimental neoplasms is more a reflection of the
inappropriate expression of certain properties of normal
cells than the expression of properties unique to the
cancer cell. The behaviour of a tumour may therefore
represent the combined behaviour of heterogeneous cell
populations rather than reflect the behaviour of any one
eel1 "species".
Variations in degree and combination of these expressions
underly the spectrum of behaviours that are designated as
benign (small deviations from normal) or malignant (large
deviations from normal). It follows from this that while
tumour cells undoubtedly express some properties
inappropriately, the fact that they also continue to
express a great number of appropriate properties offers
the hope that they may remain responsive to at least some
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of the controls that influence normal cell behaviour. This
possibility is seen to be all the more likely when it is
appreciated that the transformation of a proportion of
cells in a tissue into neoplastic cells is likely to be
accompanied by damage to other cells, in the same tissue,
that falls short of full neoplastic change. The processes
of normal tissue maintenance and response to injury
(Simnett, 1981; Riley, 1981) are mediated by cellular
interactions which control cell proliferation and
migration. There is no reason why these interactions
should not persist, at least in part, in tissues in which
only a proportion of the cells are abnormal (Heppner et
al, 1983) even if the balance results in continued and
(from the point of view of the organism) inappropriate
growth. One possible mechanism of neoplastic
transformation could be a reversal of responsiveness to
environmental controls so that what had previously acted
as an inhibitory stimulus now elicited a proliferative
response. One could hypothesise that if interactions occur
between neoplastic cells and normal cells within a tumour
this possibility could be greater if they shared a common
lineage; this situation is commonly encountered in human
gliomas where non neoplastic glial cells may be intimately
mixed with neoplastic cells.
The inhibition of non-neoplastic cells by tumour cells
(Fontana et al, 1985), and inhibitory and stimulatory
interactions between populations of neoplastic cells
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(Heppner et al, 1983) have been demonstrated
experimentally. Such interactions have been shown to
determine the expression of surface antigens and to thus
affect the immunogenicity of a tumour and the efficacy of
any host response (Wang et al, 1982).
The development by tumour cells of the capacity to invade
tissue and metastasise is of importance in the progression
of the neoplastic state from one in which cells are
confined to an epithelium (in-situ carcinoma). The
expression by neoplastic cells of plasminogen activator
(PA), which is thought to be involved in the processes of
invasion and metastasis can be shown to be influenced by
intratumoural cell interactions (Kyner et al, 1978;
Newcomb et al, 1978) .
The metastatic potential of a tumour has been shown to
reside in only a small proportion of its cells (Franks,
1983) and the ability to establish metastases requires not
only a capacity to penetrate blood or lymphatic channels
but also the ability to survive and grow at low population
densities. The latter property is measureable in
clonogenic assays (Guner et al, 1977) and the relative
infrequency with which cells from human tumours are
capable of growth in these low densities emphasises that
most tumour cells need specific environmental conditions
for continued survival and growth.
- 11 -
Modulation of tumour cell phenotype - possible mechanisms.
The phenotype of any cell should be seen as the result of
an interplay between its intrinsic potential to express
characteristics and the environment in which it is
situated. Gene expression will determine the cell's
ability to alter the environment, while the environment,
and specifically the extracellular matrix which may be
seen as an extension of the cell, will, in turn, modulate
the pattern of gene expression (Bissel et al, 1987; Rutka
et al, 1987). Consideration of examples from
non-neoplastic states such as osteoclastic resorption of
bone, trophoblast invasion, epithelial regeneration after
injury and vascular proliferation in granulation tissue
emphasises the fact that there are, under normal
circumstances, interactions between environment and cells
which control cellular function and are reflected in
alterations in cell phenotype. Any examination of tumour
cell phenotype must take account of the fact that such
alterations can take place.
Tumour antigens differ quantitatively rather than
qualitatively from those of normal cells, and not only is
expression heterogeneous within a given tumour but it is
often not consistent for a given tumour type (Smith et al,
1988). Focal expression may be found in tumour sections
and the same antigen may show cytoplasmic or surface
distribution in different cells (Greiner, 1986).
Modulation in tumours may reflect a change in cell cycle
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times where the expression of a given antigen is a feature
of a certain stage of the cell cycle (Kufe et al, 1983)
and this may underly the observation that antigen
expression may decline with contact inhibition (Horan Hand
et al, 1985). Antigen expression is affected by the
spatial relationships of cells and thus expression may be
found in vivo but not in vitro (Greiner, 1986), and cells
that do not express a particular antigen in monolayer
culture may do so if allowed to form cellular aggregates
in vitro or tumour masses in vivo (Horan Hand et al,
1985). Cells may vary in their sensitivity to
antigen-inducing factors such as interferon (Greiner et
al, 1985) which may be secreted into the environment,
either by neoplastic cells or other elements within the
tumour such as reactive lymphocytes or macrophages.
The interesting question is raised of the normal role of
many of these surface antigens and their relation to cell
proliferation. Whether such antigens are involved in a
cell's interactions with the environment (both cells and
matrix) by cell recognition (such as the HLA antigens), by
acting as receptors for soluble factors or by interacting
with extracellular matrix components, they provide a means
whereby environmental conditions can affect cell function
and conversely a means whereby a cell can fit its
behaviour to that environment. There is considerable
evidence that the extracellular matrix influences both the
growth and differentiation of cells (Toole, 1981; Hynes,
1980; Rutka et al, 1987) and since interactions with the
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matrix are central to the expression of at least one
neoplastic property, namely invasion, an understanding of
these interactions is clearly of importance.
If cellular phenotypes are subject to control or
alteration by interactions between the different cell
populations that make up a tumour how may such control be
effected and could it be exploited therapeutically? An
understanding of the mechanisms involved might, for
instance, allow therapeutic induction of a defined antigen
which might enhance the effectiveness of an immunological
attack relying on antibodies specific to such an antigen.
Two major possibilities exist for mechanisms of such
phenotypic control, one mediated through soluble factors
and the other depending on cell contact. There is evidence
for the former in the observations of induction of surface
antigen expression by interferon (Greiner et al, 1985;
Carrel et al, 1985; Takiguchi et al, 1985; Lampert et al,
1985) although part of such an effect may be mediated by
increasing the numbers of cells that expressed the surface
antigen as well as by increasing the amount of expression
on each cell. These studies have shown, however, that not
all cells in a tumour are capable of responding to
inducing agents, not, it is postulated, because of a lack
of surface receptors for the agent but because of a defect
in the pathways modulated by activation of such receptors.
Factors derived from neoplastic cells have been able to
induce reversible transformed behaviour in normal cells,
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apparently by activation of surface receptors for
epidermal growth factor (DeLarco et al, 1978; Stoscheck et
al 1986; Todaro et al, 1978) which appears to be expressed
in abnormal amounts by some neoplastic cells (Libermann et
al, 1985, 1985a; Ozanne et al, 1986). It has also been
suggested that non-neoplastic stromal and immune elements
in tissues may be the source of abnormal growth factor
production which is responsible for subsequent
transformation of parenchymal cells (Lancet, 1986).
Although neoplastic cells may differ from their non
neoplastic counterparts in their sensitivity to diffusible
factors they may still be subject to a degree of control
by such factors whatever their source.
Studies of both normal and neoplastic cells have
demonstrated the existence between cells of communication
channels (thought to correspond to the morphological gap
junction) which are potentially capable of transferring
molecules, thus allowing metabolic co-operation (Furshplan
et al, 1968) and possibly controlling cell growth
(Lowenstein, 1979). In vitro studies have shown that
normal cells can control the growth of transformed cells
via a mechanism dependent on such functioning channels
(Mehta et al, 1986); in some experimental systems,
however, transformed cells can only communicate with each
other and not with normal cells indicating a degree of
cell specificity for such a process (Enomoto et al, 1984).
Although considerable attention has been paid to the
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failure of neoplastic cells to respond to high population
density by inhibition of proliferation (contact
inhibition) (Alberts et al, 1983) less interest has been
shown in the the possibility that individual cells in a
tumour may be dependent on a certain cell density to
proliferate. The degree to which cells are capable of
growth in low densities (the ultimate example being the
capability of clonal proliferation from a single cell)
varies from tumour to tumour but is rarely great,
especially in human lesions. If the component cells of a
tumour not only interact but are also interdependent then
the role of contacts between cells and the influence of
cell-derived soluble factors are potentially of
considerable importance (Mehta et al, 1986). The reduction
in the number of specialised cell junctions that
accompanies the progression of neoplastic lesions in the
cervical epithelium (Schindler at al, 1982; Shingleton et
al, 1968, 1974) may not only reflect the potential for
invasion but also the potential for independent survival.
The latter would allow the individual cell to survive and
proliferate in the lower densities which are likely to be
found at the advancing edge of a neoplasm, or in the even
lower densities that will exist in an early metastatic
deposit. Such independence may be acquired by individual
cells by their producing for themselves those factors
required for growth which are normally supplied by their
neighbours (Lotem et al, 1983). Only with the development
of such reduced dependence on cell density can properties
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which may have been present for some time (such as reduced
substrate adhesion, motility and invasiveness) become
manifest as invasive or metastatic tumour. Such
dissociation of the property of invasion from that of
metastasis is seen in human basal cell carcinomas,
meningiomas, astrocytomas and some salivary gland tumours.
The relative lack of variation in cellular DNA levels
which is found in metastatic tumours in the brain when
compared that found in primary glial lesions (Hoshino et
al, 1978) supports the concept that metastasis is
dependent on the development of a subset, or clone, of
cells possessing the necessary properties.
In vitro studies provide evidence that the properties of
transformed cells may be in part dependent on
environmental conditions and that these cells differ from
normal cells in their reactivity or response to external
stimuli (Vasiliev et al, 1981). While the transformed
state probably reflects a genotypic alteration the
expression of phenotype, at least in the early stages of
tumour induction, may be conditional on environmental
factors. The acquisition of the ability to maintain the
transformed state independently (by further genomic
change) could be seen as being essential for invasion or
metastasis.
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Heterogeneity in human astrocytic tumours.
The heterogeneity that is seen in many experimental and
naturally occurring tumours is also seen in human
malignant astrocytomas and encompasses most aspects of
cell morphology and behaviour including the expression of
surface antigens (Budka et al, 1985, 1985a; DeMurault et
al, 1985; Rettig et al, 1986; Wikstrand et al, 1985) and
growth factor receptors (Libermann et al, 1984; Nister et
al, 1986), intermediate filament content (Dahl et al,
1986; Eng et al, 1978; Herpers et al, 1984, 1986;
Roessmann et al, 1983; Schiffer et al, 1986),
susceptibility to differentiating (Bullard et al, 1981;
McLean et al, 1986; Frame et al, 1984; Freshney et al,
1986) and chemotherapeutic agents (Rosenblum et al, 1982;
Yung et al, 1982), terminal cell density in culture
(Westermark, 1973), and both DNA (Hoshino et al, 1978) and
chromosome content (Bigner et al, 1986; Shapiro et al,
1985; Rey et al, 1987, 1987a).
If the principle is accepted that tumour cell phenotype,
and thus behaviour, is susceptible to environmental
influences (in the broadest sense encompassing
extracellular matrix, adjacent cells and their secretions)
one is led to consider the degree to which the
heterogeneity observed in human malignant gliomas is a
reflection of inherent or intrinsic variability, and to
what extent it is a reflection of variations in the local
environment (that is a mixture of stimulatory and
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inhibitory influences deriving from cells that are normal,
stimulated but un-transformed, partially transformed or
fully neoplastic). The possibility that tumour progression
is the result of continuous alteration in tumour cell
populations in response to these environmental influences,
rather than an inevitable consequence of the acquisition
of the neoplastic phenotype, raises the prospect of
manipulating the environment so as to reduce the rapidity,
or even the occurrence, of such progression. This is of
especial importance in glial tumours where a low grade
lesion may follow a long clinical course with the
eventual, but almost inevitable, development of malignant
properties (Rubinstein, 1972).
The heterogeneity referred to above has been posited as
the explanation for the frequent isolation from human
gliomas of cells which express phenotypes not usually
associated with glial cells (Kennedy et al, 1987) and
which are interpreted as less differentiated. Alterations
in dominant populations in vitro as a result of
experimental manipulations are interpreted as phenotypic
change in individual cells; there is however the
possibility that selective growth and survival of
subpopulations of cells may underly some of these
observations (Freshney, 1985). The use of cells, isolated
in vitro from gliomas, to assay the effects of various
potential therapeutic agents depends on their being both
neoplastic and of glial origin if the results of the
- 19 -
assays are to have any validity. The use of an isolated
cell line may provide a greater guarantee that the cells
are truly neoplastic but the isolation of such a line
removes the element of cellular interaction that may be
essential in determining the growth, progression and
behaviour of the tumour in vivo.
Human cerebral tumour classification
As a preliminary to a consideration of the nature of cells
derived from human gliomas in-vitro it is necessary to
give consideration to tumour components in-vivo.
The majority of taxonomic schemes for tumour
classification attempt to combine a statement concerning
the present understanding of the cell type from which the
tumour has arisen (histogenesis), and an assessment of the
likely rate at which the tumour will progress in terms of
clinical disease (degree of malignancy). Although a case
has been made for the inclusion of factors that have a
clear bearing on outcome (such as tumour site and patient
age) (Burger, 1985; Gilles, 1985) and other features that
may require more specialised techniques such as ploidy
(Rorke, 1987), morphological classifications remain
dominant (Russell et al, 1977).
When considering tumours of a body system, or organ, it is
customary to consider the normal tissue elements found in
that system or organ and then to delineate the tumours
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that can arise from each of these.
In the central nervous system the two most common tumours
arise from glial cells (gliomas) and the arachnoidal cap
cell of the leptomeninges (meningiomas). Tumours of the
glial cells include those derived from the astrocyte (the
most common), the ependyma, the choroid plexus and
probably the oligodendrocyte, although there is debate as
to the true histogenesis of tumours designated as
oligodendrogliomas. Less common tumours include those
derived from vascular structures (haemangioblastomas),
lymphoreticular cells (lymphomas) and tumours composed of
primitive cells showing a range of differentiations which
probably reflect a neuroglial origin (the so-called
primitive neuroectodermal tumours).
Although a number of different tumour types have been
studied at various stages of the work presented in this
thesis it is predominantly concerned with tumours of
astrocytic origin. These tumours encompass a range of
clinical types and behaviour but can be most easily
understood if seen as spanning a clinical spectrum from
benign slowly growing (low grade) lesions to malignant
rapidly progressive (high grade) tumours. Many attempts
have been made to produce a clinically relevant,
biologically credible, easily applicable and reproducible
classification of these tumours (Bailey et al, 1926,
Kernohan et al, 1949; Ringherz, 1950, Zulch, 1979) but
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while there may be broad agreement over the principles
this can hardly be said for the details. As a consequence
there is confusion over terminology and a brief account of
this is necessary to provide a key for the terminology
used in this work.
The two extremes of the histological spectrum are readily
recognised. The low grade astrocytoma is composed of cells
which are easily recognised as astrocytic and show little
cellular variation or mitotic activity. Although there may
be variation from area- to area in the proportions of
fibrillary cell processes to cell body, subclassifications
depending heavily on such histological criteria are of
limited clinical value if tumour site and patient age are
not taken into account.
The malignant end of the spectrum is recognised by the
combination of cellular anisocytosis often with giant cell
formation; nuclear pleomorphism and hyperchromatism; focal
necrosis; mitotic activity; and often prominent vascular
endothelial proliferation. The term glioblastoma
multiforme is often applied to such a tumour. Some
classifications attempt to separate such a lesion from
other malignant astrocytomas in the belief that there is a
difference in cellular origin but since such a distinction
is hard to make, both in theory and in practice, it is not
made here. A four grade classification can be constructed,
low grade tumours being designated Grade I and high grade
Grade IV, with two intermediate grades (II and III)
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inserted between these extremes. Grade II tumours are
recognisably astrocytic and while they may show some
cellular variation, mitoses are scarce and neither
necrosis nor vascular proliferation are features. Grade
III tumours are malignant by the histological criteria of
mitotic activity and cellular pleomorphism, and although
vascular proliferation may be present necrosis is not a
feature.
Such an empirical classification derives its validity from
the observation that its categories correlate broadly with
clinical outcome (Burger, 1986 ; Fulling et al, 1985;
Nelson et al, 1985; Schiffer et al, 1988) but, as with
most classifications, its prognostic value for the
individual patient may be limited. Studies employing a
"points" system which takes semi-quantitative account of
vascular proliferation, pleomorphism, mitoses and necrosis
have confirmed the collective value of these features in
providing an indicator of likely tumour behaviour (Cohadon
et al, 1985).
In any consideration of classification the factor of
sampling error cannot be neglected. The nature of the
lesion and the investigative approaches applied often
result in small focal samples on which diagnosis will be
based. The variability of these tumours from area to area,
referred to above, may result in an inaccurate assignment
to grade I instead of II, or grade III instead of IV; the
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more important distinction between high and low grade is
likely to be less of a problem unless the biopsy derives
from the edge of the tumour, where the relationship of the
invasive tumour cells to residual normal structures
obscures the primary pattern of tumour structure on which
morphological diagnosis is usually based.
It will be apparent from the above account that in
addition to the differences in the appearance (and by
implication behaviour) of high and low grade tumours there
are also differences in the appearances of the
non-parenchymal (vascular/mesenchymal) elements. The
capacity to induce new vessel formation is a feature of
malignant tumours, and, indeed, is a prerequisite for
progressive growth. The fundamental nature of this process
has been emphasised by studies of the angiogenic potential
of experimentally induced tumours and of cells transformed
in vitro. Such studies have shown that the capacity of
altered cells to induce the formation of new vessels may
precede the acquisition of the capacity to form tumours
(Ziche et al, 1982). The florid formation of new blood
vessels, often grossly abnormal in structure, is such a
noteworthy feature in human malignant gliomas of the
cerebral hemispheres that it forms one of their cardinal
diagnostic features; it also raises the question as to
whether this reflects an intrinsic susceptibility of the
cerebral vasculature to angiogenic substances or the
presence in malignant astrocytic tumours of angiogenic
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substances that are more potent than those found in other
neoplasms. The impact which the mesenchymal component has
on the nature and behaviour of the cells that are isolated
in-vitro from gliomas has been specifically addressed in
the work to be described.
This thesis is based on a series of studies undertaken to
investigate heterogeneity in human astroglial tumours by
examining the behaviour of human glioma samples in vitro
and the possible influences of environment, cell density
and population interactions. The composition of
non-neoplastic components, specifically proliferating
blood vessels and cells of the immune system, was also
studied in a attempt to identify the origins of the cells
that can be identified in human gliomas in-vitro, and to
consider possible interactions between such components and
the neoplastic glial cells that comprise the tumour
parenchyma.
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CHAPTER 2. THE NATURE AND ORIGIN OF THE HETEROGENEOUS
POPULATIONS IN HUMAN GLIOMAS STUDIED IN VITRO
INTRODUCTION
In vitro studies of gliomas
The hope that cells derived in-vitro from human gliomas
could be used to investigate the behaviour of the tumour
under controlled circumstances and thus predict clinical
behaviour and the response of the tumour to potential
therapeutic agents (Freshney, 1980; Oktar et al, 1987)
provided an impetus to such studies. Such a hope depends
on two basic assumptions, namely that the behaviour of
individual cells reflects the behaviour of the complex of
heterogeneous cell populations that comprise the tumour
in-vivo, and that the cells isolated are both neoplastic
and representative of the in-vivo population of
transformed cells (Pertuiset et al, 1985).
The presence of variant cellular morphologies in explant
cultures of human gliomas has been noted (Freshney, 1980;
Lumsden, 1971) but only occasionally studied in detail
(Gazso et al, 1978). Similar degrees of morphological
heterogeneity have been noted in cell lines derived from
human gliomas (Bigner et ai, 1981; Westermark, 1973)
although a dominant pattern tends to occur in each line.
That these morphological types are not immutable is
apparent from the response of cells to agents which induce
a change to a morphology resembling a more differentiated
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cell (i.e. with more processes) although there is
considerable variation in response to these agents and
conflicting evidence of an association between initial
morphology and responsiveness (Bigner et al, 1981; Bullard
et al, 1981; Freshney, 1985).
Intratumoural phenotypic heterogeneity may reflect an
underlying genotypic heterogeneity (Shapiro et al, 1985)
or merely local effects on the component cells; the
resulting cell populations may therefore reflect the
presence of differentiating influences, cell
responsiveness to such influences, and differential
subpopulation survival or selection in the conditions of
culture.
The relative ease with which the cells that result from
primary dispersion of human gliomas can be handled and
studied has resulted in a relative lack of interest in
study of primary tumour explants (Franks et al, 1986 ;
McKeever et al, 1987). The very complexity of their growth
patterns and the time required for their analysis have
overshadowed the fact that they bear a far closer
resemblance to the tumour in-vivo than do separated cells.
It is also known that cell aggregates may differ radically
from monolayer cultures of the same cells in the
expression of surface antigens (Horan Hand et al, 1985).
Moreover the admixture of cells that exists in vivo is
still present, at least initially, and the subsequent
behaviour of these cells in-vitro is more likely to
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reflect the influences operating in life.
The ready growth and survival of the cells that can be
isolated from gliomas (Ponten et al, 1978) has lead to the
not unreasonable assumption that the derived cells are
neoplastic. This view is supported by the findings of
chromosomal abnormalities (Kennedy et al, 1987; Shapiro et
al, 1981) and plasminogen activator synthesis (Frame et
al, 1984), the latter being assumed to reflect the finding
in both experimental systems and human tumours that
plasminogen activator activity is associated with the
transformed state (Mullins et al, 1983).
Separation of tumour fragments into their component cells,
subgroups of which are selectively cultured, eliminates
any possible influence of intratumoural heterogeneity on
individual cell behaviour. This, and further changes that
may occur in vitro, may invalidate the results of a number
of potential therapeutic strategies. These include
chemosensitivity testing, antigenic expression (as an
index of differentiation), and antigenic specificity for
antibody targeting (Lashford et al, 1988; Takahashi et al,
1988) or for the induction of a tumour specific immune
response by the injection of tumour derived cells (Bullard
et al, 1985).
The heavy dependence upon dissociated cells for such
studies necessitates a careful examination of the
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relationship which isolated cells bear to the cell
populations that constitute the tumour in vivo. Arguments
in favour of the use of isolated cells instead of explants
include the observation that chromosomal patterns change
with time in explants (Shapiro et al, 1981) ; this could,
however, be taken as an indication that natural
progression occurs in-vitro, and this would support the
use of explants.
The identification in vitro of cells that are
intrinsically abnormal and, by implication, neoplastic is
usually dependent on the demonstration of an abnormality
of growth pattern, an abnormality of relationship to the
substrate upon which the cells are growing, or an
abnormality of requirements for growth. Although these
features are assumed to equate with malignancy they are
really a measure of the cells' ability to survive and
multiply in a selected environment and there is no single
property in vitro that correlates absolutely with the
capacity to form tumours in vivo. Sequential studies of
cells during induced transformation have shown that
although certain features relating to reduced adhesion of
cells to their substrate (one marker of transformation)
correlated with each other they did not correspond with
loss of growth control (Curatolo et al, 1983) . The
assumption that the presence of properties of transformed
cells in a different population identifies them in turn as
transformed may not therefore be justified. It has been
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shown, in fact, that discrepancies exist between
biological malignancy of cells (as assessed by the ability
to form tumours in vivo, or actual origin from a naturally
occurring tumour) and their behaviour in-vitro (Franks,
1983). This occurs with sufficient frequency to indicate
that in-vitro criteria of "transformation" do not
necessarily equate with the capacity to form tumours, and
by extension should not necessarily be taken to indicate
origin from a neoplastic population.
Among the measures most frequently used of in-vitro
transformation are growth in soft agar, loss of contact
inhibition, growth in low serum concentration and survival
on serial transfer. These properties rely on differential
survival in culture conditions to identify cells capable
of growing in defined environments. Any studies that
involve passage will, by definition, destroy those aspects
of the microenvironment in a primary explant culture which
cell density and cell subpopulation mixture contribute.
Without comparison of residual and passaged cells the
potential influence of passage in determining the outcome,
in terms of the type of cell isolated, may not be
appreciated.
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Fibronectin and Glial cells
In 1973 Ruoslahti and co-workers described the production
by fibroblasts in tissue culture (Ruoslahti et al, 1973)
of a surface protein which was subsequently found to be
lost following in-vitro viral-induced transformation of
cells (Gahmberg et al, 1974; Vaheri et al, 1974;
Wartiovaara et al, 1974). Further studies revealed this
protein to be a major component of connective tissue
matrices and, although variously named Large External
Transformation Sensitive protein (LETS) (Hynes et al,
1974) or Fibroblast Surface Antigen (Ruoslahti et al,
1973), recognition of its fibrous structure and cell
binding properties resulting in universal adoption of the
name Fibronectin. Fibronectin was found to be secreted by
cells in a soluble form which could be polymerised to form
an extracellular matrix (Furcht et al, 1979; Hedman et al,
1978).
Ruoslahti later emphasised that the loss observed in
transformed cells resulted not from decreased production
but from a failure to bind the protein to cell surfaces
and to deposit it in a surrounding insoluble matrix,
although the surface receptors for fibronectin were
retained (Ruoslahti, 1984). This defect in matrix
formation could be reversed in virally-transformed cells
by dexamethasone (Furcht et al, 1979) or butyrate (Hayman
et al, 1980) . The binding of cells to their substrate that
was mediated by fibronectin was found to further depend on
the state of S-S bounds (Ali et al, 1978; Grinnel et al,
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1980); reduction of these to -SH groups reduced cells'
ability to adhere.
A significant role for fibronectin is as a modulator of
interactions between cells and their environment. It has
been found to act as a growth factor for fibroblasts
(Bitterman et al, 1983), to determine migration (Schor et
al, 1981) and growth patterns in-vitro through its close
transmembrane relationship with intracellular actin
microfilaments (Hynes et al, 1978; Marshall et al, 1978),
and similar influences are postulated to operate in
embryonic cell migration where reduced surface fibronectin
acts as a permissive or facilitating factor (Erickson et
al, 1980).
Studies of tissue localisation of fibronectin show that it
is widely distributed within connective tissue matrices,
in particular in relation to basement membranes (D'Ardenne
et al, 1983; D'Ardenne et al, 1984), and it is also
localised to the pericyte/endothelial interstitium of the
microvasculature (Courtoy et al, 1983).
In the central nervous system fibronectin appears
histologically to be restricted to mesenchymal structures
(vascular or meningeal) in both normal and neoplastic
tissue, including glial tumours (Schiffer et al, 1984;
Chronwall et al, 1983; Kochi et al, 1983; Paetau et al,
1980). The finding that many cells derived in short and
long term cultures from malignant human gliomas expressed
the surface fibrous adhesion protein fibronectin, and not
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the typical glial intermediate filament Glial Fibrillary
Acidic Protein (GFAP) (Kennedy et al, 1987; McKeever et
al, 1987; Paetau et al, 1980a; Ponten et al, 1978;
Rajaraman et al, 1978; Schachner et al, 1978; Vaheri et
al, 1976) together with the earlier observations that
fibronectin was usually less expressed in transformed than
normal glial cells (Vaheri et al, 1976) thus seemed to
present a paradox. It was also observed that cells
expressing fibronectin appeared to be distinct from those
that expressed GFAP (Paetau et al, 1980a). Explanations
proffered for these findings included a number of
possibilities: that glial tumours were composed of a mixed
population of neoplastic cells and that culture conditions
favoured one subtype (a fibronectin-expressing stem cell);
that phenotypic alteration was taking place in vitro
(de-differentiation) and a property not evident in-vivo
was becoming apparent; that mesenchymal elements were
growing from mixed cultures; or even that gliomas were
composed of neoplastic mesenchymal elements with a glial
component represented by stimulated but non-transformed
glial cells.
Against this background an in-vitro study was carried out
on a series of human gliomas paying particular attention
to the differences in cell type that were isolated under
different conditions and the effect that culture




Biopsy specimens from a total of 71 tumours were studied,
consisting of 67 astrocytomas (50 grade IV, 11 grade III
and six grade I & II), three gangliogliomas and one
subependymal giant-cell astrocytoma. Material from 37 of
the astrocytomas (26 grade IV, six grade II and five grade
I & II), one of the gangliogliomas and the subependymal
giant-cell astrocytoma was studied immunohistochemically
after culture.
Tissue culture
Preliminary studies had shown that growth was far better
on the plastic surface of tissue culture flasks than on
plain glass coverslips and, although coating the latter
with collagen did offer some improvement, the
autofluorescence of collagen was a major impediment to
immunohistochemistry and all subsequent cultures were
standardised to plastic flasks.
Tumour specimens, obtained at operation, were immersed in
sterile RPMI 1640 tissue culture medium with antibiotics
for transport to the tissue culture laboratory. After
washing in fresh RPMI 1640 the tissue was divided into the
following culture systems:-
1. 3-5 explants of approximately 1 cu mm were placed
directly onto the plastic surface of Corning 25cm2 tissue
culture flasks with 5 ml of RPMI 1640 containing
- 34 -
morpholinopropane sulphonic acid (MOPS) 2.62g/l (Sigma)
with 10% heat inactivated donor calf serum (Gibco,
Paisley, Scotland), penicillin 100 IU/ml and streptomycin
100 ug/ml. The nutrient medium was left unchanged for the
first 5-7 days and thereafter changed twice weekly.
2. Cell Suspensions. The remaining tissue was finely
chopped and either dispersed by repeated syringing until a
uniform suspension of cells was obtained or, if too tough
to be treated in this manner, incubated for varying
periods at 37°C in 10 mis MOPS buffered saline containing
ImM Ca++ and 250y.l collagenase. In the early phases of the
study Sigma brand collagenase was used but later
Worthington brand was used since this was found
empirically to result in more consistent growth of
separated cells.
Experimentation with the period of exposure to collagenase
failed to reveal a consistently optimum period but
satisfactory results were obtained with periods as short
as one and as long as 72 h. In the case of the longer
periods viable cells were obtained by pipetting
supernatant cells in suspension at 24 h intervals and
leaving the collagenase to act on the residual tissue
fragments.
In general, treatment was continued for 24 or 48 h and for
longer periods only when sufficient tissue was available.
After centrifugation of the suspension at 500G for 5 min
the pellet was washed with MOPS buffered saline and
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incubated in 4ml phosphate buffered saline with lOOy.1
Dithiothreitol and 50y.l Papain for 5 min at 37°C. After
washing twice in phosphate buffered saline the pellet was
resuspended in nutrient medium in 25cm2 tissue culture
flasks of the same type as used for explants.
The cultures were examined regularly using a phase
contrast inverted microscope which allowed study and
photomicrography (using Kodak Ektachrome 50 ASA tungsten
film) to be carried out without disturbance. Note was
taken of the pattern and amount of growth, and the
morphological features of the cells and their
relationships to each other.
Primary explant cultures were maintained for up to 41 days
and primary cultures of dispersed cells for a maximum of
56 days.
In cultures from 15 tumours the effects of passage on the
component cells were studied.
Passage was carried out when an established growth pattern
was recognised or when it was apparent that the
proliferating cells were approaching confluence. There was
considerable variation in the time taken to reach this
stage which was usually within 21 days of initiation
although it might be reached as early as 7 days. At this
point the culture was treated with 0.1% trypsin (Gibco),
0.1% EDTA (Sigma) in Ca++ and Mg++ free phosphate buffered
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saline for 15-30 min and new flasks with fresh nutrient
medium were seeded. In a few cases direct observations
were carried out on the cells and their behaviour during
the process.
The passaged cultures were studied as above and the
process repeated up to a maximum of 10 times with a
maximum total period in-vitro of 100 days.
Immunohistochemistry
One purpose of this work was to examine the possible
effects of culture in determining cellular phenotypes and
population mixtures. Therefore the standard devices of
studying cells from primary cultures by removing them from
their primary culture substrate and depositing them on
glass cover slips, or actually carrying out the culture on
a substrate designed primarily for microscopy were
avoided. Entire cultures in their plastic Falcon flasks
were fixed for 15 min in either methanol or a mixture of
95% ethanol/5% ether following five washes in sterile Tris
Buffered Saline (TBS). The flasks were then stored at 4°C
until required. Areas of interest which had been
previously identified by phase contrast microscopy and
outlined on the flask base by marker pen, were cut from
the flask by means of an electrically heated wire. This
method allowed multiple samples, as small as 1cm2 to be
studied from one flask and had the advantage that
histochemistry was carried out on the same specimens that
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had been observed by phase contrast microscopy.
Wherever possible double staining was utilised to maximise
the information obtained from each specimen.
Most specimens were stained using a four layer technique
(see below) combining fluorescein and rhodamine conjugates
which could be visualised using a fluorescence microscope
with mean excitation wavelengths of 490 and 540 nm. These
wavelengths were obtained by a simple filter switching
device without disturbing the specimen and thus
co-localisation patterns could be studied and photographed
(on 3M tungsten film, ASA 400 rated at 3200 ASA to allow
short exposure times).
- 38 -
Four layer immunohistochemical technique
All stages were carried out at room temperature.
1. Pre-treatment with normal goat serum (NGS) diluted 1:5
in Tris buffered saline (TBS) to block non-specific
binding sites.
2. Stain for 1 h with mouse anti-human monoclonal antibody-
diluted in NGS (diluted 1:20 in TBS). The dilution of the
antibody was determined by prior staining of control
sections of tissue appropriate to the antibody. 3. Wash in
TBS
4. Goat anti-mouse fluorescein conjugate diluted 1:50 in
NGS diluted 1:20 in TBS.
5. Wash in TBS
6. Rabbit anti-human polyclonal antibody applied for 30
min. The dilution of the antibody was determined by prior
staining of control sections of tissue appropriate to the
antibody.
7. Wash in TBS
8. Swine anti-rabbit rhodamine conjugate (diluted 1:50 in
TBS) for 30 min.
9. Wash in TBS
10. Mount in citifluor or glycerol/TBS 1:9 with glass
coverslip cut to a size appropriate to the specimen.
In a number of preparations steps 2 to 4 were replaced by
a 30 min exposure to Ulex europaeus lectin conjugated to
FITC (diluted 1:50 in phosphate buffer) followed by steps
5 to 10 as above. All washes and dilutions were with
Phosphate buffer at pH 6.8 rather than TBS.
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Identification of proliferating cells.
Tumour growth in vivo can be studied indirectly by
counting mitotic figures in a section (which will include
only that proportion of dividing cells actually in an
identifiable stage of mitosis) or by the use of antibodies
to nuclear antigens which are only expressed by
proliferating cells irrespective of their stage in the
cell cycle. Such a protein was identified by a monoclonal
antibody Ki67 (Gerdes et al, 1983) which was raised during
a search for a marker specific to Reed-Sternberg cells.
The protein was found to be expressed on chromosomes from
all stages of the cell cycle and in interphase cells, but
not in GO cells. Subsequent work validated these findings
(Gerdes et al, 1984) although G1 expression was variable
and depended on whether the cell was entering the cycle
for the first time (in which case it was not expressed).
The antigen was thought to be bound to DNA and possibly a
histone necessary for DNA synthesis (Sasaki et al, 1987).
The use of this antigen as a marker of cell proliferation
in human tumours (as opposed to experimental cells in
vitro) gained credibility with the finding that counts of
cells expressing it histologically in breast tumours
correlated with other conventional markers of grade of
malignancy such as nuclear morphology, mitotic activity
and degree of differentiation (McGurrin et al, 1987).
Consequently commercially available Ki67 was used to
identify cells in a proliferating state in vitro.
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Binding of Ki-67 was demonstrated by a peroxidase method
combined with a second polyclonal antibody
(anti-fibronectin) demonstrated by a fluorescent
technique. This allowed counts to be made both of Ki67
stained and unstained cells using ordinary tungsten
illumination, while still allowing fluorescent
identification of a surface antigen that would have
obscured the nuclear staining had a standard visible
reaction product been used. Since the two antigens being
studied were clearly distinguished by their localisation
cross reaction of the second conjugate with the first
antibody was not considered to constitute a problem.
In these cases the first layer was demonstrated by a
rabbit anti-mouse peroxidase conjugate diluted 1:50 for 30
min and subsequently developed with 3"3 diaminobenzidine
tetrahydrochloride monohydrate solution with hydrogen
peroxidase for 5-10 minutes. The second antibody was
demonstrated with goat anti-mouse fluorescein conjugate as
step 4 above.
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The following antibodies and fluorescent conjugates were
used at the dilutions indicated:
Polyclonal
Glial Fibrillary Acidic Protein (GFAP) (Dakopatts; diluted
1:200)
Factor 8 Related Antigen (F8-RAg) (Dakopatts; diluted
1:100)
Fibronectin (FN) (Dakopatts; diluted 1:200)
Monoclonal
Fibronectin (A gift from Dr G Hodges, Tissue Interaction
Laboratory, ICRF, London; diluted 1:25) (Trejdosiewicz et
al, 1985)
Desmin (Dakopatts; diluted 1:10)
Vimentin (Dakopatts; diluted 1:10)
Ki67 (Dakopatts; diluted 1:5)
Conj ugates
FITC goat anti-mouse - Fab2 fragment (ICN; 1:50)
FITC swine anti-rabbit (Dakopatts; 1:50)
Rhodamine goat anti-mouse (Nordic; 1:50)
Rhodamine swine anti-rabbit (Dakopatts; 1:50)
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RESULTS
Growth from one ganglioglioma and five grade IV
astrocytomas was insufficient for study. Information was
therefore gathered from a total of 65 tumours.
There was considerable variation from case to case in the
time taken for growth to occur and for the pattern of that
growth to become apparent. Histochemical studies were, by
definition, associated with the termination of the
particular flask studied and so the account that follows
is a composite picture built up from many separate
specimens, in some cases deriving from the same tumour and
observed in parallel, and in some cases from different
tumours examined after different periods in-vitro. The
majority of specimens were from high grade astroglial
tumours and it is on these that the account concentrates.
The findings in the subependymal giant cell astrocytoma
(SEGCA) and one ganglioglioma differed so radically that
they are accorded separate consideration.
Although the cell densities of the suspensions used to set
up primary cultures were not quantified it was apparent
that low concentrations of cells only rarely gave rise to
growing cultures even though the individual cells were
capable of survival for many weeks. When collagenase
treatment or aspiration dispersal resulted in suspensions
containing small intact tissue fragments growth of these
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seemed to be enhanced when compared to larger single
explants.
Morphology
At an early stage in the study it was apparent that two
simple morphological attributes could be used to classify
cells growing from tumour explants or cell suspensions.
These were the production of long cell processes and the
adhesion of the cell body to the growth substrate. These
attributes were exemplified in their extreme (and largely
exclusive) forms as Process Forming (PF) cells and
Flattened Adherent (FA) cells (fig.2.1).
The behaviour of these cell types differed depending on
their density and admixture, and although intermediate
forms were seen these were usually in defined
circumstances (see below) and it was usually relatively
easy to allocate a cell to one or other category.
a) Process Forming cells
In low density these tended to be elongate, bi- or
unipolar (fig.2.2), and, although, with time, process
formation became more complex they did not proliferate,
and in older cultures (30+ days) began to degenerate
(fig.2.3). These cells consistently stained strongly for
GFAP (fig.2.4) and showed vimentin staining that was
usually as strong as that for GFAP (fig.2.4) although
occasionally only a weak reaction was seen.
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Fig.2.1 Typical process forming (PF) cells contrast with
single flattened adherent (FA) cell (arrow) near
centre of picture. High grade astrocytoma, 21
days in vitro, phase contrast x264
Fig.2.2 Bipolar PF cell from low density dispersed
culture, showing adherence points at angulations
of its processes (arrows). High grade




Fig.2.3 Residual FA and PF cells in a low density
dispersed culture. The processes of the upper
cell are showing granular fragmentation which,
together with irregular cell body outline,
indicate imminent cell death. High grade
astrocytoma, 47 days in vitro, phase contrast
x264
Fig.2.4 Multiprocessed PF cell showing uniform staining
for GFAP (left) and Vimentin (right). High grade
astrocytoma, 41 days in vitro, polyclonal
anti-GFAP, monoclonal anti-Vimentin, x260
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Although such cells in early cultures stained for Desmin
(fig.2.5) this was extremely rare in older or passaged
preparations.
In high density, typically at the edge of an explant but
also in high density cultures from collagenase treated
tissue, PF cells formed a dense complex net of refractile
processes and cell bodies (figs.2.6 & 2.7), almost
invariably associated with FA cells which lay within or
beneath the mesh of cell processes in interstitial
locations (fig.2.8). PF cells were GFAP+ (fig.2.9) and
their processes frequently made contact with FA cells
(fig.2.10) and studies of a small number of cultures by
time lapse photography showed what appeared to be random
extensions and retractions of cell processes before
permanent contacts were formed. Only very rarely did PF
cell bodies overlie FA cells.
In explants the interstitial FA cells were almost all
GFAP+ (fig.2.11) and FN- although occasional single cells
were seen that were GFAP-/FN+ (fig.2.12). The
process-forming cells invariably stained strongly GFAP+
and usually contained vimentin. FN was occasionally
identifiable as small spots of fluorescence on single
cells but was never uniform over cell surfaces, and as a
result there was an almost mutually exclusive expression
of FN and GFAP (figs.2.13 & 2.14).
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Fig.2.5 Irregular PF cell showing strong staining for
desmin in an early dispersed culture. High grade
astrocytoma, 3 days in vitro, monoclonal
anti-Desmin, x260
Fig.2.6. Composite view of small explant showing typical
complex network of glial cell processes, with
smaller numbers of FA cells lying beneath
(arrows). High grade astrocytoma, 17 days in
vitro, phase contrast, x85
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Fig .2.7 Glial network at the edge of an explant culture.
Same specimen as 2.6, 17 days in vitro, phase
contrast, xl32
Fig.2.8 At higher magnification the complexity of glial
cell processes is apparent and more detail can be
discerned of the relationship between PF cells
and interstitial FA cells (arrow). High grade
astrocytoma, 17 days in vitro, phase contrast,
x264
Fig.2.9 All PF cells and their processes at the edge of an
explant contain GFAP. High grade astrocytoma, 20
days in vitro, polyclonal anti-GFAP, x260
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Fig.2.10 Processes extended from PF cells make contact with
the cell body of an FA cell (centre). Time-lapse
photography showed that some of these contacts
were transient. High grade astrocytoma, 6 days in
vitro, phase contrast, x264
Fig.2.11 Both PF and FA cells in an explant show uniform
staining for GFAP. High grade astrocytoma, 9 days
in vitro, polyclonal anti-GFAP, x520
Fig.2.12 Double exposure showing GFAP+ glial network with
single FN+/GFAP- cell outlined by its surface
staining pattern (arrow). High grade astrocytoma,
21 days in vitro, polyclonal anti-GFAP (orange),
monoclonal anti-FN (green), x520
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Fig.2.13 Double exposure showing the mutually exclusive
expression of FN (green) and GFAP (orange) by
cells. High grade astrocytoma, 36 days in vitro,
polyclonal anti-GFAP, monoclonal anti-FN, x520
Fig.2.14 In this view of a GFAP+ (orange) PF cell process
attached to the body of an FN+ (green) FA cell
the extension of fibronectin onto the glial cell
process can be seen (arrow). High grade
astrocytoma, 31 days in vitro, polyclonal
anti-GFAP, monoclonal anti-FN,x520
 
Where the relative proportion of PF cells remained high a
mixed growth continued without loss or degeneration of PF
cells. As cell densities increased the space between cells
diminished although overgrowing of cells to form heaps
above the level of general cell growth was not seen.
In three preparations, consisting largely of PF cells,
studied at 15, 16 and 20 days 5.2%, 35% and 9% of PF cells
(all FN-) showed nuclear staining with Ki67 (fig.2.15).
In dispersed cell preparations GFAP+ PF cells dominated in
the early days and occasional PF cells were seen that were
strongly Desmin+. By 13 days, in the absence of small
explant-like aggregations of PF cells, the numbers of
single GFAP+ cells had often begun to decline and although
at 20 and 31 days they persisted in small numbers they
only occasionally had the typical morphology of PF cells
and were more usually of FA type (see below) although
still FN-.
b) Flattened Adherent cells
In low density large cells of this morphology showed no
proliferation and might remain unchanged for the entire
culture period. With prolonged culture some cells would
develop cytoplasmic elongations, with small numbers of
fine refractile processes (fig.2.16). Only very
occasionally was a slow transition to a typical PF cell
seen.
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Fig.2.15 Proliferating PF cells show positive nuclear
staining with Ki67 antibody (examples marked by
arrows). High grade astrocytoma, 16 days in
vitro, Ki67 peroxidase, x!67
Fig.2.16 FA cell showing the development of peripheral
processes after prolonged culture at low density.




Single large FA cells showed a range of histochemical
reactions. The majority stained strongly for surface FN
and intracellular vimentin (fig.2.17) with no GFAP or
Desmin. Some cells however showed a pattern of strong GFAP
positivity with variable vimentin staining and no FN
(fig.2.18). The latter were interpreted as isolated cells
of the type forming the interstitial cells seen in
explants (described above).
Where FA cell numbers increased, a phenomenon often first
observed at the advancing edge of an outgrowth, they began
to heap up before reaching confluence. In many cases the
appearances suggested the "escape" of cells from the edge
of an established PF cell explant (figs.2.19 & 2.20),
although sometimes FA cells formed the sole outgrowth from
small explants. PF cell progression over these denser FA
areas diminished as did the contacts between PF cell
processes and FA cells that were a feature of
intra-explant growth. This would be followed by
progressive loss of overlying PF cells which showed
process retraction, rounding up and cytoplasmic
granulation (figs.2.21 & 2.22). That this was not simply
the result of prolonged culture was apparent from the
observation that of two adjacent explants one might show
persistent mixed growth and maintenance of a complex
network, while the other would show PF cell loss
associated with increasing numbers of FA cells (fig.2.23).
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Fig.2.17 FA cell with strong staining for vimentin (green)
shows extension of its surface fibronectin
(orange) onto the adjacent substrate (arrow).
Polyclonal anti-FN, monoclonal anti-vimentin,
High grade astrocytoma, 56 days in vitro, x520
Fig.2.18 FA cell showing intracellular GFAP+ cytoskeletal
filaments. High grade astrocytoma, 36 days in
vitro, polyclonal anti-GFAP, x520
Fig.2.19 FA cells (arrow) grow from the edge of a typical
glial explant (top left). Recurrent High grade




Fig.2.20 In contrast to the cells that form the bulk of the
explant (at the left) the FA cells which can just
be discerned at the right (arrow) do not express
GFAP. High grade astrocytoma, 20 days in vitro,
polyclonal anti-GFAP, x260
Fig.2.21 As FA cells come to dominate a culture so the PF
cells diminish. A single PF cell (arrow) remains
on the surface of underlying FA cells. The denser
granular cells are degenerating PF cells. High
grade astrocytoma, 23 days in vitro, phase
contrast, x!32
Fig.2.22 Single GFAP+ (orange) PF cells survive in relation
to a proliferating mass of FN+ (green) FA cells.
High grade astrocytoma, 36 days in vitro,
polyclonal anti-GFAP, monoclonal anti-FN, x260
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Fig.2.23 Composite photograph of a dispersed culture
showing the simultaneous development of PF
dominant (lower) and FA dominant (upper) areas.




These FA cells formed a disorderly spreading population
which only occasionally formed confluent monolayers, but
instead formed cell clusters or aggregates piling up above
the substratum and then forming sheets with continual
focal heaping up of cells (fig.2.24) which were all FN+
(fig.2.25).
In dispersed cell preparations heaping disorderly growth
of FN+ FA cells was seen as early as 9 days and in the
absence of small explant-like fragments of tumour, by 21
days they had usually came to form the dominant
population.
Small FA cells were rarely seen in low density but in
cultures from five high grade astrocytomas, all older than
9 days, they formed more orderly growths resulting in a
regular "cobblestone" pattern with some peripheral
cellular irregularity but little overgrowing of one cell
by another (fig.2.26). These cells invariably expressed
plentiful surface FN but staining with Ulex europaeus
lectin was always negative. In four such cultures (9 - 14
days in vitro) such sheets of small FA cells were negative
for F8RAg. In four other cultures of similar age (8 - 14
days in vitro) from four different high grade tumours
small FA cells formed small groups without either
disorderly growth or sheet formation. In such
circumstances the cells showed focally weak staining for
F8RAg (fig.2.27) with strong surface FN staining.
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Fig.2.24 FA cells showing aberrant growth, piling up to
form heaps of cells. High grade astrocytoma, 27
days in vitro, phase contrast, x264
Fig.2.25 Extensive FN expression in a heap of FA cells.




Fig.2.26 Small FA cells showing a relatively orderly growth
pattern with minimal cell overlap. High grade
astrocytoma, 22 days in vitro, phase contrast,
xl3 2
Fig.2.27 Single small FA cell in low density growth shows
positive staining for Factor 8-Related Antigen




Three preparations, consisting mostly of large FA cells,
were stained with Ki67. In two preparations at 16 days 25%
of single cells, between 10% and 50% of cells in heaps and
3.7% of cells in sheets showed positive nuclear staining.
In one preparation at 21 days 100% of cells at the edge of
a disorderly sheet of cells showed Ki67 nuclear staining.
Although it was difficult, or impossible, to distinguish
morphologically between the single interstitial FA cells
in explants and the proliferating cells that were
associated with PF cell loss they could be clearly
separated by their immunohistochemical profiles. In
contrast to the GFAP+ interstitial cells the
proliferating, heaping, cells were uniformly strongly
positive for surface FN and cytoplasmic vimentin, but
always GFAP-.
This disorderly pattern of growth, apparently resulting
from loss of contact inhibition, was seen in at least one
culture in 24 out of 51 malignant astrocytomas and in 3
out of 6 low grade astrocytomas. The earliest time at
which it was seen was after 6 days in-vitro but in one
case did not appear until after 47 days.
For the high grade tumours, when account was taken of the
type of culture, striking differences were apparent.
Explant cultures from 20% (9 out of 45) of tumours gave
rise to abnormal FA cells compared to 57% of tumours (17
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out of 30) when dispersed culture was used. The 37%
difference was statistically significant (95% Confidence
Limits 15%, 58%; p=0.0025, X2 test). The time taken to
develop such a pattern also varied, with median times of
17 days for dispersed cultures (range 9-27) and 21 days
for explants (range 6-47). The numbers of low grade
tumours examined was too small to allow comparable
analysis but FA cells were seen after 30 days in one
explant (1 out of 4 tumours), and after 13 and 15 days in
two dispersed cultures (2 out of 3 tumours) (p>0.05,
Fisher's Exact test).
c) Intermediate cells
These were of a variable morphology, usually with a polar
elongation, a generally flattened adherent cell body and
varying degrees of short process-formation (fig.2.28).
They were usually found in low density, often in cultures
from which few cells grew, or as a residual population in
deteriorating low density cultures. They were not seen in
higher densities nor as a growing population and were
interpreted as an expression of motility in a variety of
cells rather than as a defined cell population. This
interpretation was borne out by the finding that there was
no consistency in their staining reactions. Some were
FN+/Vimentin+ but GFAP- whereas others (sometimes in the
same specimen) were GFAP+/FN-.
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Fig.2.28 Cells with intermediate morphology showing a range
of shapes. Their refractile appearance is
characteristic of cells in a deteriorating
culture. High grade astrocytoma, 6 days in
vitro, phase contrast, xl32
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Comparison of tumour types
The qualitative similarities of the growths from high and
low grade astrocytic tumours has already been referred to,
as has the similar frequency of development of FA cells.
The effect of culture type on the pattern of growth of FA
cells has already been described and a similar influence
of culture type was apparent when the growth of cells
whose processes formed complex networks, which analysis
had shown to be consistently GFAP+, was considered. Such
growth was seen from explants in 87% (39 out of 45) high
grade tumours and in 100 % (4 out of 4) low grade
astrocytomas and in dispersed cell cultures from 47% (14
out of 30) high grade tumours and in 100% (3 out of 3) low
grade astrocytomas. None of these differences between
tumour grades were statistically significant (p>0.25, X2
test) .
Effects of Passage
The effects of passage were studied in a total of 15
tumours (13 high grade astrocytomas, the subependymal
astrocytoma and one ganglioglioma). Up to 10 serial
passages were carried out (histochemistry was available up
to the 7th), the maximum period in vitro being 100 days in
the case of one high grade astrocytoma. As before the
description that follows relates to the high grade tumours
and separate consideration will be given to the
subependymal astrocytoma and the ganglioglioma.
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a) Residual cells
Trypsin/EDTA treatment resulted in extensive loss of PF
cells and partial retraction of the cytoplasm of FA cells
(figs.2.29a & 2.29b). Within 18 hours the latter cells
reverted to their original flattened shape (fig.2.29c),
began to proliferate and formed "nodes" (fig.2.30a) as
seen in untreated areas of FA cell predominance and in the
cells transferred by the passage process (fig.2.30b). This
proliferation only occurred in areas where the cells were
initially present in moderate density and was not seen to
occur among single cells in low density. In the few areas
where PF cells survived, the initial growth patterns were
those of the original culture with the admixtures
described.
In three residual cultures studied 24 to 27 days after a
single treatment with trypsin/EDTA (after a total of 48,
52 and 56 days in vitro) the cells were in one case
entirely, and in two cases almost entirely,
FN+/GFAP-/Desmin-/Vimentin+. Where other cell types were
seen they consisted of a few residual GFAP+/FN- PF cells
(24 days after treatment) and scattered single
GFAP-/Desmin+ FA cells.
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Fig.2.29 The effects of trypsin/EDTA treatment on FA cells
from a High grade astrocytoma. All phase contrast
xl3 2
a. Disorderly heaps of FA cells prior to
treatment. 26 days in vitro.
b. 30 minutes after treatment residual FA cells
show retraction of their cytoplasm and rounding
of the cell body.




Fig.2.30. The effects of trypsin/EDTA treatment on FA cells
from a High grade astrocytoma. All phase contrast
xl32
a. After 36 hours a disorderly proliferation is
apparent.
b. Passaged cells 10 days after transfer show the




To test whether the apparent enhancement of FA cell growth
was due to some unexpected effect of the technique being
used, a few cultures were treated with collagenase as in
the initial cell dispersal. Although this was far less
selective in its effects, both cell types being equally
likely to be lost from the original culture, where medium
to high densities of FA cells resulted from the
elimination of PF cells the same enhanced pattern of FA
cell proliferation was generally seen.
b) Passaged cells
Study of the cells transferred following treatment with
trypsin/EDTA showed fairly consistent patterns of growth.
It soon became apparent, however, that the morphology of
the cells was not a reliable predictor of their
histochemical reactions unless complex networks of
cytoplasmic processes were formed, which invariably
identified the cells as glial.
Although in three cases GFAP+ cells (both PF and FA in
morphology) were still seen at 5, 7 and 11 days after
passage, longer periods were associated with increasing
dominance by FN+ cells with disordered growth and by 27
days after passage no GFAP+ cells were seen.
One exception to this was a culture that had been passaged
29 days previously and after 14 days had been treated
again with trypsin. Although the residual cells 15 days
after the second treatment were predominantly FN+/GFAP- a
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few GFAP+ cells were seen which showed spotty deposits of
surface FN.
After a second passage cultures maintained from 7 to 35
days all showed FN+/Vimentin+/GFAP- cells. As before these
cells commonly showed the heaping growth pattern described
above. In these and all subsequent passaged cultures no
GFAP+ cells were seen.
In one case cells from passage number 3 were snap frozen
in liquid nitrogen and recovered after 28 days storage.
These too were all FN+/Vimentin+/GFAP- when studied after
a further 14 days in culture.
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Subependymal giant cell astrocytoma and Ganqlioglioma
These two tumours differed from the majority of astrocytic
tumours already described in that GFAP+ cells showed an
unusual degree of persistence. Some of these GFAP+ cells
were also unusual in showing degrees of coexpression of
FN, although never in quantities seen in GFAP- FA cells.
1) Subependymal giant cell astrocytoma
Sections from the original tumour (fig.2.31) showed that
the giant cell elements were predominantly positive for
vimentin but not GFAP, while the latter was more commonly
found in the smaller, more typically astrocytic cells with
which the giant cells were mixed.
The general pattern of growth was similar to that seen in
other gliomas with small fragments or larger explants
forming complex networks from which, in time, flattened
cells grew. These were frequently small and showed a far
less disturbed growth pattern than that shown by the
larger FA cells grown from other tumours and by 10 days
they had formed endothelial-like clusters (fig.2.32). The
PF cells showed considerable variation in size (fig.2.32)
and were not invariably GFAP+, a number containing
vimentin alone (fig.2.33). The endothelial-like cells
showed much surface FN but this was not a feature of the
PF cells.
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Fig.2.31 Supependymal giant cell astrocytoma.
a. Giant cells (arrow) contrast with background
of smaller cells. Paraffin section, H&E, x260
b. Vimentin is present in both large and small
cells. Paraffin section, monoclonal
anti-vimentin, peroxidase, x260
c. GFAP is essentially restricted to the smaller
cells, leaving the larger ones unstained.




Fig.2.32 At the edge of an explant culture large (centre),
and variable, PF cells are mixed with smaller
endothelial-like cells (arrow). Supependymal
giant cell astrocytoma, 15 days in vitro, phase
contrast, xl32
Fig.2.33 PF cell (left) and adjacent large FA cell (right)
both show uniform staining for vimentin.
Supependymal giant cell astrocytoma, 30 days in
vitro, monoclonal anti-vimentin x260
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Some larger FA cells were seen and by 30 days some
abnormal heaping of these cells was seen. At this stage
some large FA cells showed strong vimentin staining and
weak GFAP staining, while others showed strong vimentin
staining, no GFAP staining and strong FN staining. PF
cells, both singly and in small explant-like fragments,
showed strong vimentin staining, usually (but not
invariably) no GFAP and varying amounts of FN, although
this was always focally, rather than uniformly,
distributed over the cell surface.
In a culture passaged after 10 days and observed after a
further 31 days the mixture of cells described above
persisted; some of the PF cells showed GFAP positivity and
surface FN although the latter was never in the amounts
seen on GFAP- heap-forming cells, and appeared to have
been passively transferred from adjacent FN+ cells
(fig.2.34).
After a second passage FN+/Vimentin+/GFAP- FA cells
predominated and although they showed an irregular heaping
growth pattern they were often smaller than the cells seen
in cultures from other astrocytomas. Numbers of PF cells
persisted (fig.2.35) and although they were mostly
Vimentin+/GFAP-, some of them, together with some large FA
cells, contained GFAP and bore varying amounts of surface
FN.
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Fig.2.34 Irregular strands of FN (green) adhere to GFAP+
(orange) cells but do not form a uniform surface
layer. Supependymal giant cell astrocytoma, 49
days in vitro, second passage, polyclonal
anti-GFAP, monoclonal anti-FN, x520
Fig.2.35 Large, complex, PF cell in first passage culture.
Supependymal giant cell astrocytoma, 50 days in




The original tumour showed a background of well
differentiated fibrillary astrocytes with scattered
abnormal ganglion cells, some of which were binucleate.
The astrocytic elements were strongly GFAP+ contrasting
with the negative neuronal elements (fig.2.36).
Primary cultures showed a predominance of GFAP+ PF cells
in explant cultures and dispersed cell preparations with
few FN+ FA cells (fig.2.37). After passage the numbers of
FN+ cells increased although a disorderly growth pattern
was not noted until after the fourth passage (27 days in
culture) . GFAP+ cells were still evident 7 days after the
first passage (17 days in culture) and 17 days after the
fourth passage (34 days in culture) (fig.2.38). In both
these circumstances there were small patches of FN
discernible on the cell surfaces, some of which appeared
to have resulted from extension from strongly FN+ FA cells
suggesting cell surface transfer of FN.
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Fig.2.36 Ganglioglioma showing strongly stained glial
elements and unstained large neuronal cells
(arrow). Paraffin section, polyclonal anti GFAP,
peroxidase, x270
Fig.2.37 Glial elements, with both PF and FA morphology,
stain strongly for GFAP. Ganglioglioma, 13 days
in vitro, polyclonal anti-GFAP, x260
Fig.2.38 GFAP+ cells (orange) persist after fourth passage
admixed with FN+ cells (green). Ganglioglioma, 34




The properties of PF cells and the two types of FA cells
can be summarised as follows:
PF cells
-consistently express GFAP and frequently express vimentin
-usually lack surface fibronectin
-can develop from explant or dispersed cell cultures but
are more likely to persist in the former
-are usually lost with sequential passage
-persist in ganglioglioma and SEGCA cultures
-do not show overtly transformed properties
FA cells (i)
-properties as PF cells differing only in morphology
FA cells (ii)
-consistently express surface fibronectin and vimentin
-consistently lack GFAP
-can develop from explant or dispersed cell cultures but
develop with significantly greater frequency and
generally more rapidly from the latter
-become dominant population following sequential passage
-growth pattern suggests a transformed nature
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DISCUSSION
The observation that human malignant glial tumours in
culture give rise to a variety of morphologically distinct
cell types has been made in a number of studies (Frame et
al, 1984; Franks et al, 1986; Jacobsen et al, 1987;
Kennedy et al, 1987; Lolait et al, 1983; Lumsden, 1971;
Manoury, 1977; McKeever et al, 1987; Paetau, 1988; Ponten
et al, 1978; Rutka et al, 1987a). Interpretations of the
nature of the cells have varied, and although most workers
have identified glial elements with varying degrees of
certainty (depending on whether or not immunohistochemical
confirmation was carried out) some have also argued that
non-glial elements may be developing in-vitro (Franks et
al, 1986; Jacobsen et al, 1987; Manoury, 1977; McKeever et
al, 1987; Rutka et al, 1986a; Rutka et al, 1987a).
The ability to identify GFAP immunohistochemically in
tissue sections led to the recognition that it was present
in neoplastic cells in the majority of astrocytic tumours
(Deck et al, 1978; Eng et al, 1978). Not all tumour cells
expressed GFAP and anaplastic tumours were more likely to
contain such negative cells (Eng et al, 1978) but the
relationship between intermediate filament expression and
cellular differentiation was far from clear. Developmental
studies of glial cells in vivo had suggested that GFAP
replaced vimentin as glial cells matured (Bignami et al,
1985) but in vitro work had shown that GFAP could be
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induced by a variety of external factors including
hydrocortisone, prostaglandins, Fibroblast Growth Factor
(Morrison et al, 1985) and extracellular matrix (Rutka et
al, 1987). GFAP expression in neoplastic cells was found
to be increased when they were in close relation to
mesenchymal tissue, either when invading the meninges
(Herpers et al, 1984) or in extracranial locations such as
liver (Kawasaki et al, 1987). This led to the suggestion
that GFAP was of importance in both cytoskeletal
construction and the subsequent maintenance of the
"mature" or process-forming phenotype, whether induced as
a part of the process of normal development or in response
to external factors acting on neoplastic cells (Eng et al,
1982; Morrison et al, 1985). The fact that staining for
GFAP in neoplastic astrocytes tends to be stronger in cell
processes (Duffy et al, 1982; Herpers et al, 1986) gives
some credence to this interpretation. Related to this idea
was the suggestion that paucity of GFAP in some tumour
cells was responsible for the characteristic pleomorphism
of malignant gliomas (Duffy et al, 1980) .
Although all mature non-neoplastic astrocytes were found
to express GFAP only some expressed vimentin (Lazarides,
1982). The significance of the pattern of expression of
these two intermediate filaments is far from clear but it
has been suggested that different cellular functions may
impose different structural requirements which are met, in
part, by the assembly of intermediate filaments
appropriate to the cell's needs. As an example the
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expression of vimentin by astrocytes involved in the
healing of an experimental injury was attributed to a
proliferative state and a possible need for motility
rather than to cellular immaturity (Schiffer et al,
1986a). The direct observation in vitro of the
relationship between motility and GFAP expression supports
such a view (Duffy et al, 1982); GFAP was found to
correlate inversely with the degree of motility of human
astrocytoma cells and was postulated to be directly
involved in process extension but to inhibit cell
movement. Others have considered the possibilities that
the patterns of expression may have no functional
significance or may be related to some undetermined
regulatory function (Sharp et al, 1982).
The question of the relationship between GFAP and vimentin
has been addressed by a number of studies of human and
animal astrocytes, both normal and neoplastic. In human
astrocytic tumours vimentin and GFAP are usually
co-expressed although not every cell contains both
filament types and there does not appear to be any clear
correlation between the degree of vimentin expression and
tumour grade (Herpers et al, 1986; Reifenberger et al,
1987; Schiffer et al, 1986; Yung et al, 1985) . The latter
point contrasts with the situation observed in a
chemically-induced animal glioma where increasing cellular
anaplasia was associated with increased numbers of
vimentin-containing cells (Yoshimine et al, 1988).
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The co-expression of two intermediate filaments, which has
also been observed in vitro in the cells of an established
human glioma cell line (Sharp et al, 1982), has been
attributed to copolymerisation with coassembly of
filaments from a pool of common precursor fragments (Sharp
et al, 1982; Wang et al, 1984).
Any immunohistochemical analysis of the pattern of
intermediate filament expression must recognise that
variations in reported patterns may reflect differences in
the affinities and specificities of the antibodies used.
This is well illustrated in the case of desmin where
studies of astrocytes variously reported that it was
present (Dahl et al, 1982, 1986) or absent (Debus et al,
1983; Raemaekers et al, 1983). These findings were
reconciled by the suggestion that desmins from different
sites or cell types may differ antigenically, and
antibodies raised against one type might not necessarily
react with another type in a different location (Dahl et
al, 1986) .
The expression of GFAP, vimentin and occasionally desmin,
but not fibronectin, by the majority of PF cells and by
the FA cells in interstitial locations within networks
formed by such cells is sufficient to identify them both
as being glial in nature.
In the cultures studied with Ki67 antibody these cells are
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seen to be actively dividing although the percentage of
cells thus engaged was generally small. Although small
spots of fibronectin were seen on occasional glial cells
dense surface and interstitial deposits were never a
feature. It is of interest, however, that in both the
subependymal giant cell astrocytoma and the ganglioglioma,
fibronectin was more prominent on glial cells (although
never as a dense surface network) and that in these
tumours glial cells apparently persisted longer than was
usual in malignant astroglial tumours.
A dense surface and interstitial pattern of fibronectin
deposition characterised the population of flattened
adherent cells with a heaping growth pattern. These cells
always expressed vimentin, but never GFAP or desmin. These
cells, as simple morphological observations of their
growth would suggest, were found to have a far higher
proportion of cells in a proliferative state (as
identified by Ki67 staining), especially in the areas of
abnormal heaping growth. Although the pattern of
fibronectin staining indicated both surface and
interstitial deposition of the type described in a number
of studies of normal fibroblasts (Ruoslahti et al, 1981;
Bitterman et al, 1983; Vaheri et al, 1976; Lim et al,
1982; Trejdosiewicz et al, 1985; Fromme et al, 1982) the
failure to form monolayers and the frequency with which
growth formed local heaps were quite unlike the pattern
typical of normal fibroblasts in culture (Vasiliev et al,
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1981). None of these cells expressed either of the two
endothelial markers used and they appeared to differ from
the smaller cells which were occasionally observed to form
small clusters with inconstant staining for F8RAg, or
larger regular cobblestone like sheets without F8RAg
reaction. These latter cells would appear to be
endothelial despite the absence of UE1 reaction. The
apparent loss of F8RAg in later cultures suggests that
absence of endothelial markers may not be a valid
criterion for excluding an origin of the larger FA cells
from endothelium; this is in accord with deBault's finding
that F8RAg is lost early in cultures of known endothelial
origin (deBault, 1982). That readily identifiable
endothelial-like elements survive and grow from human
gliomas seems likely, but the relative infrequency of this
suggests that their growth (in their ordinary state at
least) is not favoured by the conditions of culture used
in the present studies.
In the work presented in this thesis culture of a variety
of astrocytic tumours has shown remarkably consistent
patterns of growth. There is a clear contrast between
cultures in which explants are established and those in
which the component cells of the tumour are initially
separated by the action of collagenase. In the former
astrocytic elements persist in a coherent network which
shows progressive peripheral extension, although with time
focal proliferations of FN+ cells develop and either
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overwhelm the explant, or inhibit further extension. In
dispersed cell preparations low densities of glial cells
fare badly, and rarely form thriving cultures, whereas
these conditions favour the emergence of FN+ cells even
though parallel explant cultures from the same tumour show
that only very small numbers are present initially.
The growth pattern of the FN+ cells is disorderly, they
appear to demonstrate loss of contact inhibition, and they
are capable of surviving up to 10 passages. This contrasts
with the glial cells (identified by their GFAP content)
which in their typical process-forming state rarely show
cell crowding and instead preserve considerable cell-cell
distances although interconnected by cell processes. Those
glial elements which show less process formation remain
dispersed through the interstices of explants and were not
seen to form cell masses comparable with those of the
fibronectin-bearing cells.
The present studies show that the manipulations associated
with passage have a profound effect on the populations of
cells available for study; they serve to destroy the
microenvironment in which cells are developing and thus
alter the conditions in ways that may favour the
differential survival and growth of a single cell type.
Thus passage enhances the emergence of FN+ cells to the
detriment of glial elements that will survive for far
longer periods if left undisturbed. This suggests that the
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glial cells depend for their survival on environmental
conditions which are disrupted by passage and possibly
compromised by techniques that utilise disruption of
tumour tissue prior to culture.
Three major questions need to be addressed:
i) Why do the GFAP+ glial cells, in high density, maintain
a relatively orderly, complex, network and yet, in lower
densities, fail to survive (with few exceptions) in
prolonged culture?
ii) What underlies the apparently transformed behaviour of
the FN+ cells?
iii) What is the origin of the FN+ cells?
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Behaviour of glial cells in culture.
Studies of embryonic cell populations in culture
(Steinberg, 1970; Townes et al, 1955) have given some
indications of how cells of differing type interact. Cell
motility and differential adhesion will allow cells of
similar types to combine to form tissues in ways which can
be modulated by those surface properties that determine
such adhesion. The adhesion of like cells is seen in the
formation of tumour cell spheroids (De Ridder et al, 1987;
Mareel, 1983) and in embryonic tissues; in the latter
changes in adhesion preference with time (one element of
embryonic differentiation) will alter the pattern of
adhesion allowing the progressive restructuring of tissues
which is necessary for organogenesis. Such a process is
considered to underly the "sorting out" which is seen
among mixed embryonic cell populations (Steinberg, 1970),
and may also be operating in the mixed cell populations
which result from primary dispersion of tissue from a
glioma.
Cell contacts have been shown, in some cases, to be via
specialised low resistance junctions (Furshplan et al,
1968) which may allow ionic transfer and thus effect
communication. It has been suggested that ionic coupling
of cells through such junctions allows the decision to be
made whether cells will bind or not. The active extension
of processes by glial cells and the making of contact with
other glial cells and FA cells could provide the means for
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such communication. There is certainly evidence that
aggregations of glial cells, both normal and neoplastic,
spread and become polarised with respect to their
substrate more rapidly than do single cells (Forsby et al,
1985). The persistence of density-dependence, as far as
growth is concerned, among cells derived from a number of
glial tumours (Westermark, 1973) and the maintenance of a
relatively orderly network in explants may reflect the
importance of cell contacts both in maintaining growth,
and controlling it in a way that results in a form of
contact inhibition. Such contacts would be extremely
susceptible to physical disruption and manipulations such
as passage would be expected to reduce the chances of
re-establishing communication and so reduce survival, or
at least active growth. The process of passage might be
more likely to disrupt such an active mechanism of cell
communication than one dependent on cell binding based on
fibronectin and transmembrane modulation via actin, a
mechanism conceivably utilised by FN+ FA cells. As a
result passage would be expected to favour the survival of
FA cells rather than PF cells.
The fact that glial elements survived longer in cultures
from two extremely low grade tumours (the subependymal
giant cell astrocytoma and the ganglioglioma) would
require confirmation with larger numbers but it does
suggest that the degree of malignancy of the original
tumour is not a good predictor of survival in the type of
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culture system used in the experiments described above.
This is of interest in the light of the observation that
cell lines have never been developed from well
differentiated gliomas (Collins et al, 1980; Ponten et al,
1973; Onda et al, 1988) and touches on the question of
what range of transformed properties are actually
possessed by the parenchymal cells of a glioma. Thus the
failure of PF cells to survive on the surface of FA cells
may be a "toxic" effect, may indicate the retention of a
specific anchorage dependence normally only satisfied by
the properties of the culture flask, or may result from an
interference with the formation of cell-to-cell contacts
required for glial cell survival. The fact that the glial
components were influenced by FA cells cannot be taken to
indicate that they are not neoplastic since some
metastasising clones of HeLal cells have been found to be
incapable of attaching to, or penetrating fibroblast
monolayers, in apparent contrast to their in vivo
properties (Benke et al, 1984) .
FN+ cells appear more readily in cultures from dispersed
tumour preparations, and only slowly from explants. It is
possible that the structures in the original tumour from
which the FN+ cells derive require to be disrupted before
the cells can grow. Alternatively there may be an
inhibitory influence of glial cells (which grow better in
explants) on the growth of the FN+ cells. Gliomas are
known to produce growth inhibiting factors, which act on T
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lymphocytes and neuroblastoma cells (Fontana et al, 1985),
and it is possible that factors may be produced in vitro
that act on the progenitor cells of the FN+ population.
The manipulations of passage could therefore be seen as
reducing the glial population and thus minimising any
inhibitory effect it might have on FN+ FA cells.
The nature of the interstitial GFAP+ cells in the
interstices of the glial networks is not clear. They may
be cells in the process of migration within the culture
which have not formed contacts, or conceivably cells which
are more transformed and do not need to form such
contacts. In vitro studies of rat glioma cells have shown
that FA-like cells can be induced by exposure to Nerve
Growth Factor whereas Glial Maturation Factor enhanced
process formation and the development of PF-like cells
(Marushige et al, 1987) suggesting that the two cells
types are interconvertible depending on environmental
influences. The invariable presence of GFAP+ FA cells in
high density PF growths also raises the possibility that
the latter may derive some stimulus from the former and
the cis-oncogene product Platelet Derived Growth Factor
(PDGF), which is produced by some glioma-derived cells
(Westermark et al, 1985), has been suggested as playing a
role in such an interaction (Nister et al, 1986). The
techniques used in the studies presented in this thesis
did not allow any phenotypic distinction to be made
between those glial cells that formed contacts in networks
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and those that did not. Nevertheless there is considerable
heterogeneity among cell lines derived from gliomas
(Jacobsen et al, 1987; Bigner et al, 1981; Rutka et al,
1987a; Dewhurst et al 1987; Bullard et al 1981) including
heterogeneous secretion of PDGF (Nister et al, 1985,
1986). Studies of the morphology of cloned cell lines
producing PDGF or cells bearing PDGF receptors have
suggested an inverse relationship between the two
properties: high receptor levels characterise large
stellate cells, and high PDGF production is a feature of
smaller polyhedral cells (Nister et al, 1986). Similar
studies in mixed culture would be of considerable interest
and might shed further light on the interdependence of the
two morphological variants of glial cell observed in
explants in the present study.
The apparent paradox that cells derived from a tumour and
considered to represent the parenchymal, that is the
neoplastic, population do not show all the properties of
transformed cells was discussed earlier (page 86 et seq).
Whilst it is apparent that neoplastic transformation is
associated with abnormal cell behaviour there is ample
evidence that transformed cells still retain, to varying
degrees, many normal properties (Vasiliev et al, 1981),
including residual contact inhibition (Westermark, 1973).
It has been shown that during transformation the ability
of cells to induce angiogenesis is acquired before the
ability to form a tumour (Ziche et al, 1982), and
antigenic heterogeneity has been shown to exist between
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primary tumours and their metastases (Enblad et al, 1985;
Parmiani et al, 1985), suggesting that there may be
considerable diversity among cells in a tumour in terms of
the possession of transformed or neoplastic properties as
well as in phenotype and genotype (Shapiro et al, 1985).
The persistence of the property of density dependent
growth may well be of importance in explaining the general
absence of metastases from malignant glial tumours despite
ultrastructural evidence that penetration of tumour
blood-vessel walls by neoplastic glial cells does occur
(Rung et al, 1969).
Behaviour of Fibronectin positive (FN+) cells
FN+FA cells are more likely to appear in early cultures
derived from dispersed preparations than from explants
although they will eventually appear in a considerable
number of the latter if culture is continued for long
enough. Although they appear to be inhibited by high
density growths of PF cells, this can be overcome by
artificially reducing PF cell density by passage. The
question of the nature and origin of the FN+ FA cells must
be addressed in view of the observation that they appear
to increase in number in culture and yet may not be common
in vivo (Schiffer et al, 1984; Chronwall et al, 1983;
Kochi et al, 1983; Paetau et al, 1980a). On the basis of
their morphology and non-confluent growth pattern they do
do not appear to be fibroblasts, and yet they appear to be
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antigenically distinct from the glial elements, confirming
the mutual exclusivity of GFAP and FN expression reported
by others (Paetau et al, 1980a; McKeever et al, 1987;
Paetau, 1988). The non confluent growth pattern with
"node" formation resembles the artificially induced cell
islands grown from glioma derived cells (Collins et al,
1980) and suggests a transformed nature as well as an
ability to adhere to each other in preference to the
substrate. FA cells appear to correspond to the cells
present in 80% of the gliomas studied by Kennedy and
colleagues in a dispersed cell system (Kennedy et al,
1987). These bore surface FN which might be expected to
enhance initial cell adhesion and thus survival, and
similar cells have been reported to be derived from
gliomas in a number of other studies (Franks et al, 1986;
Lolait et al, 1983; McKeever et al, 1987; Paetau, 1988).
FN is known to play an important role in mediating the
adhesion of cells to extracellular matrix (Yamada et al,
1978) and to each other (Saison et al, 1983) although the
latter function is also mediated by other unidentified
surface proteins. This process of cell to cell adhesion
appears to be an active one requiring prolonged cell
contact rather than a passive "gluing" phenomenon,
implying that alterations in the cell surface need to
occur. In addition to its binding properties FN appears to
play a role in stimulating (Gullino, 1986; Rennard et al,
1981; Tsukamoto et al, 1981), facilitating (Schor et al,
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1981) and directing cell migration, possibly by providing
sites for preferential binding (Schor et al, 1983), or by
acting as a "guidance trail" (McAuslan et al, 1980) in a
way analogous to the extracellular mucins produced by
slime moulds (White, 1981) . In the latter role FN may be
only one of a number of extracellular matrix components
that are of importance in determining the growth of cells
and the direction of cell movement. There is evidence that
these substances are also required, in a permissive sense,
if cells are to be responsive to external growth factors
(Gospodarowicz et al, 1980), a fact that reinforces the
importance of substrate adhesion in the proliferation of
normal cells.
The observation that cell-associated FN was reduced with
viral transformation (Adams et al, 1977) and the finding
that FN will restore a normal appearance (Yamada et al,
1976), although not necessarily a normal growth rate
(Mosher et al, 1981), to transformed cells would seem to
argue against identification of the FN+ cells observed in
this study as neoplastic. As mentioned earlier (page 31)
the basis for FN loss in some transformed cells may be in
their ability to retain FN on their surface rather than in
the synthesis of the substance (Ruoslahti et al, 1981).
Indeed the correlation between reduced surface FN
expression and transformation is not an absolute one and
tumourigenic cells been described that bear surface FN
(Khan et al, 1979; Pearlstein et al, 1976). It has also
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been postulated that point mutations in genes coding for
FN structure may result in a functionally defective
protein (Ruoslahti, 1984), a view supported by the known
importance of FN structure in determining its cell-binding
function (Ali et al, 1978; Grinnel et al, 1980).
Discrepancies have also been observed between the in vivo
and in-vitro expression of FN (Chen et al, 1979). While
this suggests that tumour cells may express (or retain)
surface FN in culture and may not do so when forming
tumours in vivo, an alternative explanation is that such
phenomena represent differences between clones arising
within the same tumour (Jiwa et al, 1985).
The nature of the studies described in this thesis did not
allow the assessment of other transformed properties, such
as growth in soft agar, enhanced cloning ability or
tumourigenicity, and, although survival for up to 10
passages was observed, continuously growing cell lines
were not developed. Before coming to a final conclusion
about the nature of these FN+ cells it is necessary to
consider the possible identities of their cells of origin
and possible sources within the tumours from which they
are derived.
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Possible origins of Fibronectin positive (FN+) cells
There are two main schools of thought concerning the
origin (and thus the nature) of the FN+ cell.
Either i) the cell is genuinely neoplastic, is of glial
origin, and has a phenotype indicative of a less
differentiated state than those cells which express GFAP
and not FN (Frame et al, 1984; Kennedy et al, 1987)
or ii) it is not of parenchymal origin but instead is
derived from mesenchymal or endothelial elements in
response to factors produced by the tumours (Franks et al,
1986; Jacobsen et al, 1987; McKeever et al, 1987; Manoury,
1977; Rutka et al, 1987a).
Is the FN+ cell glial? Evidence in favour of the view that
the FA cell is neoplastic and glial includes an aberrant
growth pattern, its lack of contact inhibition, its
consistent derivation from glial tumours (if cell
dispersal methods are used), the finding of chromosomal
abnormalities in some cells (Kennedy et al, 1987) and an
association with fibrinolytic activity (Frame et al, 1984;
Freshney et al, 1985; Freshney et al, 1985; McLean et al,
1986 ) .
The lack of glial intermediate filament expression by
cells of putative glial origin is consistent with the
observations made on cells from optic nerve of the
developing, and adult, rat (Ffrench-Constant et al, 1986;
Raff et al, 1983) . These studies demonstrated that an
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astroglial precursor cell may not express specific
astroglial intermediate filaments, and observations on
human astrocytic tumours have similarly demonstrated that
cells may be present, although in varying numbers, that do
not express histochemically detectable GFAP (Franks, 1988;
Roessmann et al, 1983; Schiffer et al, 1984; Schiffer et
al, 1986; Yung et al, 1985). This lack of expression does
not appear to relate to tumour grade (Herpers et al, 1986)
and GFAP expression may be affected by the local
microenvironment of the neoplastic cells rather than be
determined solely by the degree of cell differentiation
(Herpers et al, 1984; Morrison et al, 1985; Rutka et al,
1987; Kawasaki et al, 1987).
If the FN+ cells are to be interpreted as being of glial
origin they might be expected to have a phenotypic
counterpart among normal glial cells. Early studies on
cells derived from normal human brain yielded flattened
polygonal cells with minor degrees of process formation
which were accepted as glial without further
characterisation (Ponten et al, 1969); these cells were
subsequently found to express surface FN (Vaheri et al,
1976). Although these authors observed that cells derived
from non-CNS tumours secreted FN and failed to retain it
on their surface, FN-producing cells isolated in vitro
from human gliomas were considered to be neoplastic
counterparts of the normal "glial" cells which had already
been described. Normal rat astrocytes, whose nature has
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been confirmed by the presence of GFAP, have been shown to
secrete FN up to nine days postnatal (Liesi et al, 1986) .
However in the majority of such cells the FN is in the
form of punctate deposits (as seen in the few GFAP+ cells
in this work which were also FN+) rather than the
fibrillar matrix seen in fibroblasts (Price et al, 1985)
and in the FA cells. In other words astrocyte FN is
secreted but not readily incorporated into a matrix.
Nevertheless results from a number of studies were
considered to provide a measure of support for the view
that GFAP-/FN+ cells were of glial nature.
Continuous cell lines derived from gliomas, and therefore
assumed to be neoplastic, may not express GFAP, or may
express FN (Bigner et al, 1981; Dewhurst et al, 1987;
Jones et al, 1980; Jones et al, 1982); GFAP may be lost
from cell lines with serial transfer (Jones et al, 1981);
in-vitro transformation of glial cells may result in
reduced GFAP expression (Laerum et al, 1985) or reduced
inducibility of GFAP by exogenous maturation factors
(Haaugen et al, 1981); GFAP+ cell lines may be induced to
express FN if they are allowed to form tumours in athymic
mice (Jones et al, 1982). These findings could, however,
all be interpreted as the result of selective survival and
growth enhancement of a population of non-glial cells
under experimental conditions. Nevertheless the view was
propounded that neoplastic glial cells need not express
GFAP, and may, in appropriate circumstances form matriceal
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rather than soluble FN resulting in the phenotype
associated with FA morphology.
Steroids are known to be capable of inducing
differentiation in neoplastic astroglial cells (Freshney,
1985; Freshney et al, 1986; McLean et al, 1986) and both
dexamethasone and methyl prednisolone have been found to
increase cellular GFAP in a human astrocytoma cell line
(Pilkington et al, 1987). The latter group have also found
that if cultures, in which GFAP+ cells are normally lost
and replaced by FN+ cells, are treated with methyl
prednisolone the GFAP+ cells persist for longer (Wright et
al, 1987) ; these results were interpreted as indicating
that the FN+ cells were being induced to differentiate to
GFAP+ cells. Steroids are however known to increase FN
expression in transformed cells (Furcht et al, 1979); the
increased expression of GFAP, in the culture as a whole,
could have been due to increased FN expression by glial
cells which thus acquired a survival advantage in the
passaging process by virtue of enhanced cell adhesion
(Grinnel et al, 1980).
Is the FN+ cell stromal? The alternative view that the FN+
cells derive from mesenchymal or endothelial elements is
supported by the absence of staining for GFAP, the lack of
forms phenotypically intermediate between the FN+ cells
and obvious glial cells, and the observation that in
explant cultures these cells arise only as a late
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phenomenon.
Although some cell lines obtained from human gliomas do
produce FN many do not (Sherbet et al, 1982; Lubitz et al,
1980) and experiments on rat glial precursors have failed
to induce interstitial FN matrix formation (Lim et al,
1982) despite their producing soluble FN. Critical studies
of the FN-producing cells derived from normal human brain,
and identified as glial (Ponten et al, 1969; Vaheri et al,
1976), have concluded that they are actually meningeal
(Rutka et al, 1986a). Similar studies of fetal mouse
cerebellum have concluded that such cells are endothelial,
fibroblastic or meningeal in nature (Ghandour et al,
1982). Studies on the effect of differentiating agents on
cell lines that did not express GFAP failed to induce GFAP
expression and the authors conceded the possibility that
this failure was due to the fact that the cells may have
been of endothelial origin (Geder et al, 1987) .
If the FN+ cells do not arise from neoplastic glial
elements explanations are required for their
quasi-transformed properties: their abnormal in-vitro
growth patterns, their chromosomal abnormalities
(Davenport et al, 1987; Kennedy et al, 1987), and the
development of continuous cell lines some of which are
tumourigenic (Jacobsen et al, 1987, Rutka et al, 1987a).
Although vascular and mesenchymal tissue in the brain does
- 99 -
not usually participate in the repair process following
ischaemic damage to the same extent as is seen in
non-neural tissue, after appropriate stimulation it will
do so. Thus fibroblast and vascular proliferation and the
formation of typical granulation tissue is characteristic
of abscesses, and occasionally of deep haematomas
(Masuzawa et al, 1985). The vascular proliferation that is
seen in malignant astroglial tumours is sufficiently
characteristic to be of diagnostic value (Rubinstein,
1972) but the fact that it may also be seen in relation to
metastatic tumours (Feigin et al, 1958) indicates that it
is an intrinsic capacity of cerebral vessels rather than a
glioma-specific phenomenon. The vessels which form are
often abnormal in the degree of maturation which they
show, and as a consequence are often thin walled and
liable to haemorrhage. Whether these abnormalities of
structure result from the rapidity of growth or reflect
acquired cellular defects resulting in defective vascular
maturation is not known, but there is evidence that
suggests that non-parenchymal elements (mesenchymal and
vascular) in tumours may not be normal.
In human gliomas, although proliferating endothelial cells
have been found to be diploid (Davenport et al, 1987a) the
tumour cells in four out of 11 high grade gliomas studied
were also diploid emphasising that diploidy does not
necessarily equate with functional or genotypic normality.
In an experimental virus-induced glial tumour a high
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labelling index was observed in the endothelium and the
possibility of direct transformation by the causative
virus was discussed (Groothuis et al, 1980). In an
autoradiographic study of glioma explants the majority of
labelling was thought to be within the non-glial
components (Haynes et al, 1978) and more recent work has
shown that explants in which FN+ cells predominate are
likely to be aneuploid (Davenport et al, 1987). To this
evidence from glial tumours can be added direct
observations of behavioural abnormalities in vitro of
stromal components from other tumours.
Stromal fibroblasts from breast tumours have been found to
show abnormal patterns of growth in-vitro which closely
resemble the "heaping-up" of FN+ cells seen in glioma
cultures (Delinassios, 1983); both tumour stromal
fibroblasts and skin fibroblasts from the same patients
have been found to show abnormal migration patterns
in-vitro that are similar to transformed cells (Durning et
al, 1984), and similar phenotypic abnormalities have been
described in fibroblasts from patients with familial
cancers (Kopelovich et al, 1979) or their relatives
(Haggie et al, 1987). Although these findings do not mean
that tumour stromal cells are transformed they do mean
that phenotypic properties typically seen in transformed
cells may be observed in non-parenchyma 1 tumour-derived
cells. It is possible that these properties may reflect
abnormalities of gene expression, either hereditary or
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acquired (conceivably as a result of the action of the
carcinogen responsible for the transformation of the
parenchymal cells), which may render the cell more liable
to further alteration, and even eventual full
transformation, if appropriate conditions apply either
in-vitro or in-vivo. Thus the development from gliomas of
tumourigenic cell lines with mesenchymal properties such
as interstitial collagen deposition (Rutka et al, 1987a)
or sarcomere formation (Jacobsen et al, 1987) could be
seen as the result of further mutations occurring in vitro
in an already susceptible cell type. Examples of such
in-vivo progression are encountered in the central nervous
system in the form of the gliosarcoma, a tumour in which
neoplastic astroglial elements are combined with
neoplastic mesenchymal elements, which may show striated
muscle differentiation (Barnard et al, 1986), in a "mixed
tumour" (Rubinstein, 1956; Russell et al, 1977).
Sarcomatous elements have been estimated to occur in from
2.3% to 5% of all glioblastomas (Feigin et al, 1958;
Morantz et al, 1976) which would be far higher than that
encountered in most carcinomas (Willis, 1948). This would
be in keeping with the hypothesis that the exuberant
vascular proliferation so characteristic of malignant
glial tumours is associated with an increased risk of
transformation and subsequent tumour development in the
mesenchyme (Feigin et al, 1958; Pena et al, 1973);
indirect support for the importance of cerebral vessel
responsiveness as opposed to glial tumour stimulation
- 102 -
comes from cases of sarcomas developing in relation to
non-glial tumours metastatic to the brain (Feigin et al,
1984; Schwarz et al, 1963). Immunohistochemical studies on
gliosarcomas have suggested that the sarcomatous element
may be more closely related to the endothelial component
of the proliferating vessel than the associated mesenchyme
(Slowik et al, 1985) although others have argued that the
sarcoma arises from non-endothelial cells (McComb et al,
1982).
The finding of large numbers of macrophages in relation to
the vessels and sarcomatous areas of human gliosarcomas
(Kochi et al, 1987) led to the suggestion that FN secreted
by the macrophages was stimulating or guiding
proliferating mesenchymal cells. This is of interest in
the light of the suggestion that immune cells may provide
the stimulus for the progression from hyperplasia to
malignancy that characterises the vascular lesions of
Kaposi's sarcoma (Brooks, 1986). Although in earlier
studies on gliosarcomas in vitro no observations were made
of antigenic phenotype (Slowik et al, 1985), later work
has demonstrated that a cell line from such a tumour
expressed FN, laminin and collagen IV and thus appeared to
be genuinely mesenchymal in nature (Rutka et al, 1986).
Mesenchymal properties have however been observed in cells
cultured from glioblastomas without sarcoma (Rutka et al,
1987a; Jacobsen et al, 1987) and serial transplantation of
vascular elements from malignant human gliomas has been
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found to result in the development of sarcomas (Greene et
al, 1968) . This suggests that sarcoma development could
simply be a progression from a state that may well exist
exist in the vessels of many malignant gliomas. Against
this view is the fact that GFAP+ and FN+ cells from such a
tumour have been found to have similar chromosomal
abnormalities (Westphal et al, 1988) which were held to
indicate a common origin and would suggest that
sarcomatous change is the result of phenotypic change in a
malignant glial population rather than malignant change in
stromal cells.
If the FN+ cells are derived from endothelium they fail to
show the formation of primitive channels described in
studies of endothelium from bovine capillaries, normal
human foreskin and an ovarian tumour (Folkman et al,
1980). Differences in culture methods could however affect
such findings since subsequent work demonstrated that
channel formation required several weeks in primary
culture (Folkman, 1984); as already described these
conditions were found not to favour the appearance of FN+
FA cells from glioma explants.
The failure of the FN+ cells to express antigens normally
associated with endothelial cells (Little et al, 1986)
would appear to preclude their origin from endothelium;
studies on endothelial cells however have shown that
endothelial-associated antigens may be lost in-vitro
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(DeBault, 1982) and this is in keeping with the findings
from the present studies: cells bearing endothelial
markers were not found after 14 days, and regular sheets
of cells, whose appearances would suggest an endothelial
nature, did not express endothelial markers. There is
evidence from histological studies that the proliferating
cells that comprise the hyperplastic blood vessels in
malignant gliomas do not uniformly express endothelial
markers (Moore et al, 1986a) although the authors of the
study interpreted their findings as indicating the
involvement of pericytes in the process.
Non-neoplastic endothelial cells have been found to
undergo morphological and behavioural changes in-vitro
which may explain some of these inconsistencies. A
spontaneously arising variant cell derived from normal
bovine endothelium shows more FN production than a normal
endothelial cell and, instead of forming regular
monolayers, grows over or under sheets of normal cells
(McAuslan et al, 1980) in a pattern very reminiscent of
the FN+ cells derived from human gliomas. Similar
behaviour, including the development of
anchorage-independent growth and enhanced
plasminogen-activator activity during active growth, has
been shown not to be associated with chromosomal
abnormality (Laug et al, 1980) supporting the view that
these are properties that can, in appropriate
circumstances, be demonstrated by non-neoplastic cells.
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Endothelial cells are not, however, the only cells related
to vascular structures and involved in new vessel
formation. In the context of vascular proliferation cells
derived from smooth muscle cells of the vascular media
have been found to function both as fibroblasts and as
precursor cells of fibroblasts and smooth muscle
(Wissler, 1967). Furthermore such cells appear to have
survival advantages over fibroblasts in vitro, showing a
longer period of logarithmic growth and reaching higher
cell densities before their growth rate levels off (Burke
et al, 1977). Detailed in vitro studies of smooth muscle
cells, of vascular and non-vascular origins, have shown
that they form aggregates 2-4 days after growing from an
explant (Kasai et al, 1964) and after approximately one
week can be seen to pile one upon the other growing in
multiple overlapping layers (Ross, 1971). These patterns
of behaviour are very similar to those observed among FA
cells derived from the tumour cultures in the present
studies. FA cells could therefore be cells of vascular
origin with properties that prevent precise definition as
endothelial, fibroblastic or smooth muscle. The stimulus
to their growth and behaviour could derive from the
neoplastic glial cells in vivo, and in vitro conditions
could provide an environment that allowed expression of
their unexpected combination of properties. PDGF, which is
produced by some glioma cells in vitro, has been mooted as
one mediator of tumour-induced vascular proliferation
(Westermark et al, 1985) but the only response of
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endothelial cells to PDGF is an increase in prostacyclin
synthesis not proliferation (Coughlin et al, 1980).
Intriguingly smooth muscle cells and fibroblasts possess
PDGF receptors and do respond by proliferation, a property
also demonstrated by some glioma-derived cell lines
(Heldin et al, 1981). The possibility of an interplay
between components of the vascular wall has been extended
to suggest that transition may occur between endothelial
cells and fibroblasts in reactive (Beranek et al, 1986)
and neoplastic processes (Slowik et al, 1985). An
ultrastructural study of a gliosarcoma (Kishikawa et al,
1986) has suggested that the cells comprising the
sarcomatous component are myofibroblastic or pericytic in
nature.
Medial smooth muscle cells, their precursors or the
postulated multipotent subendothelial vasoformative
reserve cell (Stein et al, 1969) may therefore be in a
state in tumour vessels that would allow them to
preferentially grow and survive in culture. If the vessel
were to be disrupted by collagenase prior to culture such
growth might be enhanced when compared to the situation in
a vascular fragment in an intact, largely glial, explant.
Such an explanation would fit with the observation that FA
cell predominance is more likely to occur in dispersed
cell cultures than in explants.
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Conclusions from in vitro studies
It is not easy at this stage to form a unitary hypothesis
concerning the origin of the FN+ cells which constitute
one component of the heterogeneous populations observed in
these in-vitro studies on human gliomas. It is apparent
that culture method is a more important determinant of
their development than tumour grade. They may be
transformed cells, and there is certainly evidence that
fully transformed cell lines can develop from them, but
they could in many cases be cells which exhibit behaviour
interpreted as transformed but which is in fact normal for
endothelial, or at least vascular precursor, cells. The
possibility that they are showing phenotypic
characteristics in-vitro that are not apparent in-vivo
does not preclude a glial derivation but the evidence that
neoplastic glial cells can produce FN is often indirect
and open to alternative explanation.
In a search for cells showing the antigenic expressions of
the cell types identified in-vitro attention was turned to
the phenotypic characteristics of parenchymal and
non-parenchymal cells in astroglial tumours.
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CHAPTER 3. VASCULAR AND PARENCHYMAL ELEMENTS IN HUMAN
GLIOMAS AS POSSIBLE SOURCES OF FIBRONECTIN-PRODUCING CELLS
IN—VITRO.
INTRODUCTION
From the data presented so far it is apparent that one
major cell type derived from gliomas in-vitro, namely the
GFAP+ cell, both process-forming and non process-forming,
is of glial origin. The second major cell type, the FN+
cell, has features which could be interpreted as
transformed but its antigenic expression does not include
the intermediate filament GFAP which would identify it as
also being of glial origin. Nevertheless, as has been
discussed, the lack of GFAP does not preclude a glial
origin. The alternative hypothesis that this cell type
could be of vascular origin has been considered, and
receives support from changes known to occur in cells of
vascular origin in response to appropriate stimulation
(Laug et al, 1980; McAuslan et al, 1980). The latter
hypothesis could be further explored by an examination of
the phenotypic characteristics of vessel-associated and
parenchymal elements in tissue sections from human tumours
to determine the location and distribution of cells with
antigenic profiles similar to those observed in-vitro.
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Anqiogenesis
The acquisition of a blood supply marks an important staqe
in the transition of a neoplastic proliferation from a
qroup of cells, dependent on diffusion of nutrients and
oxygen for survival and qrowth, to a system whose further
qrowth can be sustained so lonq as new vessels are formed
(Folkman et al, 1971; Gimbrone et al, 1972). Followinq
this contact with vascular channels neoplastic cells
possessinq appropriate properties, such as invasion and
motility, will be able to qain access to the circulation
and thus metastasise to distant sites; nevertheless the
establishment of distant tumours will depend on the
ability of such cells to grow in the initially low cell
densities that may result from such a process.
Anqioqenesis consists of the formation of new vessels from
existinq blood vessels and is not a process peculiar to
tumours. Indeed, analyses of tumour vasculature have
suqqested that the greatest vascular density is found at
the edge of growing tumours indicating that the host
vessels, rather than intratumoural vessels, are most
responsive to tumour-derived angiogenic factors (Thompson
et al, 1987), even though the concentration of such
factors is probably higher in the tumour centre than at
its edge. Whether this reflects an abnormality of
responsiveness of the constituent cells of the tumour
vessels, or an absence from their structure of components
necessary for an organised response, is unclear. The
latter possibility would accord with the observed
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structural abnormalities observed in many vessels in
malignant gliomas that are believed to be the source of
the haemorrhages frequently seen in such lesions (Liwnicz
et al, 1987).
Angiogenesis is a feature of normal growth and repair
where it constitutes an integral part of a controlled
process that is normally self-limiting. As an example the
rich vascularity that characterises granulation tissue
formed during the repair of a wound or an ulcer base
diminishes as the repair process proceeds. Even in the
angiogenesis that accompanies neoplastic growth there is a
clear indication from labelling studies that many cells in
the newly formed vessels are not proliferating, and this
has been adduced as indicating a programmed cessation of
growth akin to a maturation process (Nagashima et al,
1987). The production of new vessels by existing blood
vessels can be initiated by a wide range of soluble
factors but the process whereby the new vessels are formed
does not appear to differ significantly with different
stimuli.
The primary response of vessels to an appropriate stimulus
is the proliferation and mobilisation of resting
endothelial cells in capillaries or venules (Tannock,
1970; Warren et al, 1972). Not all endothelial cells are
equally responsive and differences have been noted between
cells from large and small vessels (Folkman et al, 1980;
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Gross et al, 1983a; Hockel et al, 1987; Nagashima et al,
1987; Zetter, 1980), and some sprouting can occur as a
result of cell migration alone without active
proliferation (Sholley et al, 1984). Activation of
endothelial cells is associated with protease production
(Gross et al, 1983a), disruption of their basement
membranes and migration towards the source of the stimulus
(Zetter, 1980).
Endothelial cells have been found to produce plasminogen
activator (PA) (Loskutoff et al, 1977) in-vitro and the
morphological features of endothelial cells associated
with such production (McAuslan et al, 1980) have already
been referred to. The plasmin produced by the activity of
such PAs has broad proteolytic properties, degrading both
fibronectin (FN) and laminin, and can also result in
collagen degradation by activation of latent local
collagenases (Schor et al, 1983). The finding of large
amounts of FN in relation to proliferating capillaries
(Clark et al, 1982), the observation that FN may direct
cell migration in-vitro (as discussed in Chapter 2, pg93)
and studies of its enhancing effects on endothelial cells
in-vitro suggest that it may provide a substrate in-vivo
on which endothelial cells may be better able to migrate
and proliferate (Gospodarowicz et al, 1980).
The migration of endothelial cells appears to take place
as cohesive cords of cells rather than as single separated
cells (Schoefl, 1963; Schor et al, 1983) and it is the
subsequent canalisation of these cords that gives rise to
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new vessels. It is apparent that the stimulating factors
do not operate only on the endothelial cells since other
mesenchymal components (pericytes and fibroblasts) also
proliferate (Molne et al, 1987; Tannock, 1970; Warren et
al, 1972).
The newly formed vessels undergo a process of maturation:
basement membrane is laid down and an adventitial
component is acquired consisting of fibroblasts and
pericytes (possibly derived from medial fibroblasts or
undifferentiated precursors). These also appear to
contribute to the formation of the basement membrane.
Control of this process of recruitment and maturation is
complex and ill-understood, but there is in-vitro evidence
that endothelial cells can produce factors that are
chemotactic for smooth muscle cells (Harris-Hooker et al,
1983), and that Platelet Derived Growth Factor (PDGF)
produced by endothelial cells may induce proliferation of
fibroblasts and smooth muscle cells, both of which bear
PDGF receptors (Barrett et al, 1984, Rubin et al, 1988).
Cellular behaviour is known to be affected by a cell's
relation to its substrate and it has been postulated that
this is achieved by alterations in membrane expression of
growth factor receptors (Gospodarowicz et al, 1978). The
relationship between a cell and its substrate may be
radically altered when it develops the capacity to
synthesise basement membrane; this may be an important
stage in both achieving structural integrity for the newly
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formed vessel and in terminating the proliferative
process. Although the process of maturation described
above is commonly observed in vivo, capillary endothelial
cells do have the capacity to form new vessels in vitro
without the involvement of other cells (Folkman et al,
1980).
Although new vessels may arise predominantly from
intrinsic vascular elements there is evidence to indicate
that the final structure of tumour-associated vessels is
determined in part by the nature of the stimulus.
Defective development of medial and adventitial layers in
vessels in the centre of experimental tumours (as opposed
to those at the periphery) has been attributed to abnormal
blood flow through them (Warren et al, 1966), but in other
studies the pattern that resulted was found to be peculiar
to a given tumour type rather than vessel position (Goodal
et al, 1965). The latter observations, and the finding of
endothelial features similar to those of the kidney in a
metastatic renal carcinoma (Hirano et al, 1972) indicate
that, in the process of neovascularisation, growing
parenchymal cells can effect considerable control over
other cell populations. Nevertheless abnormalities of
maturation might also be attributable, in part, to
acquired defects in the angiogenic cells from which the
new vessels derived.
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Numerous stimuli to angiogenesis have been described.
Implants of intact tissue, both malignant (Goodal et al,
1965; Tannock, 1970; Warren et al, 1966; Warren et al,
1972) and normal (Molne et al, 1987) elicit a vascular
response from appropriate hosts. In some experimental
systems there appears to be a direct relationship between
the capacity of a particular tissue to induce an
angiogenic response and the extent to which the component
cells have been altered by a carcinogenic agent (Maiorana
et al, 1978). A wide range of naturally or virally
transformed cells produce angiogenic factors in vitro
(Klagsbrun et al, 1976; McAuslan et al, 1979) and,
significantly, such cells may still show residual features
of normality (such as density-induced growth inhibition).
These findings emphasise the point that angiogenic
capacity is not restricted to fully transformed or
neoplastic cells. Endothelial growth factors have been
derived from cultures of human gliomas (Hirschberg et al,
1984; Libermann et al, 1987) and from tissue extracts of a
number of human CNS tumours including a single
glioblastoma (Lye et al, 1986). Oligosaccharides derived
from the breakdown of hyaluronic acid have been proposed
as the angiogenic stimulus in diabetic retinopathy (West
et al, 1988) and a similar mechanism may underly the
observed angiogenic capacity of synovial fluid from
non-inflammatory arthropathies (Brown et al, 1983).
Macrophages, both those activated in-vitro (Koch et al,
1986; Leibovich et al, 1987; Ooi et al, 1983; Polverini et
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al, 1987) and those associated with an experimental
sarcoma (Polverini et al, 1984), lymphocytes, either
directly or by activating macrophages (Auerbach et al,
1979), and neutrophils (Fromer et al, 1975) have all been
shown to produce angiogenic substances. The possibility
that endothelial cells play a central role in the
induction and control of the process is strengthened by
the observation that they can utilise serum components to
produce factors that enhance their own growth and that of
other mesenchymal cells in vitro (Gajdusek et al, 1982),
and can induce new vessel formation (Harris-Hooker et al,
1983) in vivo.
Studies of the active components isolated from a variety
of sources have revealed a range of soluble angiogenic
factors with varying properties. In an analysis of
vasogenic agents BenEzra made the useful conceptual
distinction between those that induce the migration of
endothelial cells such as prostaglandins and copper, and
those that induce mitogenesis. He also expressed the
reservation that the demonstration of activity in vitro
was not necessarily associated with equivalent in vivo
activity (BenEzra, 1978).
Tumour Angiogenesis Factor (TAF) was first identified
(Folkman et al, 1971), in a crude tumour extract. Further
purifications yielded a low molecular weight (210kD)
Endothelium Stimulating Factor (ESF) (McAuslan et al,
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1979) which appears to mobilise endothelium by virtue of
the copper it contains but does not actually stimulate
proliferation. Copper, especially in association with
heparin, is a potent stimulator of endothelial cell
migration (Gullino, 1986) and the effect of mast
cell-derived heparin (Azizhan et al, 1980) can be
inhibited by protamine (Taylor et al, 1982) . The action of
copper in vitro can be further enhanced by the presence of
FN which seems to act not as a chemo-attractant but rather
by enhancing cell attachment to the substrate via cell
surface gangliosides. The cumulative effect of a
combination of heparin and FN can be further increased by
using cleavage fragments of both, of the sort likely to be
produced locally by the action of proteases of endothelial
origin (Gullino, 1986) . Evidence that similar interactions
may be operating in vivo is found in the correlation that
is observed between FN levels and endothelial cell
proliferation in healing skin wounds in guinea-pigs (Clark
et al, 1982) .
Endothelial proliferation has been related to the action
of a number of growth factors. These include Endothelial
cell Stimulating Angiogenic Factor (ESAF) (Schor et al,
1983), Fibroblast Growth Factor (FGF) (Gospodarowicz et
al, 1986; Hayek et al, 1987), Epithelial Growth Factor
(EGF) (Schreiber et al, 1986) and Transforming Growth
Factor (TGF) (Schreiber et al, 1986,Folkman et al, 1987).
ESAF, which does not contain copper and requires the
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presence of type I collagen to be effective in vitro
(Schor et al, 1980), has been found with a molecular
weight of 600 in tissue extracts from meningiomas,
neurilemomas and a glioblastoma (Lye et al, 1986). The
requirement for the type of collagen that is typically
associated with interstitial tissues may reflect its role
as a binding site for ESAF, or as a modulating factor
determining, in some way, the expression on the cell
surface of receptors for specific stimulating factors
(Gospodarowicz et al, 1978). During this phase of
proliferation endothelial cell migration will be through
tissue containing type I collagen in contrast to the
resting state when the predominant contact will be with
the type IV collagen of basement membrane. It is therefore
of interest that the production of basement membrane by
maturing endothelial cells in new vessels is enhanced by
contact with type I collagen (Schor et al, 1983) . The
maturation of vessels could therefore be seen to be, in
part, dependent on the concurrent proliferation of
fibroblasts and other cells capable of synthesising type I
collagen and might arguably be delayed if new vessel
formation is taking place into tissues, such as the brain,
which are poor in interstitial collagen. The interplay
between these different factors is obviously complex; it
seems likely that some factors that are capable in their
own right of affecting endothelial cells in vitro may
exert their effect in vivo by stimulating the release of a
final active factor from another cell type. Thus TGF and
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FGF may have more influence by their effect on fibroblast
production of extracellular matrix (Gospodarowicz et al,
1986; Schreiber et al, 1986) or by stimulating macrophages
to release angiogenic factors (Folkman et al, 1987) .
Further examples of such interactions come from studies of
Tumour Necrosis Factor (TNF) which is secreted by
activated macrophages. In vitro TNF is cytostatic for
endothelial and smooth muscle cells and acts as a
non-competitive antagonist of FGF; in vivo it acts as a
vasogenic stimulus by virtue of its capacity to induce a
local inflammatory response (Frater-Schroder et al, 1987).
The role of the extracellular matrix and non-endothelial
cell elements in control of the angiogenic process has
already been mentioned; recent observations have however
suggested that interferons, which are more typically
associated with the cellular interactions and control of
proliferation that take place in the cellular immune
response, may also have a controlling function in
angiogenesis (Sidky et al, 1987). The angiogenic response
to implanted tumour, or to injected lymphocytes, was
inhibited by interferon but the effect was species
specific and was less marked for tumour-induced
angiogenesis. This observation suggested that interferon
was operating by an action on angiogenic factor release
which was more effective on lymphocytes, rather than by




The association of PA secretion with neoplastic
transformation has been discussed in Chapter 1. This
association has been thought to relate to invasive
capabilities conferred on the cell by such secretion
(Pauli et al, 1987). However doubts have been cast on the
significance of PA and its value as a marker of malignancy
by the finding of an inconsistent relationship with the
induced transformed state (Wigler et al, 1976) and by
studies of the mode of action of inducing agents
(Plagemann et al, 1980; Rovera et al, 1977). The latter
studies showed that these acted on basic cell processes
such as differentiation and hexose transport while the
induction of PA appeared to vary as much with cell type as
with development of a transformed state and was probably
epiphenomenal. PA production was shown to be a property of
endothelial cells (Levin et al, 1982; Loskutoff et al,
1977; Soreq et al, 1981; Takashima et al, 1969; Todd,
1959) and could be induced in such cells by the same
tumour promoters shown to act on other cell types.
Furthermore studies on endothelial cells showed that the
matrix degradation and collagenolysis on which the
invasive properties of PA-producing cells were thought to
depend were not dependent on PA production (Laug et al,
1985) .
Two distinct groups of plasminogen activators are
recognised: urokinase (UK), so named because of its
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presence in urine, and tissue associated (t-PA), which has
been isolated from a variety of normal and abnormal
tissues.
UK appears to have two components, with molecular weights
of 31.5kD and 54.7kD (White et al, 1966) . The latter was
originally thought to be a complex of the lower molecular
weight component with an inert carrier protein (White et
al, 1966) but it is now accepted as a distinct heavier
chain (Soberano et al, 1976).
Although estimates of the molecular weight of t-PA vary
between 72kD for human melanoma (Rijken et al, 1981) and
68kD for human uterine t-PA (Rijken et al, 1979) other
estimates have yielded values in the range 52.5 (for pig
heart) to 80kD (Reddy et al, 1980a) and 67kD (Binder et
al, 1979) (for human cadaveric vascular trees). There is
however general agreement that the molecule is separable
into two subunits with molecular weights variously
estimated at 33 and 39kD (Rijken et al, 1981) or 31 and
38kD (Rijken et al, 1979).
Many tumour cells have been found to produce UK in vitro
(Reddy et al, 1980a; Rijken et al, 1981) but studies on
animal and human glial tissues and tumours have yielded
rather confusing results. Normal mouse astrocytes were
found to secrete t-PA (Toshniwal et al, 1987, Toshniwal et
al, 1987a) although in-situ fibrinolytic activity in
rodent and human brain was largely found in endothelium,
choroid plexus and meninges (Soreq et al, 1981; Takashima
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et al, 1969). Short term cultures of both normal and
neoplastic glial tissue yielded fibrinolytic activity
(Wilson et al, 1978) but the cells responsible were not
characterised. Subsequent analyses showed that three out
of four glioblastomas studied produced UK and one produced
a PA that was distinct from UK although again no attempt
was made to characterise the cells responsible for this
activity (Wilson et al, 1980). Cloned cells from a human
glioblastoma, which were S-100 positive and thus thought
to be of neural origin, also produced PA that was distinct
from UK (Tucker et al, 1978). More recently PA activity of
human glioma cell lines has been found to be UK (Dano et
al, 1982) and to correlate with tumourigenicity (Gross et
al, 1988) and studies on short term cultures found PA
activity, not characterised as UK or t-PA, to correlate
inversely with the expression of glial characteristics
(Frame et al, 1984; McLean et al, 1986). In the latter
studies PA was used as a direct marker of malignancy and
in an extension of this PA from wet tissue has been
assayed without characterisation and in the belief that it
is derived from neoplastic cells (Quindlen et al, 1987).
The problem is compounded by the finding that
discrepancies may occur between the type of activator
found in solid tumour tissue and that synthesised by cells
cultured from the same tumour (Markus et al, 1984).
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There appear, therefore, to be several uncertainties:
i) can PA activity alone can be used as an in-vitro marker
of malignant glial cells (Frame et al, 1984; McLean et al,
1986)?
ii) what is the nature of the cells responsible for PA
activity, rather than UK, in cultures from some human
gliomas (Tucker et al, 1978; Wilson et al, 1980)?
iii) what possible sources could there be for this
activity in the original tumours (Quindlen et al, 1987)?
The importance of proteolytic activity in the early stages
of angiogenesis has been mentioned; tissue fibrinolytic
activity was localised to vascular endothelium nearly 30
years ago (Todd, 1959), and subsequently identified in the
endothelium of normal brain vessels (Takashima et al,
1969, Soreq et al, 1981). Few histological studies have
been carried out of the distribution of PA in human
tumours but Kohga and colleagues (Kohga et al, 1985)
compared t-PA with UK in colonic cancer and found the
former in stroma and vessel endothelium and the latter in
tumour cells. The availability of a monoclonal antibody to
t-PA provided an opportunity to combine an examination of
other characteristics of vessel-associated elements in
gliomas with a study of the localisation of t-PA in such
tumours. Such a study was seen as a means of helping to
determine whether t-PA-producing cells in cultures from
human gliomas could have originated from tumour parenchyma
or from elements of the fibrovascular stroma. A series of
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human central nervous system tumours was, therefore,
studied with particular reference to those elements in
malignant gliomas of non-parenchymal origin: proliferating
blood vessels and mesenchymal cells associated with them.
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MATERIALS AND METHODS
The tissue examined in this study derived from diagnostic
specimens received in the Neuropathology Laboratory,
University of Leeds between 1983 and 1987. Fresh tissue
was frozen in isopentane or directly in liquid nitrogen
and examined after storage periods ranging from 36 hours
to 3 years.
When this section of the work was carried out material was
available from four low grade astrocytomas (including one
gemistocytic astrocytoma), 22 malignant astrocytomas, (20
grade IV and 2 grade III), three meningiomas, three
metastases, two pieces of cortex (one normal and one from
vicinity of a malignant astrocytoma), two choroid plexus
papillomas, one ependymoma, one ganglioglioma, one
oligodendroglioma and one astroblastoma.
Cryostat sections were cut at 8y.m, mounted on
poly-L-lysine coated glass slides, air dried overnight and
fixed for 15 min in Acetone. After pre-treatment with
normal goat serum (NGS) diluted 1:5 in Tris buffered
saline (TBS) to block non-specific binding sites sections
were stained for lh with the monoclonal antibody ESP6
(Bioscot, Edinburgh), which recognises cell-associated
t-PA but not urokinase, diluted 1:2 in NGS (diluted 1:20
in TBS) followed by a goat anti-mouse fluorescein
conjugate diluted 1:50 in NGS (diluted 1:20 in TBS).
Double staining was then carried out with a rabbit
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anti-human polyclonal antibody applied for 30 min,
followed by a swine anti-rabbit rhodamine conjugate
(diluted 1:50 in TBS) for 30 min.
One or more of the following polyclonal antibodies were
used for each tumour:
Glial Fibrillary Acidic Protein (GFAP) (Dakopatts; diluted
1:200 in TBS)
Factor 8 Related Antigen (F8RAg) (Dakopatts; diluted 1:100
in TBS)
Fibronectin (FN) (Dakopatts; diluted 1:200 in TBS)
Other sections were double stained with Ulex europaeus 1
lectin (UE1) conjugated with FITC (diluted 1:50 in
phosphate buffer) although for these the t-PA was
demonstrated with a rhodamine rather than a fluorescein
conjugate.
Sections from all tumours were stained with ESP6 and
F8RAg, and ESP6 and UE; sections from the astrocytic
tumours were also stained with ESP6 and Fibronectin, ESP6
and GFAP, vimentin and desmin, in the case of the latter
two antigens using the same monoclonal antibodies detailed
in Chapter 2, double stained with the polyclonal
anti-GFAP. The final preparations were viewed under
fluorescent light using mean exciting wavelengths of 490
nm and 540 nm for fluorescein and rhodamine respectively.
Sections of full-term placental bed were used as positive
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controls for t-PA, EU1 and F8RAg, a glioblastoma provided
positive control for FN, GFAP and vimentin, and human
myometrium was used as a control for desmin staining.
Specificity of UE1 staining was checked by co-incubation
with a 0.1M solution of alpha-L(-) fucose which bound the
lectin and abolished positive staining in the tumour and
control sections.
Western Blot.
To assess the affinities of the ESP6 (Bioscot) antibody a
western blot was performed on an extract of protein from a
glioblastoma multiforme.
The protein extraction was carried out from one gram of
glioblastoma multiforme tissue by grinding the tissue
under liquid nitrogen and then adding 1ml TES buffer (20
mM Tris HC1 ph 7.8, 90 mM NaCl, 1 mM disodium EDTA)
containing 0.1% Triton X100. The resulting homogenate was
covered with a thin layer of liquid paraffin and
centrifuged at 40000 rpm for lh at 4°C.
Protein separation was by discontinuous SDS gel
electrophoresis (Laemmli, 1970) using 10% polyacrylamide
gels with duplicate lanes of test material and molecular
weight standards (12.3, 18.4, 25.7, 43, 68, 92, and
200kD). The separated proteins were visualised with
Coomassie blue and the test material transferred by
blotting to nitrocellulose sheet (Towbin et al, 1979).
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Final visualisation was with a three layer
immunoperoxidase method using repeated washes of the
diluting buffer (Tris buffered saline - TBS) between
stages:
i)Non-specific binding sites were blocked by pre-treatment
with normal goat serum (NGS) diluted 1:5 for lh at 37°C
ii) Mouse monoclonal antibody ESP6, diluted 1:5, for 2h at
room temperature
iii) Rabbit-anti-Mouse IgG, diluted 1:50, for 45 min at
room temperature
iv) Goat-anti-Rabbit Peroxidase (Biorad), diluted 1:500,
for 45 min at room temperature.
v) Develop in 4-chloro-napthol.
From a plot of log Molecular Weight against distance
migrated by the known standards and direct measurement of
the distances migrated by bands stained on the blot the
molecular weights of the stained proteins were calculated.
Tissue cultures
As an adjunct to the studies carried out on the tissue
sections described above cell preparations from two high
grade astrocytomas were also examined immuno-
histochemically for t-PA activity. The methods used were
identical to those described for the tissue sections with
the exception that fixation was with ethanol/ether as
described in Chapter 2. The cultures derived from material
already described in the previous section and consisted of
- 128 -
explants from one case after 8 days in primary culture and
two preparations from a different tumour 8 days after
first passage and a total of 28 days in-vitro.
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RESULTS
The nitrocellulose blot demonstrated four bands of
reactivity (fig.3.1): a very faint one at 72kD, a defined
band at 55kD, and two less defined bands centred on 41 and
3 lkD.
Control sections from placenta stained for t-PA showed
variable staining of villous trophoblast, consistent
staining of extra-vi1lous trophoblast and patchy staining
of the vascular endothelium (fig.3.2). In contrast only
the endothelium showed staining for F8RAg or with UE1 (the
latter staining being abolished by prior incubation with
fucose (fig.3.3)).
Malignant gliomas and normal or adjacent brain
Parenchymal cells
Process-bearing cells constituted the majority population
in most of these tumours and in general the expression of
intermediate filaments was far greater in the processes
than in the cell bodies.
All the tumours examined expressed GFAP in the majority of
the cell processes and similar expression of vimentin was
also found (fig.3.4). Desmin was much less widespread but
was present in some stellate cells in most tumours
(fig.3.5). This was in marked contrast to the intense
expression found in three desmoplastic lesions (see
below).
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Fig.3.1 Western blot of protein extract from glioblastoma
multiforme (left) showing bands at 55kD, 41kD and
31kD. Right hand strip shows protein of standard
molecular weights. See text for interpretation.
Fig.3.2 (left) Placental bed showing UE1 staining of
endothelium (green) and t-PA (orange) in
extra-villous trophoblast and endothelium
(beneath surface UE1 reaction). Cryostat section,
direct EUl, monoclonal anti-t-PA, x520
Fig.3.3 (right) Placental bed showing no reaction of
endothelium with UE1 after preincubation with






Fig.3.4 The distribution of vimentin (left) corresponds
with that of GFAP (right) except where cell
processes extend into the perivascular zone
(arrow). High grade astrocytoma, cryostat
section, polyclonal anti-GFAP, monoclonal
anti-vimentin, x520
Fig.3.5 Process-forming glial cells stain strongly for
desmin (arrow). High grade astrocytoma, cryostat
section, monoclonal anti-desmin, x520
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Interposition of cell processes into FN+ areas associated
with blood vessel walls was common but, while they usually
stained for GFAP, staining for vimentin was much less
consistent (fig.3.4); only very occasionally were single
FN+ cells, that did not form small channels, seen outside
the confines of vascular areas (fig.3.6). Such cells did
not express GFAP or F8RAg.
Stellate astrocytes in normal and infiltrated cortex
stained with GFAP, vimentin and sometimes with desmin,
although cells whose size and arrangement suggested a
neuronal nature also showed faint staining with desmin.
The presence of t-PA in tumour cells (expressing GFAP) was
found in only one Grade IV astrocytoma (fig.3.7a) which
was characterised by plentiful giant cells (fig.3.7b)
although the reaction did not seem to be limited to them.
In a few tumours occasional single round cells, lacking
processes and not staining with GFAP, showed intense
staining for t-PA (fig.3.8).
Endothelium
The cells lining blood vessels showed uniform positive
reaction of the cell surface with UE1. Both the basal and
luminal surfaces of the lining endothelium stained with FN
(fig.3.9) although basal staining was often much stronger.
Reaction for F8RAg was generally granular and cytoplasmic
(fig.3.9) although in the larger vessels, typically those
not associated with glomeruloid proliferations, which may
in some cases have been pre-existing vessels in
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Fig.3.6 Small FN+ profiles adjacent to a blood vessel
(arrows) could be single cells, or, more likely,
small vascular sprouts. High grade astrocytoma,
cryostat section, monoclonal anti-FN, x520
Fig.3.7 (left) Glioblastoma multiforme showing focal t-PA
reactivity which is predominantly on cell
surfaces. Cryostat section, monoclonal anti-t-PA,
x520
(right) Same tumour showing plentiful giant cells,
although the t-PA reactivity corresponded more
with the smaller cells. Cryostat section, H&E,
x200
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Fig.3.8 Single cell in tumour parenchyma staining strongly
for t-PA. High grade astrocytoma, cryostat
section, monoclonal anti-t-PA, x520
Fig.3.9 Small tumour vessels show closely corresponding
staining for FN (left) and F8RAg (right). One
small vessel (arrow) shows staining with FN but
not F8RAg. High grade astrocytoma, cryostat
section, polyclonal anti-F8Rag, monoclonal
antiFN, x520
Fig.3.10 Vimentin is present in the thin endothelium
(arrow) of a relatively large vessel. High grade




infiltrated brain, expression was more restricted to the
luminal surface. There was usually co-expression of F8RAg
and FN in identifiable vascular structures (fig.3.9)
although occasional small channels visible as slits with
FN+ lining were F8RAg-. Cells in these areas were also
positively stained with UE1.
In sections that were clearly derived from the interface
between infiltrating tumour and brain there was a
noticeable reduction in FN staining in the walls of
residual normal cerebral vessels when compared to the new
vessels of the tumour, and F8RAg was more consistently
restricted to the luminal surface. Vimentin expression
varied with vessel size and was generally more obvious,
and sometimes restricted to, larger vessels with thinner
endothelium (fig.3.10). As a consequence many small
vessels composed (presumably) solely of endothelial cells
were negative for vimentin. In all cases the vimentin
content of the tumour was generally greater than that of
the endothelium.
No desmin positivity was recorded in any cells
identifiable by location or staining reaction as
endothelial.
In all the tumours examined, reactivity for t-PA, when
present, was clearly localised in vascular endothelium,
which was identified by co-expression of F8RAg or FN, or
UE1 staining, although the intensity of staining varied
from case to case. The staining was of a granular or
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punctate appearance, distributed largely within the cell
cytoplasm although some surface activity was also
resolvable (fig.3.11).
In 17 Grade IV and both Grade III astrocytomas (86% of
high grade tumours) vascular staining for t-PA was strong
and uniform and particularly easy to see in the
hyperplastic endothelial cells of proliferating
glomeruloid clusters of vessels (fig.3.12). In two Grade
IV astrocytomas strongly and weakly stained vessels
co-existed, and in one Grade IV tumour only occasional
vessels stained.
In the cortical specimen adjacent to a Grade III
astrocytoma the majority of vessels stained strongly
although they were not obviously hyperplastic (fig.3.13);
in contrast the specimen of normal cortex showed generally
very weak staining in numerous small vessels although
stronger reaction could be detected in the few larger
vessels (fig.3.14).
Perivascular structures.
In larger clusters of tumour vessels a pale halo of FN+
tissue could be seen (fig.3.15) around individual vessels.
The interposition of cell processes into this zone has
already been commented on. This area was consistently
F8RAg-.
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Fig.3.11 Double exposure demonstrating t-PA (green), which
is predominantly cytoplasmic, in the lining
endothelium of small blood vessels, distinct from
GFAP (orange) containing tumour cells. High grade
astrocytoma, cryostat section, monoclonal
anti-t-PA, polyclonal anti-GFAP, x660
Fig.3.12 Two photomicrographs of the same field showing a
cluster of proliferating blood vessels in a
glioblastoma multiforme staining with UE1 (left),
and anti-t-PA (right). Note exact correspondence
of the two staining patterns which show
restriction of reactivity to endothelial cells.
Cryostat section, direct UE1, monoclonal
anti-t-PA, x660
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Fig.3.13 Vessels from brain adjacent to an infiltrating
grade III astrocytoma show uniform staining with
UE1 (left) and strong granular staining for t-PA
(right). As in tumour vessels (3.12) the two
staining patterns correspond. Cryostat section,
direct UE1, monoclonal anti-t-PA, x660
Fig.3.14 Large and small vessels from normal brain show
similar degrees of staining with UE1 (left) but
t-PA (right) is less obvious in the small vessel
(arrow) in the centre of the field. Cryostat
section, direct UE1, monoclonal anti-t-PA, x660
Fig.3.15 Endothelium lining small vessels shows strong
fibronectin staining, but a weaker halo can be
discerned in the surrounding cuff of mesenchyme
(arrow). High grade astrocytoma, cryostat
section, monoclonal anti-FN, x520
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In three tumours in which a desmoplastic reaction was
identified the perivascular zone was greatly expanded and
stained much more strongly for FN. The degree of
interposition by tumour cell processes was far less and
islands of FN- parenchyma were separated by strongly
stained mesenchymal zones. In these areas however F8RAg
expression was restricted to the cells lining vessels and
there was no evidence that they formed a component of the
desmoplastic tissue.
The most striking feature of these three tumours was the
strong positivity for desmin (fig.3.16) which contrasted
with the inconstant staining seen in non-desmoplastic
tumours. It was not possible to identify an increase in
vimentin or GFAP staining in these zones since both
intermediate filaments were present in considerable
amounts in most tumours examined (see above).
Low grade astrocytomas
Parenchyma
All these tumours showed GFAP+ cell bodies and processes
and vimentin positivity was more obvious in cell
processes. Interposition of cell processes into
perivascular areas was limited to the gemistocytic tumour,
but this may have been a reflection of the paucity of
vascular structures in most tumours of this grade. None of
the GFAP+ cells stained for either FN or t-PA.
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Fig.3.16 Double exposure of a desmoplastic glioblastoma
showing intense staining of tumour parenchyma for
desmin (orange) contrasted with the vascular and
fibroblastic elements which stain for fibronectin
(green). Note the relatively small degree of
interposition of tumour processes into the
desmoplastic areas. Cryostat section, polyclonal





In low grade tumours the appearances of the vasculature
more closely resembled that of normal brain than that of
the malignant tumours, in that FN staining was generally
weaker and in one case was confined to the luminal surface
of vessels. F8RAg was likewise more likely to be
restricted to the luminal surface but this was not a
consistent finding and some vessels showed the patterns
described above of strong staining for fibronectin and
diffuse cytoplasmic F8RAg. UE1 positivity was identifiable
on the surface of all endothelial cells but vimentin
positivity was more frequent than in malignant lesions.
In contrast to the findings in high grade tumours staining
for t-PA was absent in three (fig.3.17) and only barely
detectable in the gemistocytic tumour. The difference
between the proportion of high grade tumours (86%) and of
low grade tumours (0%) showing strong vascular staining
was highly significant (95% Confidence Limits 72%, 100%;
p=0.003, X2 test).
Perivascular structures
These were poorly developed in the low grade tumours;
although in two cases, the gemistocytic lesion and one
other, there was a defined zone of strong staining for
fibronectin surrounding the endothelial layer, in the
other two lesions this area was represented only by a halo
which stained faintly for FN.
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Fi-g.3.17 A thin walled blood vessel from a low grade
cerebral astrocytoma shows defined staining of
the endothelium with UE1 (left) but no
corresponding staining for t-PA (right). Compare





Staining in these was limited to UE1, F8RAg and t-PA.
UE1 positivity was restricted to endothelium in all cases
except the three metastases (see below) which showed
strong staining of the cell surface of the majority of
tumour cells, and two meningiomas which showed focal
positive tumour cell staining. F8RAg staining was entirely
restricted to the surface and cytoplasm of vascular
endothelium.
t-PA staining
Other gliomas: Uniform strong endothelial staining for
t-PA was seen in the ganglioglioma and one choroid plexus
papilloma (fig.3.18); mixed strong and weak endothelial
staining was seen in the astroblastoma, the ependymoma
(fig.3.19) and one choroid plexus papilloma; the
oligodendroglioma showed uniformly weak reaction.
In one choroid plexus papilloma and the oligodendroglioma
scattered single cells, similar in size and shape to those
seen in a few malignant gliomas, showed strong positive
staining; in the oligodendroglioma these cells were
restricted to an area in which macrophages were present,
and in the choroid plexus papilloma the pattern of
staining also suggested that non-tumour cells were
reacting.
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Fig.3.18 Vessels from a choroid plexus papilloma show
granular endothelial staining for t-PA. Cryostat
section, monoclonal anti-t-PA, x520
Fig.3.19 Vessels in an low grade ependymoma show defined
staining of the endothelium with UE1 (left) but
no corresponding staining for t-PA (right).
















Meningiomas: two of these showed no reaction for t-PA and
one showed a few faintly stained vessels. The latter
lesion also showed focal staining of tumour cells around
psammoma bodies.
Metastases; two showed strong endothelial staining for
t-PA although in one (an adenocarcinoma) the vessels
showed little UE1 positivity; a similarly weak reaction
for UE1 was seen in the third, completely anaplastic,
tumour with very weak staining for t-PA. By contrast
tumour cells in all three showed strong uniform surface
staining with UE1 but no t-PA reaction (fig.3.20).
Cell culture preparations
In all these t-PA staining was weak, although above the
background level; it did not however compare in intensity
with that observed in the endothelium in tissue sections.
In the explant specimens a typical pattern of growth was
observed: GFAP+ cells comprised the explant with a
population of smaller flattened GFAP- cells growing from
one edge. As in the cultures described in detail in
Chapter 2 the GFAP- cells corresponded morphologically to
FN+ cells. GFAP+ cells showed no t-PA staining but FN+
cells showed a weak positive reaction (fig.3.21).
As expected the passaged cultures consisted largely of FN+
cells with only occasional residual GFAP+ cells. There was
weak co-expression of t-PA on FN+ cells but not on GFAP+
cells (fig.3.22).
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Fig.3.20 Two photomicrographs of the same field of an
anaplastic metastatic carcinoma show that t-PA is
focally present in vascular endothelium (left)
but not in tumour cells, whereas UE1 (right)
stains tumour cells but not the endothelium.




Fig.3.21 Weak t-PA reactivity (left) in cells from a high
grade astrocytoma after 28 days in vitro is
restricted to FN+ FA cells (right). Polyclonal
anti-FN (orange), monoclonal anti-t-PA (green) ,
x520
Fig.3.22 t-PA reactivity (left) in first passage cells from
a high grade astrocytoma after 28 days in vitro
is restricted to FN+ FA cells (right). Polyclonal





The co-distribution of the intermediate filaments GFAP and
vimentin in the parenchymal cells of the astroglial
tumours irrespective of grade is in accord with the
findings of previous studies (Herpers et al, 1986;
Schiffer et al, 1986; Yung et al, 1985) although a greater
degree of cell body staining has been found using an
immunoperoxidase technique (Schiffer et al, 1986).
The finding of occasional cells staining for desmin was to
be expected given the finding of desmin in normal
astrocytes by Dahl and co-workers (Bignami et al, 1985;
Dahl et al, 1982; Dahl et al, 1986) but the high levels of
expression in the cells of desmoplastic tumours requires
some explanation. Given the comments made earlier about
the differing specificities of monoclonal antibodies to
desmin and the possibility that desmin from different
sources may differ antigenically one should concentrate on
the distinctive pattern of expression in this group of
tumours rather than the specific nature of the
intermediate filament. The stimulus to desmoplasia in
glial tumours is not always clear but it may be found when
glial tumours infiltrate the meninges, or, in a few cases,
may develop from what appears to be an essentially
perivascular fibroblastic proliferation. The effect on
GFAP expression of the proximity to mesenchymal elements
has already been referred to; the finding of greater
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staining for GFAP than for vimentin in cell processes
interposed into perivascular structures and the expression
of desmin in desmoplastic lesions could be seen as further
examples of such an effect. The alternative explanation
that those tumours that express desmin are also the source
of a stimulus to fibroblast proliferation remains possible
but seems less likely. In vitro studies of cells of known
glial nature and the effect on intermediate filament
content of exposure to cellular and matriceal components
of mesenchyme might provide further insights into this
phenomenon.
The differential staining reactions of the vascular
endothelium for UE1 and F8RAg in all the primary tumours
studied showed that such structures are more consistently
stained by Ulex lectin than by anti-F8RAg, especially in
smaller vessels. This observation confirms the greater
sensitivity of UE1 for identifying vascular endothelial
cells in a variety of tissues including skin and
cerebellum (Holthofer et al, 1982), thyroid carcinoma
(Stephenson et al, 1986), benign and malignant vascular
neoplasia (Leader et al, 1986; Little et al,1986), and
cerebral tumours (BohJing et al, 1983; Slowik et al, 1985;
Weber et al, 1985).
The tendency for F8RAg in astroglial tumours to be
restricted to the luminal surface in larger, apparently
non-proliferating, vessels and to show cytoplasmic
staining more frequently in the vessels of malignant
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lesions may reflect the greater synthesis of F8RAg that
has been postulated to occur in proliferating vessels
(Miyagami et al, 1987) . The latter study found
ultrastructural localisation of F8RAg in dilated cisternae
of the endoplasmic reticulum in vessels from six out of
seven malignant tumours but only one of five benign
lesions.
The staining of non-endothelial cells by UE1 has been
described previously. Normal squamous epithelium in the
skin (Holthofer et al, 1982), squamous carcinoma (Leader
et al, 1986; Weber et al, 1985) and carcinomas of
prostate, large bowel and endometrium have all been found
to stain (Leader et al, 1986) but without any consistency.
Although this study did not set out to examine the value
of UE1 reactivity in the diagnosis of tumours the pattern
observed in the three metastases is of interest in the
light of the observation that staining of breast
carcinomas with UE1 correlates with outcome (Fenlon et al,
1987) and might repay further study using both cryostat
sections and paraffin processed tissue.
With one exception (Kennedy et al, 1987) previous reports
of FN localisation in human gliomas have indicated that it
is restricted to vascular or mesenchymal structures
(Chronwall et al, 1983; Kochi et al, 1983; Paetau et al,
1980; Schiffer et al, 1984). This was the case in all the
astroglial lesions in the present study, FN being
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restricted to endothelial cells, identified by UE1
staining, or to perivascular zones corresponding to areas
of vascular or fibroblastic proliferation. The identity of
the small number of FN+/GFAP- cells is not obvious. They
could be macrophages which have been reported to secrete
FN (Rennard et al, 1981) or represent tangentially cut
small vessels. The possibility that they represent a sub
population of neoplastic glial cells cannot be completely
ruled out but seems unlikely on morphological grounds. It
is noteworthy that no cells were seen that co-expressed
GFAP and FN. The greater FN staining that was observed in
vessels in malignant astrocytic tumours when compared to
those in normal brain and low grade astrocytomas is in
keeping with the known increase in local FN production by
proliferating vessels (Clark et al, 1982). The associated
observation that there seemed to be less vimentin
expression in putatively proliferating endothelium is of
interest; it may point to there being a functional
association between cell mobility and intermediate
filament expression as has already been suggested to exist
in glial cells (Duffy et al, 1982).
The monoclonal antibody used to demonstrate t-PA in this
study was raised against human melanoma t-PA which has a
MW of approx 72kD (Rijken et al, 1981) and appears to be
similar to, if not identical with, uterine t-PA which
itself appears to be closely related to vessel-associated
PA (Ogston, 1983; Rijken et al, 1980). In the present
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study it would seem from the nitrocellulose blot that,
under the conditions of extraction used, the majority of
t-PA in the sample glioblastoma was in the form of two
subunits with molecular weights 41 and 31kD, corresponding
to previous published findings and a parent molecular
weight of 72kD. The weakness of the reaction at 72kD would
be in keeping with this interpretation. The nature of the
substance reacting at 55kD is not clear; its molecular
weight would be consistent with its being a species of
t-PA but further studies would be needed to confirm this.
This study shows minimal tumour cell positivity for t-PA
in a wide range of human nervous system tumours which is
in sharp contrast to the predominant localisation in
endothelium. The pattern of cellular distribution also
differs, with granular/punctate positivity in endothelium
and uniform surface reactivity in the few parenchymal
cells that reacted. These findings are consistent with
some of the activity being lysosomal in endothelial cells,
as found in other species and tissues (Ali et al, 1965),
and the finding that in-vitro tumour cell PA is membrane
associated (Quigley, 1976).
The fact that only one Grade IV astrocytoma showed tumour
cell positivity may reflect the production of
cell-associated t-PA in a form not recognised by the
antibody used, or may indicate that the bulk of activity
measurable in wet tissue is in fact derived from vascular
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endothelium. The staining of cells that could have been
macrophages in two tumours would accord with the
observation that, with appropriate stimulation, PA
activity can be induced (Unkeless et al, 1974) although
the number of such cells that express t-PA is small when
compared to the numbers found with more specific
macrophage markers (see Chapter 4).
The finding that t-PA is largely localised in the
endothelium of malignant gliomas and some non malignant
tumours is not totally unexpected but it highlights the
danger of interpreting in-vitro results without knowledge
of tissue localisation. From these results it will be
apparent that biochemical studies of t-PA levels in tumour
specimens will have to take account of tumour vascularity
or else demonstrate clearly that the t-PA under study is
not localised in vessels.
The degree of staining observed in the cell culture
preparations bore no comparison with the intensity of
staining seen in tissue sections. Sections stained for
t-PA after fixation with ethanol/ether showed no
discernible difference from those fixed with acetone
confirming that the poor cellular staining was not the
result of fixation differences. It is possible that the
discrepancies reflect the fact that in vitro most t-PA is
secreted into the medium where it will be measureable by
its fibrinolytic action (Frame et al, 1984; Freshney et
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al, 1985; Hince et al, 1980; McLean et al, 1986) rather
than retained in the cell cytoplasm where it would be
identifiable immunohistochemically. Endothelial cells in
vitro have been found to synthesise an inhibitor of t-PA
in vitro as well as the active protease and it is
conceivable that such a product could bind to those sites
on t-PA that were recognised by the ESP6 antibody.
Whether the form of t-PA observed in this study has a role
in nervous system tumour cell invasion is questionable.
Identification of other immunologically distinct PAs, such
as those studied in colonic carcinomas (Kohga et al,
1985), might reveal secretion by tumour parenchymal cells
in gliomas. The finding that t-PA was present in brain
vessels adjacent to tumour indicates that its production
is an intrinsic property of endothelium which is enhanced
when it is stimulated to proliferate by tumour
angiogenesis factors. A purified Fibroblast Growth
Factor-like substance derived from a human hepatoma cell
line has recently been shown to promote angiogenesis in
vivo and induce PA activity, enhance DNA synthesis and
promote motility in confluent bovine endothelial cells
(Presta et al, 1986). Lymphokines have also been shown to
have a similar inductive effect on endothelium (Tiku et
al, 1985).
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These observations provide support for the view that the
phenotypically transformed t-PA and FN producing cells
derived in-vitro from human malignant gliomas are of
vascular origin and are responding to factors produced by
neoplastic glial cells (Franks et al, 1986; Jacobsen et
al, 1987; McKeever et al, 1987; Manoury, 1977; Rutka et
al, 1987a). Cells derived in vitro from human gliomas have
been found to secrete an Endothelial Cell Growth
Factor-like polypeptide (ECGF) (Libermann et al, 1987)
and, more significantly, to possess specific receptors for
ECGF. Whilst this may be interpreted variously as a
non-specific mechanism for autocrine growth stimulation in
neoplastic cells or as a possible mechanism whereby new
vessel formation is induced by malignant gliomas, it could
be interpreted as evidence for an endothelial origin for
the cells concerned. Clearly a study of receptor
expression and growth factor production by endothelium,
both neoplastic, reactive and normal, from other tissues
and the response of cultured cells to glioma-derived
factors is required to address this problem in more
detai1.
The failure of the vessels of the majority of low grade
astrocytomas to show t-PA activity raises the possibility
that this phenomenon could be utilised in grading of these
tumours although this would need examination of larger
numbers of cases and of intermediate forms. Vascularity of
malignant gliomas, and in particular aberrant vascular
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proliferation, has been found to correlate with a poorer
prognosis (Cohadon et al, 1985; Fulling et al, 1985) and
there might be profit in attempting to correlate t-PA
activity with outcome. It should however be stressed that
any correlation that was found would be likely to simply
reflect the greater degree of new vessel formation that
occurs in malignant tumours. Some indirect support for a
correlation comes from the finding that the only
gemistocytic tumour in this series showed vascular
staining for t-PA which resembled that of the majority of
high grade tumours despite its lack of histological
malignancy; gemistocytic tumours have been held to have a
poorer prognosis with a high conversion rate to
glioblastomas (Rubinstein, 1972; Schiffer et al, 1988).
The important role of the extra protease and FN produced
by activated endothelial cells in the process of
angiogenesis is underlined by the observed pattern of
staining for t-PA and FN in the vessels of high grade
gliomas.
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Conclusions from in vivo studies
This section of the work has failed to identify cells in
the parenchyma of astroglial tumours that show the
phenotypic characteristics of the FN+ FA cells derived in
vitro from such tumours. With the exception of one grade
IV tumour, t-PA expressing cells were restricted to
vascular endothelium where they also expressed FN. The
possibility that cells of vascular origin, stimulated by
factors present in glial tumours, may be capable of
overgrowth in culture with phenotypic features interpreted
as neoplastic therefore receives support.
The exuberance of the proliferative vascular response in
routine sections from many glioblastomas suggests that the
component cells of cerebral vessels differ in their
responsiveness or are subject to a stimulus that differs
at least quantitatively from that provided by other
(non-glial) tumours. This would appear to reflect the
greater angiogenic stimulus provided by malignant glial
cells (Freshney et al, 1985) and cells subject to such a
stimulus in vivo might be capable of preferential survival
in culture with the phenotypic properties described. Such
cells are not restricted to cultures from malignant
tumours, and their appearance in cultures from some low
grade lesions suggests that a stimulus deriving from
malignant glial cells may not be the only factor involved.
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This prompts consideration of other possible sources of
angiogenic stimuli in astroglial tumours. Lymphokines can
induce endothelial t-PA (Tiku et al, 1985) and lymphocytes
(Auerbach et al, 1979) and macrophages (Leibovich et al,
1987; Martin et al, 1981; Polverini et al, 1984), either
independently or in concert, can provide an angiogenic
stimulus. The possibility that such cells might have a
bearing on the isolation in vitro of altered vasogenic
cells led to a consideration of the cellular immune
response to glial tumours.
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CHAPTER 4. INTER-RELATIONSHIPS BETWEEN CELLS OF THE IMMUNE
SYSTEM, TUMOUR CELL PROLIFERATION AND GROWTH FACTOR
RECEPTOR EXPRESSION.
INTRODUCTION
Interest in the body's immune response to glial tumours
has derived its impetus from the hope that a natural
response to abnormal cells might be exploited
therapeutically. Example of such studies have included the
effect of the lymphokine leukoregulin on human glioma
cells in-vitro (Merchant et al, 1986a) and the potential
use of a monoclonal antibody against glioma cells that was
also able to complex with liposomes which could deliver
drugs directly to tumour cells (Yoshida et al, 1987).
Comparable in-vivo work has examined the use of a
monoclonal antibody to inhibit growth of experimental
grafts of a rat glioma (Stavrou et al, 1986), the direct
injection of stimulated autologous lymphocytes into
tumours (Ingram et al, 1987) and the use of systemic
interferon in humans with malignant gliomas (Boethius et
al, 1983). In the latter study, in which only one patient
appeared to benefit and even then not clearly as a result
of therapy, it was noteworthy that there was no
correspondence between the response of tumour cells to the
agent in vitro and the response of the same tumour in
vivo. Intratumoural antigenic heterogeneity and the rarity
of tumour-specific antigens that are not also expressed by
some normal cells have been identified as major
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difficulties in this approach to therapy (Colnaghi et al,
1988).
Detailed examination of the immune response to glial
tumours has revealed complex cellular interactions. Among
the possibilities that have to be considered are not only
i) an inhibitory effect of immune cells on tumour cells
but also ii) an inhibitory effect of tumour cells on
immune cell function, iii) the production of specific
factors by glioma cells that protect against an immune
response, iv) the enhancement of an immune reaction by
tumour cells and v) a stimulatory effect of the immune
response on tumour cells.
i) Do immune cells inhibit tumour cell growth?
Peripheral circulating lymphocytes taken post-operatively
from patients with malignant glial tumours can be induced
in vitro to kill cells derived from the tumours only when
subjected to prior stimulation with Interleukin-2 (IL-2)
(Jacobs et al, 1986). It is of note that such killing was
not restricted to autologous cells suggesting that the
mechanisms may be non-specific although initiated by an
immune interaction. This interpretation is supported by
the observation that non-specifically activated
lymphocytes release factors in vitro that inhibit DNA and
RNA synthesis in glioblastoma cell lines irrespective of
the patient's immune status or even whether or not a glial
tumour was present (Merchant et al, 1986). In the latter
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study the factors that were inhibitory to neoplastic glial
cells also appeared to both stimulate and induce
differentiation in fetal rat glioblasts, emphasising that
the observed effect of any interactions between immune and
glial cells will also depend on the susceptibility of any
target cells to any factors that are produced by such
interactions.
ii) Can tumour cells have an inhibitory effect on immune
cell function?
Studies that have pursued the question of why autologous
lymphocytes from patients with malignant gliomas
frequently fail to kill cells from such tumours in-vitro
(Gately et al, 1982) have directed attention to inhibitory
factors produced by the tumour cells. The lymphocytes
appear to have a reduced proliferative response to stimuli
that would normally evoke proliferation (Elliot et al,
1984; Miescher et al, 1988); such proliferation as does
occur is associated with lower than expected levels of
production of the lymphokine IL-2 (Elliot et al, 1984;
Elliot et al, 1987; Elliot et al, 1987a) and lymphocytes
also bear fewer surface receptors for IL-2 (Elliot et al,
1987). A number of factors produced by glioblastoma cells
have been identified as being responsible for these
effects including Prostaglandin E2 (Lauro et al, 1986) and
larger molecules with molecular weights variously reported
as 97 (Fontana et al, 1985), 25 (Roszman et al, 1987) and
12.5kD (Wrann et al, 1987). The latter factor showed
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homology with 8 out of the first 20 amino acids in
Transforming Growth Factor (TGF) and may be the active
component in the larger molecular weight fractions
reported. Studies of inhibitory factors produced by
non-glial tumours have demonstrated a close homology of a
19kD protein with the pl5E fragment of a retrovirus
envelope (Cianciolo et al, 1986) raising the possibility
that an oncogene is involved. Further speculation along
similar lines (Normann, 1985) has suggested that the
immunosuppression observed in relation to certain tumours
may be the result of the activation (in both immune and
neoplastic cells) of mechanisms evolved to reduce the
immune response to the developing fetus. Such a process
could be locally initiated by macrophages attracted to the
tumour and subsequent events are then the inevitable
consequence of activation of intrinsic mechanisms in which
the tumour is not only the inadvertent initiator but also
the unintended beneficiary. Reports of a more generalised
impairment of immune function in glioma patients include a
degree of cutaneous anergy proportional to tumour grade
(Mahaley et al, 1977), the finding of a reduced ratio of
helper to suppressor subtypes of peripheral blood T
lymphocytes (Bhondeley et al, 1988; Bullard et al, 1986;
Uegaki et al, 1988) and reduced lymphocyte mitogen
sensitivity (Blom et al, 1985). The influence of therapy
in these studies varies and others have attributed the
observed changes to secondary effects of disturbances of
the brain-pituitary-endocrine axis on immune function
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(Uegaki et al, 1988). This is supported by series in which
no differences from normal are found except in cases with
tumours so located that hypothalamic function might have
been interfered with (Palma et al, 1987).
iii) Do glioma cells produce specific factors that protect
against an immune response?
The observation that some glial tumours appeared to have
very few infiltrating lymphoid cells (in contrast to
others which had many) led to the suggestion that
sialomucins secreted by the tumour may inhibit the
development of a specific immune response to tumour
antigens (Ridley et al, 1971; Stavrou et al, 1977). More
direct in-vitro analysis demonstrated the production of a
hyaluronidase-sensitive coating around some glioma cells
which physically interfered with contact by surrounding
lymphocytes (Gately et al, 1982). This coating seemed to
reduce the capacity of the cells to evoke a non-specific
cytolytic response from autologous and allogeneic lymphoid
cells. Its secretion could also be stimulated by factors
in the supernatant from mixed lymphocyte reactions but
glial cells from later passage cultures (Oberc-Greenwood
et al, 1986) were no longer capable of its production,
possibly because selection of cells had resulted in the
loss of genuine glial elements.
- 164 -
iv) Can tumour cells enhance an immune reaction?
Interleukin-1 (IL-1) is secreted by macrophages as part of
the response to interactions between macrophages and
lymphocytes that follow the presentation of antigen by the
former to the latter (Roitt et al, 1985). One of its main
functions in this context is to stimulate the
proliferation of lymphocytes with immune specificity to
the presented antigen. Normal rat (Fontana et al, 1984;
Frei et al, 1985; Frei et al, 1986) and neoplastic human
astrocytes (Fontana et al, 1984; Fontana et al, 1985)
produce interleukins which enhance lectin-induced
mitogenesis in lymphoid cells (Fontana et al, 1984) and
can directly induce macrophage proliferation (Frei et al,
1986). With the evidence that anti-proliferative factors
are produced by astroglial cells the net effect may depend
on the balance existing in a tumour between stimulating
and inhibiting factors; conflicting findings relating
immune status to clinical outcome may reflect the fact
that such a balance may change with time thus complicating
interpretation.
v) Can an immune response enhance tumour cell growth?
As stated above glioblastoma cells produce interleukins,
and both fetal rodent astrocytes (Giulian et al, 1985) and
a human glioma cell line have been reported to show a
proliferative response to IL-1 (Lachman et al, 1987).
There is a considerable body of evidence concerning the
capacity of macrophage-produced factors to enhance,
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promote or stimulate tumour growth. Although much of this
stems from studies of an experimental murine fibrosarcoma
(Currie, 1981; Evans, 1977, 1978, 1984; Evans et al, 1984;
Evans et al, 1984a) which may have had singular properties
and growth requirements, Tumour Necrosis Factor (TNF),
which is of macrophage origin, has been shown to act as a
growth factor in chronic B-cell malignancies in humans
(Cordingley et al, 1988). Macrophages are probably present
in varying amounts in most tumours and a 12kD factor has
been identified in supernatants from experimental and
human tumour cell cultures that is chemo-attractant to
macrophages (Botazzi et al, 1983). The finding that
embryonic fibroblasts (both human and murine) also
produced the factor suggests that it is part of a
fundamental process of cellular interaction rather than a
phenomenon associated with the neoplastic state. The
attraction of macrophages to tumours gains some importance
with the suggestion that they may play a role in
determining the onset of neovascularisation and thus an
accelerated rate of growth (Folkman, 1984). The direct
involvement of macrophage-derived factors in angiogenesis
has already been mentioned in Chapter 3.
The possibility that neoplastic glial cells may derive a
positive stimulus to growth from factors secreted by cells
of the immune system receives some support from
observations of the expression of certain surface proteins
by tumour cells.
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The expression of Major Histocompatibility Complex (MHC)
Antigens by tumour cells
Some interactions between cells of the immune system are
dependent on the presence of a class of surface antigens
of the Major Histocompatibility Complex (MHC). The MHC
gene is located on chromosome 6 and encodes for a series
of surface proteins which in combination are unique to the
individual; because of their original discovery in the
context of transplant matching using leucocytes these were
originally termed Human Leucocyte Antigens (HLA).
The gene coding for these proteins is divided into five
regions:
Three of these, A, B and C, code for MHC Class I proteins
which are expressed on the surface of all nucleated cells
and are concerned with the recognition of self and
non-self cells, the latter being either foreign tissues or
cells expressing viral antigens during a productive
infection.
Region D codes for MHC Class II proteins which are usually
only found on the surface of cells which fulfil the role
of presenting foreign antigen to cells such as lymphocytes
which will react by the development of an appropriate
immune response. MHC Class II proteins are found therefore
on macrophages, Langerhans cells in the skin and some
endothelial cells. The interactions of Class II-expressing
cells with potentially responsive cells often result in
the secretion of growth factors that stimulate the
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reacting cell to proliferate. Three subtypes of D antigens
are recognised, namely P Q and R, although they are often
collectively referred to as HLA-DR (D-related).
The fifth region codes for some complement components but
these are not expressed on the cell surface.
MHC, and other, antigens typically associated with the
surface of haemopoietic cells were found to be expressed
by cells (assumed to be glial) in sections from gliomas
(Budka et al, 1985; Budka et al, 1985a; Chilosi et al,
1986; Motoi et al, 1985), and also by renal (Borowitz et
al, 1986) and pulmonary tumour cells (Patterson et al,
1985; Ruff et al, 1984). The authors of such studies saw
such expression mainly in terms of a marker of tumour type
and as a source of potential confusion if these antigens
were to be used as diagnostic markers. In gliomas these
positive cells were usually considered to be astroglial in
nature, often on the basis of a process-forming
morphology, but at the time the extent of macrophage
infiltration in gliomas was not generally appreciated
(Chilosi et al, 1986).
Expression in vitro of similar antigens by glioma-derived
cells or cell lines (Carrel et al, 1982; De Murault et al,
1985; Studer et al, 1985; Wikstrand et al, 1985) was
generally found to be heterogeneous with no obvious
correlation with morphology. It was suggested that these
antigens had a potential value in classification of tumour
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type or grade and that they might be of functional
importance.
Further study provided evidence that functionally
astrocytes might have much in common with macrophages. In
the normal brain Class II antigens were found to be only
sparsely expressed, mostly on endothelial cells and a few
astrocytes or microglia (De Tribolet et al, 1984; Lampson
et al, 1986) . Astrocytes were found to express not only
much more Class II antigen in active chronic multiple
sclerosis (Traugott et al, 1988) and around abscesses and
metastases (Frank et al, 1986), but rat astrocytes, both
normal and neoplastic, were also found to possess
phagocytic properties in vitro (Bjerknes et al, 1987).
Class II antigen expression could be experimentally
induced on astrocytes by measles antigen;
macrophage-derived TNF enhanced the response, but was not
not capable of eliciting it on its own (Massa et al,
1987) .
Class II antigens were found to be inducible by gamma
interferon on the surface of cultured fetal (Hirayama et
al, 1986; Pulver et al, 1987), adult (Kim et al, 1985) and
neoplastic (Piguet et al, 1986; Piguet et al, 1986a;
Takiguchi et al, 1985) human astrocytes. This induction
seems to be a specific effect involving active
transcription of the gene, one section of which appears to
be sensitive to interferon (Basta et al, 1987). Not all
neoplastic glial cells were found to be sensitive to
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interferon, apparently due to a transcriptional block at
the level of the HLA-DR gene rather than a lack of
interferon receptors (Piguet et al, 1986a). The HLA
antigen that is induced on neoplastic glial cells, and
that naturally present on melanoma cells (Guerry et al,
1984), is functional and capable of evoking an appropriate
lymphocyte response (Takiguchi et al, 1985). Astrocytes
have been found to be capable of replacing monocytes in an
in-vitro test of lymphocyte mitogen response but
interestingly this did not appear to depend on surface
Class II antigen expression (Schnyder et al, 1986). The
authors of this study suggested that in addition to
interleukin-1 (IL-1) neuraminidase may also be involved;
they postulated that this, by reducing the high surface
negative charge on the lymphocytes, would facilitate cell
to cell contacts which, in turn, would enhance cell
interactions and thus proliferation. All these studies
suggest that the normal astrocyte may serve the function
of an antigen-presenting cell in the CNS and that the
interactive capabilities of such a cell might be retained
following neoplastic transformation.
Immune cell infiltrates in gliomas
Early studies of the lymphocytic infiltrate in gliomas
highlighted the often strikingly perivascular location of
the infiltrate (Bertrand et al, 1960; Ridley et al, 1971);
lymphoid infiltration has been associated with tumour
necrosis (Brooks et al, 1978; Ridley et al, 1971) or
- 170 -
(Bertrand et al, 1960; Takeuchi et al, 1976) the presence
of gemistocytic cells in the tumour.
Studies relating the degree of lymphoid infiltrate to
survival have found some association between survival and
a high level of perivascular (Brooks et al, 1978) or
interstitial (Palma et al, 1978) lymphoid infiltrate in a
small number of high grade gliomas (Brooks et al, 1978;
Palma et al, 1978). A relation between the degree of
lymphocytic infiltrate and mean survival time was found
for a larger series of tumours but the values were found
to be of little value for prognosis in an individual
patient (Boker et al, 1984). That these could constitute a
distinct subgroup is suggested by the apparently
contradictory finding that in general cellular infiltrates
were higher in high grade than low grade lesions (Bertrand
et al, 1960) . Published (Palma et al, 1978) and
unpublished observations (Cooper MH, 1986) have indicated
an inverse association between lymphocytic infiltration
and patient age; an apparent effect of the former on
survival could therefore be explained by a direct effect
of the latter. In studies of the associations between
survival and lymphocytic infiltration neither patient age
nor the influence of lymphocyte subtypes have been studied
in any detai1.
A number of studies have been aimed at assessing the
pattern of the cellular response to human gliomas, with
particular reference to the cell types involved. Although
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one group claimed to have identified a relatively high
proportion of B cells on the basis of surface
immunoglobulin (Yasuda et al, 1983) others emphasised the
presence of T cells and the frequent absence of B cells
(Hitchcock et al, 1988; Paine et al, 1986; Stavrou et al,
1977; Von Hanwehr et al, 1984). Comparison between the
quantitative analyses of T cell subtype are difficult due
to the lack of consistency in the methods used to present
cell counts, but it is clear that no consistent pattern is
found in astroglial tumours. Although T4/T8 ratios were
often low, in keeping with a suppressor effect (Hitchcock
et al, 1988; Stevens et al, 1988 ), some tumours showed a
predominance of helper cells and others showed no
significant lymphoid infiltrate. Although an antibody
against Human Natural Killer (HNK) cells had shown
apparent reactivity on some tumour cells in astrocytic and
oligodendroglial tumours (Motoi et al, 1985) other authors
concluded that HNK cells were themselves scarce in gliomas
and played little part in the immune response to these
tumours (Stevens et al, 1988). Earlier studies assumed the
majority of mononuclear cells to be lymphoid but recent
studies have noted the high proportion of monocytes in
many tumours (Hitchcock et al, 1988; Rossi et al, 1987;
Rossi et al, 1988) .
Even when a statistical association was found between the
level of histological infiltrate and an in vitro measure
of lymphocyte function the fact that a number of
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individual cases failed to show such an association
emphasised the importance of assessing the pattern of cell
types as well as the degree of cellular infiltration
(Boker et al, 1982).
It would seem from the above considerations that glioma
cells are potentially capable of responding to a range of
factors produced by cells of the immune system
infiltrating the tumour as part of an evoked response.
They are however also potentially capable of responding to
at least one defined growth factor as judged by their
expression of the cell surface receptor to it, namely the
Epidermal Growth Factor (EGF).
Epidermal Growth Factor and glial tumours
EGF was first described in 1962 (Cohen, 1962) in an
isolate from salivary gland and shown to have mitogenic
properties. The receptor for EGF (EGFR) was one of the
first human gene products shown to be homologous with the
product of an experimental oncogenic virus, the avian
erythroblastosis virus (Downward et al, 1984). EGFR is a
complex protein encoded for by the erb-B proto-oncogene on
chromosome 7 (Waterfield et al, 1983). It possesses an
extracellular portion responsible for EGF binding, an
intramembrane domain, and an intracellular portion which
has tyrosine kinase activity which is thought to be
responsible for linking receptor binding to cell division
(Thompson et al, 1985) . In cells transformed by the
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Erythroblastosis virus (Downward et al, 1984) and in
malignant human epidermal cells (Ozanne et al, 1985;
Ullrich et al, 1984), EGFR is expressed in a truncated
form, lacking the extracellular domain, and in this form
it appears to act as if EGF has bound to it despite the
absence of its external section. Not only is the EGFR in
these circumstances abnormal but it is often present in
increased amounts either due to amplification of its
coding gene, or to increased transcription which may
relate to chromosomal translocations that have freed the
gene from the influence of its normal regulators (Ozanne
et al, 1985; Ullrich et al, 1984). As a result cells show
the inappropriate proliferation that is one of the
features of the malignant state. The central part played
by this mechanism in the transforming process is attested
to by the fact that the function of a growth factor that
apparently effects cellular transformation in-vitro
(Transforming Growth Factor - TGF) is now known to depend
on its binding to EGFR although it differs in structure
from EGF (DeLarco et al, 1980).
The expression of EGFR on normal glial cells was reported
in 1977 (Westermark, 1977) but it was not until seven
years later that the receptor was described in gliomas by
Libermann and colleagues (Libermann et al, 1984). This
group found that the levels of expression varied from
tumour to tumour and, while some did show a definite
increase in levels, it was not clear whether this
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reflected an general increase in expression by neoplastic
cells or the growth of a population that naturally
expressed higher levels of receptor but were scarce in non
neoplastic tissue. They subsequently showed (Libermann et
al, 1985, 1985a) that enhanced receptor levels were
associated with gene amplification and that up to one
third of malignant glial tumours might show such enhanced
expression.
Studies on glioblastoma cell lines have yielded more
detailed information on EGFR structure and function. The
EGFR of gliomas differs from that of neoplastic squamous
cells in that it has a higher affinity for EGF and is more
heterogeneous in its structure (Westphal et al, 1985).
More significantly the receptor seems to be more uncoupled
from the normal processes of cell growth inhibition
rendering the cells that express it less susceptible to
control by cell density (Westphal et al, 1985).
Against this background of the known expression of EGFR
and of surface HLA class II proteins by some gliomas, and
indirect evidence that immune elements could serve to
stimulate tumour growth a study was undertaken to
determine the relationship, if any, between tumour antigen
expression, immune cell (especially monocyte) infiltration
and tumour growth.
MATERIALS AND METHODS
The work described in this section was carried out in
three separate phases determined by a combination of
tissue and antibody availability. The initial study was
aimed at assessing the degree and pattern of MHC Class II
antigen (MHCII) expression in a small series of astroglial
tumours. Subsequently a larger series was examined and an
analysis was carried out of correlations between
lymphocyte and macrophage infiltration, MHCII expression
and tumour cell proliferation. In the last section the
pattern and degree of Epithelial Growth Factor Receptor
(EGFR) expression is explored.
The tissue examined in this study derived from diagnostic
specimens received in the Neuropathology Laboratory,
University of Leeds between 1983 and 1987. Fresh tissue
had been frozen in isopentane or directly in liquid
nitrogen and examined after storage periods of up to three
and a half years. All tissue cultures derived from the
material that has been fully described in Chapter 2 and
the technical methods used were identical to those
detailed in that section.
The methodology for this section is detailed together for
convenience. However since the findings in the first study
had a bearing on the nature of the next two these results
are presented and discussed separately.
- 176 -
Reagents
A panel of antibodies was used to identify MHCII antigens,
lymphocytes and their subsets. The specificities of the
antibodies used and their dilutions are detailed below.
The main lymphocyte markers used were Til and T28, chosen
because they would identify the great majority of
lymphocytes infiltrating tumours irrespective of their
subset and their state of activation. While this fails to
take account of the functional significance of T cell
subsets wide variations in the numbers of such cells have
been reported in gliomas (Hitchcock et al, 1988; Miescher
et al, 1988; Paine et al, 1986; Rossi et al, 1987; Von
Hanwehr et al, 1984) and a broader approach was felt
necessary to address the question of any relationship
between lymphocyte and monocyte infiltration and tumour
antigen expression.
In all studies on tissues 8pm cryostat sections were
freeze-dried overnight, then fixed for 20 minutes in
acetone.
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Details of the Monoclonal Antibodies used:
MHC Class II:
Name Source Dilution Identifies
TAL-IB5 ICRF
(Adams et al, 1983)
Neat HLA DP, DQ, DR
CR3/43 MRC-CG*
(Falini et al, 1986!
1:10 HLA DP, DQ, DR
DA6.231 MRC-CG*
(Guy et al, 1982)
1:10 HLA DP, DQ, DR
DA6.147 MRC-CG*
(Guy et al, 1982)
1:10 HLA DQ, DR
B721 MRC-CG* Neat HLA DP
DA6.164 MRC-CG*
(Krajewski et al, 1985]




HLA DP, DQ, DR
(not DR3 and DR7)
*A gift from Dr M Steel, MRC Cytogenetics Unit, Edinburgh.
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Lymphocytes; all diluted 1:10 except T6 (1:20)
Name Source Identifies Cluster of
Differentiation
(Bernard et al, 1984)
T28 Unipath Mature T cells





Dako-macrophage Human macrophages; antigen unidentified
Dako-pl59,95 Macrophages (Schwarting et al, 1985;
Falini et al, 1986)
Epithelial Growth Factor Receptor: diluted 1:200
EGFRl a gift from Dr M Waterfield, ICRF, London
(Waterfield et al, 1983)
Proliferating cells: diluted 1:5
Ki67 Dakopatts recognises nuclear protein in
proliferating cells (Gerdes et al, 1984;
Gerdes et al, 1985; McGurrin et al, 1987)
Polyclonal antisera
anti-GFAP, anti-Fibronectin and anti-F8RAg all from
Dakopatts used at 1:200 dilution
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Demonstration of MHC Class II antigens
1. Rehydrate sections in Tris buffer
2. Incubate with primary monoclonal antibody (TAL-IB5,
CR3/43, DA6.231, DA6.147, B721, DA6.164, LeulO) at optimum
dilution in tris buffer, for 2-3h
3. Rinse in tris buffer then wash for 1 to 5 min in Tris
4. Incubate with 1:50 rabbit-antimouse peroxidase
conjugate (diluted in 1:20 human AB serum) for at least 15
min
5. Two 5 min washes in tris buffer.
6. Visualise in 0 . 005% DAB (3'3' diaminobenzidine
tetrahydrochloride monohydrate solution with hydrogen
peroxide in tris) for 5-10 min
7. Wash in water
8. Incubate in 0.5% copper sulphate (in 0.9% saline) for 5
min
9. Wash in water
10. Counterstain with methyl green
In sections stained with these antibodies a
semi-quantitative assessment (0,+, ++) was made of whether
antigen was present on cells identifiable as tumour cells,
by virtue of size and process formation, and on smaller
process-free cells tentatively identified as lymphocytes.
Note was also taken of the pattern of staining with
particular reference to perivascular enhancement.
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Demonstration of lymphocytes, macrophages and
proliferating cells
a) Sections from four grade IV astrocytomas were stained
by the double labelling immunofluorescent technique
described earlier (pg 39) using a number of monoclonal
antibodies against lymphoid (T28, Til), macrophage
(Dako-macrophage, Dako-pl50,95) and MHCII (CR3/43,
DA6.231, DA6.147) antigens, in combination with a
polyclonal anti-GFAP antiserum. The distributions of
positively stained cells and their coexpression of GFAP
and FN were noted.
b) Cultures from five astrocytomas (four grade IV and one
low grade) were examined for co-expression of MHCII using
the monoclonal antibody DA6.231, and GFAP or fibronectin
(FN) using a polyclonal antiserum, with a double
immunofluorescent method.
Note was taken of the patterns of coexpression among the
different cell types previously recognised in tissue
cultures from gliomas.
c) In 29 tumours serial sections were stained with
antibodies to identify T lymphocytes (T28, Til),
macrophages (Dako macrophage, Dako-pl50,95), MHCIIs
(DA6.231) and proliferating cells (Ki67) using the
indirect immunoperoxidase method described above. These







It was intended initially to assess the relative density
of cells in perivascular and interstitial areas of
tumours. Perivascular cells included all those within 30pm
of a vessel or within a cuff of infiltrating cells, and an
index was derived by calculating the proportion of all
stained to all unstained cells. It soon became apparent
that the results were heavily affected by the type of
vessel and whether cells aggregated in a perivascular cuff
or not. Thus a mature thin walled vessel with a focal cuff
would register a very high index whereas a proliferating
vessel with relatively more cellular elements would
register a lower index despite heavy interstitial
infiltration.
This method of assessment was therefore abandoned in
favour of counts of interstitial cell density which could
be argued to more closely reflect the likelihood of tumour
cell/immune cell interactions.
Counts were therefore made of all stained and unstained
cells in ten 0.09mm2 fields (using a 10 by 10 eyepiece grid
and a 25x objective) of interstitial tumour. The latter
was defined as all tissue further than 30pm from a
vascular structure. Positively stained cells were
expressed as a percentage of the total.
Since the intention was to make comparisons between
tumours such a methodology was considered preferable to
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the use of absolute counts per unit area which would be
affected by tissue distortions that would differ from case
to case and even from section to section. It is not
unreasonable to assume that any such effect will be the
same on all cells in a section irrespective of their
staining reaction.
To assess the degree of cell proliferation in Ki67
preparations counts were made of stained and unstained
cells in successive, different fields of 0.0361 sq mm
(using a 10 by 10 eyepiece grid and a 40x objective) until
a minimum of 1000 cells had been counted. The
proliferative index was expressed as a percentage of all
cells that stained positively. To avoid bias the Ki67
preparations were stained on a separate occasion to the
remainder and analysed as a batch without knowledge of the
results of the previous measurements.
Based on the frequency distribution of values for Ki67
staining in gliomas, three grades were constructed
delineating respectively the bottom 33% (0 to 33rd
centile), the middle 33% (34th to 66th centile) and the
top 33% (67th to 100th centile). These grades were used in
a comparative analysis with the grade of EGFR1 staining.
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Demonstration of Epithelial Growth Factor Receptor
Double immunofluorescence utilising the antibody EGFR1 in
combination with a polyclonal antibody against GFAP was
used to study expression of EGFR on parenchymal cells in
tumour sections. In tissue culture preparations EGFR1 was
used in combination with polyclonal antisera against GFAP,
FN and F8RAg.
The double staining technique used has already been
detailed in Chapters 2 and 3.
In tissue sections and culture preparations EGFR1 staining
was assessed semiquantitatively (0 negative, + focal weak,
++ focal strong, +++ uniform strong). In culture
preparations co-expression of other antigens was noted.
Statistical analyses
Correlations between the percentage of cells staining
positively with each method were carried out using
Spearman's rank correlation with two tailed significance
testing. Differences between the findings in high and low
grade astrocytomas were determined by a Mann Whitney U
test with two tailed significance testing. The differences
between the two measures of macrophages and T cells were
assessed by 95% limits of difference for each pair of
markers, and a paired t significance test (Bland et al,
1986) .
Possible associations between EGFR1 grade and the level of
Ki67 staining were studied with a Kruskal-Wal1is one-way
analysis of variance (Siegel, 1956).
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A. THE FREQUENCY, DISTRIBUTION AND SOURCE OF MHC CLASS II
ANTIGEN STAINING IN GLIOMAS.
MATERIALS
Tissue from 12 astrocytomas (nine Grade IV, two Grade III
and one Grade II) was used. In addition 12 primary
cultures (three explant and nine dispersed cell) from five
high grade astrocytomas were studied, all after 16 days or
less in vitro. Earlier experiment had showed that MHCII
did not survive the methanol fixation that had been
standard for cell cultures in the initial studies and in
consequence these and all subsequent cultures were fixed
with ethanol/ether as described in Chapter 2.
INITIAL RESULTS
In vivo
Peroxidase stained sections from all 12 tumours showed
some reactivity with some or all of the monoclonal
antibodies used. Positive staining of discrete round cells
in the tumour interstitium or around blood vessels was a
feature of all sections (fig.4.1). The intensity of this
infiltrate varied from case to case but was not
quantified. Distinct from this staining of what were
considered to be non-parenchymal cells was reaction
related to larger process-forming cells (fig.4.2) which in
a number of cases showed a clear enhancement in tumour
tissue around blood vessels (figs.4.3 & 4.4).
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Fig.4.1 Staining for MHCII is seen on small and large
cells, some of the latter obviously
process-bearing and morphologically resembling
astrocytes (arrow). High grade astrocytoma,
cryostat section, CR3/43 peroxidase, x432
Fig.4.2 Much of the MHCII reaction in this section is on
cell processes; the process-bearing nature and
astrocytic morphology of positively stained cells
is apparent. High grade astrocytoma, cryostat




Fig.4.3 Enhancement of MHCII staining on what appear to be
parenchymal cells. The small cells in the centre
of the field are lymphocytes infiltrating vessel
walls. High grade astrocytoma, cryostat section,
DA6.231 peroxidase, xl73
Fig.4.4 Islands of tumour (open arrows) show MHCII
staining where they abut upon vascular structures
(solid arrows) which are almost entirely
unstained. High grade astrocytoma, cryostat
section, DA6.231 peroxidase, x270
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The pattern of staining of the high grade tumours with
each of the seven antibodies and the proportion showing
perivascular enhancement is detailed in table 4.1. Every
tumour showed some degree of staining with at least one
antibody.
Enhanced perivascular staining was a feature in
approximately half the tumours for each antibody, but all
tumours showed some enhancement with some antibody. For
each tumour an analysis was made of the proportion of
antibodies which showed an enhanced perivascular reaction.
The figures ranged from 14 to 86% with a median value of
57%. The distribution of the results for all 11 tumours is
shown in Table 4.2. The highest values were found in the
two grade III tumours which showed enhanced perivascular
staining with 83% and 86% of antibodies, but two of the
three grade IV tumours showed enhancement with 80% of
antibodies.
The single low grade astrocytoma showed weak staining with
four out of seven antibodies and strong staining with
three out of seven. All antibodies showed a pattern of
enhanced perivascular staining.
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Table 4.1 Pattern of staining for MHC Class II antigens in
11 high grade gliomas.
Staining
Perivascular
0 + ++ enhancement
Antibody
IB5 9 .1 (1) CM•001—1 (2) 54.6 (6) 54 . 6 (6)
B721 9 .1 (1) 45.5 (5) 18.2 (2) 45.5 (5)
CR3/43 0 (0) 9.1 (1) 90.9 (10) 54 . 6 (6)
DA6147 9.1 (1) 18 . 2 (2) 63.6 (7) 54 . 6 (6)
DA6231 9 .1 (1) 18.2 (2) 72.7 (8) 54 . 6 (6)
DA6164 9 .1 (1) 36.4 (4) 45.5 (5) 54 . 6 (6)
LeulO 18 . 2 (2) 45.5 (5) 36.4 (4) 54. 6 (6)
Figures indicate the percentage of tumours showing each
degree of staining (actual numbers in brackets). Balance
of percentage comprises tumours in which preparations were
technically unsatisfactory or unavailable.
Table 4.2 Frequency distribution of perivascular
enhancement in 11 high grade gliomas
% antibodies showing enhancement
0-20 21-40 41-60 61-80 81-100




From this series of tumours it was apparent that MHCII
expression, often with a perivascular enhancement, was a
common phenomenon among glial tumours. Although the
frequency of enhancement with the panel of antibodies used
appeared to be inversely related to tumour grade the
numbers involved were insufficient for this to be stated
with any certainty. The differing haplotype specificities
of the different antibodies made it clear from the results
that MHCII expression is a very heterogeneous phenomenon
among glial tumours, and may even differ from area to area
in the same tumour as evidenced by cases that showed
different degrees of staining with several antibodies and
perivascular enhancement with only some. Similar
heterogeneity of MHCII expression has been commented upon
in B-cell lymphomas (Krajewski et al, 1985; Williamson et
al, 1986)
On morphological grounds the bulk of the staining for MHC
Class II antigens that was not related to a definable
round cell infiltrate was initially interpreted as being
on the surface of tumour parenchyma. The MHCII+ round
cells had the morphological features of lymphocytes;
staining of sections with a B-cell specific antibody (data
not shown) had failed to identify any B-cells and so the
MHCII+ lymphoid population were considered to be activated
T-cells (Ko et al, 1979). Others have subsequently
confirmed that B cells are uncommon (Hitchcock et al,
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1988) or rare (Rossi et al, 1987) in gliomas.
Against the background of knowledge that glioma-derived
cell lines expressed such antigens, and the fact that such
antigens could be induced by a range of factors, many
derived from lymphocytes the suggestion was made (Franks
et al, 1986) that the observed perivascular enhancement
might be a reflection of in-vivo induction in response to
infiltrating lymphoid cells. A similar association has
been postulated between MHCII expression and lymphocytic
infiltration in colonic tumours (Lampert et al, 1985).
Some support for this view was derived from the
observation that tumours showing least perivascular
enhancement tended to show less staining for a range of
surface lymphocyte antigens (data not shown). An
alternative explanation, that the expression was on the
surface of macrophages, was thought less likely because of
the numbers that would have to be present to account for
the intensity of staining. Macrophages had however been
described as being present in many gliomas (Morantz et al,
1979; Phillips et al, 1982; Wood et al, 1979) but these
studies utilised an in-vitro assay and in the one study in
which reference was made to in vivo distribution no
pictures were published.
With the finding of such intense MHC class II antigen
expression in vivo, short term tissue cultures were
thought to be more likely to demonstrate a similar pattern
of expression if it genuinely reflected a glial cell
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property. Although MHCII expression in colonic carcinoma
had been described in a cell line (Lampert et al, 1985)
and in cells from fresh explants (Garcia-Espejo et al,
1986) it was recognised that MHC class II expression might
prove labile under culture conditions and so a negative
finding would not exclude the possibility of glial
expression. Accordingly sections from four of the high
grade tumours were also examined using a double labelled
immunofluorescent technique to determine whether cells




The 16 day old explant cultures showed a typical outgrowth
of process-forming (PF) cells with focal development of
abnormal heaps of flattened adherent (FA) cells. Neither
GFAP+ PF cells nor FN+ FA cells showed any staining with
DA6.231, regardless of their position in relation to the
explant. Similarly, in dispersed cell preparations up to
16 days old, no GFAP+ or FN+ cells were seen which also
stained with DA6.231.
In the dispersed cell cultures up to 14 days old, and in
the 16 day explants, a population of scattered DA6.231+
cells were seen which expressed neither GFAP nor FN. They
were generally smaller than glial cell bodies, with a
tendency to adhere to GFAP+ cell bodies or processes and
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thereby assume an elongated profile (fig.4.5), sometimes
with small processes. Where the cells were separate from
tissue fragments or other cells they were more likely to
assume a rounded shape (fig.4.6).
Two cultures from high grade tumours were studied by time
lapse photography after 6 days in vitro. Small round
highly mobile cells could be seen, distinct from the
relatively immobile components of the explant. These cells
moved out from and back into the explant, and at the edge
of the specimen could be discerned moving in the
interstitial spaces between cell processes although the
nature of any interaction with glial elements was not
clear.
In vivo
Double labelled sections were studied from four of the
high grade tumours examined previously. This revealed
that, while there was weak expression of MHCII on the
surface of GFAP+ parenchymal cells, strong staining was
restricted to a population of cells that did not express
GFAP+ (fig.4.7), were frequently most prominent around
blood vessels and in this location corresponded to cells
that also stained strongly either with Dako-macrophage
(figs.4.8 & 4.9), or with a marker of mature lymphocytes
(T28) (fig.4.10).
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Fig.4.5 MHCII+ (green) cell (arrow) adherent to body and
process of GFAP+ (orange) glial cell which shows
no MHCII staining. The yellow spot in the lower
centre of the picture is an artefact. High grade
astrocytoma, 16 days in vitro, polyclonal
anti-GFAP, monoclonal DA6231, x520
Fig.4.6 MHCII+ cells on substrate base without direct
attachment to other cells tend to have rounded
profiles. High grade astrocytoma, 16 days in
vitro, monoclonal DA6231, x520
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Fig.4.7 MHCII+ cells (left) are relatively process free
and do not appear to express GFAP (right)
although their enclosure by glial cell processes
sometimes makes it difficult to be sure of this.
High grade astrocytoma, cryostat section,
polyclonal anti-GFAP, monoclonal CR3/43, x520
Fig.4.8 Double exposure with macrophage marker (green) and
GFAP (orange) clarifies the relationship between
the glial and MHCII expressing cells and makes
their separation easier. High grade astrocytoma,




Fig.4.9 At higher magnification the infiltrating cells
(green) are seen to be enclosed by GFAP+ (orange)
processes, but do not themselves contain GFAP.
The same cell is identified in each picture by an
arrow. High grade astrocytoma, cryostat section,
polyclonal anti-GFAP, monoclonal Dako-macrophage,
xl 0 4 0
Fig.4.10 These two pictures from the same field show that a
population of the MHCII+ cells also stain with
T28 (green), a marker for mature lymphocytes, and
are distinct from the GFAP+ (orange) glial cells
which enclose them. High grade astrocytoma,





The work presented in this section confirmed the finding
of others (Chilosi et al, 1986; Lampson et al, 1986) that
MHCII-expression was a common phenomenon in gliomas but
raised the question of how much expression was due to
glial cells and how much to other elements in the tumour.
At this stage certain conclusions could be drawn. MHCII
antigen expression in glial tumours appeared to have at
least two components. One was related to the surface of
GFAP+ neoplastic glial cells which was diffuse, relatively
weak, and appeared to be lost in vitro within 9 days. The
second was associated with a cellular infiltrate which
consisted of lymphocytes and macrophages. The presence of
the latter in any number had not been appreciated because
of the difficulties of recognising the cell in routine
preparations (Phillips et al, 1982) and of distinguishing
it from larger lymphocytes or smaller tumour cells. Such
MHCII-expressing cells whose morphology was compatible
with their being macrophages could be identified in
cultures up to 14 days old.
The in vivo and in vitro expressions of MHCII by glial
tumour cells have been compared in an exploration of the
susceptibility of such cells to the effect of interferons
(Piquet et al, 1986, 1986a). Although MHCII was found in
vivo in 9 out of 11 tumours, cells derived in vitro from
these same tumours only expressed MHCII in two cases,
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suggesting either that expression was lost in vitro, or
that the cells being studied represented a different
population selected in vitro. Such observations accord
with the current studies but the derivation from gliomas
of cell lines of confirmed glial nature that also express
MHCII (Bigner et al, 1981; Wikstrand et al, 1985), and the
direct observation of MHCII- GFAP+ cells in vitro,
suggests that culture conditions have an important
influence on MHCII expression. The techniques used in this
study would be well suited to explore the induction of
MHCII by factors known to stimulate such expression in
other neoplastic cells (Real et al, 1988).
Whether the expression of MHCII antigens further
influences the immune response is of fundamental
importance. Interactions between MHCII expressing cells
and lymphocytes result in the release of lymphocyte growth
factors and it is conceivable that the tumour cells may
themselves respond to such factors, a possibility given
credence by the observation that in a study of the effect
of interferon on cell growth one culture showed a short
term enhancement of protein synthesis (Bradley et al,
1983) .
Once the contribution of macrophages to the MHCII
expression observed in gliomas was appreciated their
potential significance in determining tumour growth and
the reactions of non-parenchymal elements in vitro was
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apparent. A larger study of the relationship between
tumour cell proliferation, immune cell infiltrate and
MHCII expression was therefore undertaken.
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B. RELATIONSHIP OF IMMUNE CELL INFILTRATION, MHC CLASS II
ANTIGEN EXPRESSION AND TUMOUR CELL PROLIFERATION IN
GLIOMAS.
MATERIALS
MHCII expression (DA6.231), lymphocyte (Til and T28) and
macrophage (Dako-macrophage and Dako-pl90,95) counts, and
cell proliferation (Ki67) markers were examined in a total
of 28 tumours consisting of 17 high grade astrocytomas (15
grade IV and two grade III), five low grade astrocytomas,
two meningiomas, one choroid plexus papilloma, one
oligodendroglioma, one astroblastoma and one ependymoma.
Ki67 staining only was also performed on one metastatic
anaplastic carcinoma. Diagnostic classifications were
based on serial sections stained H&E from the same tissue
as was used in the immunohistochemical analyses.
RESULTS
Qualitative observations
Although some specimens contained areas of infiltrated
brain which were analysed for staining pattern, cell
counts were, in all cases, carried out in areas of
unequivocal primary tumour.
In H&E stained sections the identification of macrophages
was not possible (fig.4.11).
The pattern of cellular staining with DA6.231 was similar
to that described in the earlier study although resolution
was generally better due to increased experience with the
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techniques. Two types of cell were discernible, one round
in shape with a clear rim of surface staining, and the
second larger, sometimes stellate which could have been
macrophages or astrocytes. In a number of areas these
cells were arranged around blood vessels with the
formation of a thin positively stained zone whose
distribution (fig.4.12) resembled the astrocytic component
of the blood-brain barrier in normal brain.
In addition to this staining of discrete cells was the
general tendency of fibrillary or astrocytomatous areas of
tumours, and residual neuropil in areas of diffuse
infiltration, to stain diffusely positive.
In tumours which showed a diffuse positive staining it was
sometimes difficult to distinguish between DA6.231+ cells
enclosing unstained cells in their processes and diffuse
positivity of most cells (fig.4.13). As a result counts of
DA6.231+ cells were not made in five astrocytomas (four
grade IV and one low grade) and one meningioma.
The DA6.231+ cells in the ependymoma were situated largely
around blood vessels with few in the interstitium, a
pattern of positivity reminiscent of the distribution of
astrocytes in such tumours.
In the choroid plexus papilloma and both grade III
astrocytic tumours there was patchy staining of vascular
endothelium with DA6.231. This was not noted in the other
tumours and did not appear specifically to be related to
local concentrations of other positively stained cells.
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Fig.4.11 Although small infiltrating lymphocytes can be
identified with some confidence the range of
tumour cell size precludes accurate
identification of macrophages. High grade
astrocytoma, cryostat section, H&E, xl73
Fig.4.12 In addition to discrete staining of cells in
tumour parenchyma there is strong staining,
around small vessels, of cells (arrow)
reminiscent of the astrocytes forming the
blood-brain barrier of normal brain. High grade
astrocytoma, cryostat section, monoclonal DA6.231
peroxidase, x270
Fig.4.13 The diffuse staining of process-bearing cells
shown by this tumour makes distinction between
stained and unstained elements difficult. High




In cases stained with macrophage and lymphocyte markers
there was usually sufficient morphological distinction to
allow easy delineation of positive and negative cells
(fig.4.14). Sometimes perivascular cells stained with the
Dako-macrophage antibody (fig.4.15) showed a pattern
similar to that of the discrete DA6.231+ cells including
the formation of a thin positively stained zone around
blood vessels (fig.4.16). In an area of old haemorrhage in
the oligodendroglioma foamy macrophages were focally
numerous. Although these cells stained with Dako-pl50,95
(fig.4.17) those cells in the same area that stained with
Dako-macrophage did not have the morphology of lipid-laden
cells (fig.4.18).
Ki67 staining was seen to have two types of distribution:
one was diffuse throughout the nucleus and the other
discrete staining of nucleoli which were frequently
multiple (fig.4.19). In some cells dense nucleolar
staining was combined with a paler diffuse nuclear
reaction. Cells whose nucleus showed any of these patterns
were counted as positive. Although vascular structures
could be identified in these preparations confident
exclusion of all non-glial cells was not felt to be a
practical possibility so no attempt was made to
distinguish cell types when making counts. However it was
noted that positive staining of endothelial cells was very
rare and inclusion of proliferating vascular elements was
therefore unlikely to give rise to a significant bias.
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Fig.4.14 Although there is some variation in the size of
cells that are stained with a lymphocyte marker
the pattern is essentially one restricted to
discrete cells. High grade astrocytoma, cryostat
section, monoclonal Til peroxidase, xl73
Fig.4.15 Cells stained for macrophage marker show both a
diffuse and a perivascular (arrow) distribution.
High grade astrocytoma, cryostat section,
monoclonal Dako-macrophage peroxidase, xl73
Fig.4.16 Aggregations of cells around small blood vessels
(arrows) sometimes resembled the pattern seen
with DA6.231 staining astrocytes (see 4.12). High




Fig.4.17 Foam cells in an oligodendroglioma (arrow) stain
with Dako-pl50,95 but staining of other
interstitial cells is generally weak. High grade
astrocytoma, cryostat section, monoclonal
Dako-macrophage peroxidase, xl73
Fig.4.18 In a section from the same area as 4.17 there is
more staining of interstitial cells with
Dako-macrophage, but not of foam cells. High
grade astrocytoma, cryostat section, monoclonal
Dako-macrophage peroxidase, x!73
Fig.4.19 Cells in the proliferative cycle are identified by
nuclear (large arrow) and/or nucleolar (small
arrow) staining with Ki67. Counterstaining with
haematoxylin and eosin allows easy counting of
positive and negative cells. High grade




Fields in which vascular structures formed a dominant
component, such as a focus glomeruloid proliferation, were
excluded from analysis.
Quantitative observations
The values for the high and low grade astrocytomas for
each the six antibodies are detailed in Table 4.3.
Although in general the percentages of positively stained
cells were lower in the low grade tumours only those for
Ki67+ cells were significantly different from the high
grade tumours (p<0.002, Mann Whitney U test).
Only Ki76 staining was carried out on tissue from the
metastasis. Due to inadequate material data were
incomplete for a few analyses in the remaining tumours but
the available results were used to assess correlation
between the percentages of cells staining with the various
techniques. The results for tumours other than the
astrocytomas are shown in Table 4.4
When the results for all tumours were considered there
were significant correlations between the levels of
DA6.231+ cells and the levels of both T28 + cells (r=0.78,
pCO.OOl) and Dako-pl50,95+ cells (r=0.59, p=0.005).
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Table 4.3 Percentage of positively stained cells in
high and low grade astrocytomas.
The first figure is the median, the second two
the range. Difference has been tested for










0 - 32.5 NS





0.3 - 17. 3
0.25
0.24-1.5 NS
Dako-pl50,95 17 . 9
0.8 - 43
8.7
0 - 26.4 NS
Dako-macrophage 17.7
5.5 - 51. 4
15.8
10.9 - 45.6 NS
Ki67 3 . 8
1-18
0.3
0-2.1 p< 0. 002
Table 4.4 Percentage of positively stained cells in seven
non-astrocytomas.













★ 0.6 0 . 3 3 17 0 . 3
01igodendroglioma 9.7 7.8 * 0 4.4 2
Astroblastoma 11.6 0 . 5 0.3 5.6 12.3 0
Ependymoma 4.9 0 . 2 * 4.3 3.7 0 . 9
Metastasis * * * * * 3.1
*Data not available
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Comparisons were made between the results for
Dako-macrophage and Dako-pl50,95, and T28 and Til
respectively, to try to assess the degree to which they
were each identifying the same populations of macrophage
or lymphocytes.
Dako-macrophage tended to identify larger numbers of cells
with a mean difference for the two macrophage markers of
8.16% (95% Confidence Limits 11.4, 4.9) which was highly
significant (p<0.0001, two-tailed t test; 95% Limits of
Agreement -9.7, 26); this indicates poor agreement between
the two markers and suggests that the two markers do not
identify the same population of cells. For the two markers
of mature lymphocytes the mean difference was smaller at
1.5% (95% Confidence Limits 2.6, 0.4) but this was still
highly significant (p=0.014, two-tailed t test; 95% Limits
of Agreement of 6.4 and -3.4) again indicating that
different populations of cells are being identified.
When the results were restricted to those for the 22
astrocytic lesions the only correlation that persisted was
that between the DA6.231+ cells and T28+ cells (r=0.67,
p<0.02). A correlation between the levels of Dako-pl50,95+
cells and T28 + cells was found (r=0.72, p<0.01) that had
not been apparent in the larger group. No correlations
were found between levels of Ki67+ cells and those stained
with any other marker.
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C. THE EXPRESSION OF EPITHELIAL GROWTH FACTOR RECEPTOR IN
GLIOMAS
EGFR expression was examined in sections from 28 high
grade astrocytomas (25 grade IV and three grade III),
three low grade astrocytomas and one ganglioglioma. All
sections were stained with a double labelled
immunofluorescent technique counterstained for GFAP.
30 cultures (nine explants and 21 dispersed cells) from 10
astrocytomas (nine high grade and one low grade) and one
ganglioglioma were used to determine expression of EGFR
after periods of up to 28 days in vitro. Preparations were
double stained with a variety of second antibodies (GFAP,




The three low grade astrocytomas and the ganglioglioma
showed no staining for EGFR.
Seven of the high grade tumours showed no staining. In the
remaining 19 high grade tumours the staining was in one of
three recognisable patterns.
i) In five tumours scattered single cells, usually large,
process-bearing and GFAP+, showed weak surface staining of
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the cell processes and/or the cell body (fig.4.20). These
cells were distributed throughout the tumour and did not
appear to differ in shape or size from other parenchymal
tumour cells.
ii) In four tumours the numbers of cells and their
staining intensity were both higher so that small groups
of EGFR1+ cells were seen separated by unstained cells
(fig.4.21). EGFR1+ cells showed a range of sizes but this
did not differ from that shown by EGFRl- cells nor was any
difference in GFAP staining apparent between the EGFR1+
and EGFRl- cells.
iii) In 10 tumours staining was uniform and strong
corresponding to GFAP+ parenchymal areas (figs.4.22 &
4.23) .
In the 28 malignant tumours there was no apparent relation
with grade, one grade III tumour being present in each of
the three positive groups.
Although the majority of positive staining for EGFRl was
in GFAP+ cells in parenchymal zones two exceptions to this
pattern were noted. In three grade IV tumours scattered
single GFAP- cells without obvious processes showed EGFRl
staining (fig.4.21). In two grade IV tumours with
desmoplasia EGFR1+ cells, which were also GFAP+, were seen
in small numbers in the desmoplastic area.
Identifiable vascular structures were unstained in all the
32 tumours examined and in particular no endothelial
staining was seen.
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Fig.4.20 EGFR expression grade 1. Single EGFR+ cells are
surrounded by unstained cells which are in the
majority. High grade astrocytoma, cryostat
section, monoclonal EGFRl, x520
Fig.4.21 EGFR expression grade 2. EGFR+ cells form small
clusters (left) although many cells are still
unstained. A single EGFR+ cell (arrow), without
processes, lies in close relation to the edge of
a small vessel. High grade astrocytoma, cryostat
section, monoclonal EGFRl, x520
Fig.4.22 EGFR expression grade 3. The majority of tumour
cells stain strongly and uniformly. High grade




Fig.4.23 The glial nature of the cells expressing EGFR is
confirmed by the almost complete correspondence
of GFAP expression (orange) and EGFR staining
(green). High grade astrocytoma, cryostat




The differences observed in the distribution of staining
grades for EGFR1 between the high and low grade astrocytic
tumours were statistically significant (0.05> p >0.02,
Mann Whitney U test).
Relationship with Ki67 staining
In 16 astrocytic tumours (14 high grade and two low grade)
data were available to examine the association between
EGFR expression and cell proliferation as indicated by
Ki67 staining. Ki67 grade was assigned using the 33rd and
66th centiles of the values measured for all gliomas as
demarcators of grade. On this basis a low grade (1)
comprised values 0-2.7%, medium grade (2) 2.8-4.4% and
high grade (3) 4.5-18%. The relationship between EGFRl
grade and Ki67 grade is shown in table 4.5. One-way
analysis of variance (Kruskal-Wallis) showed that this
distribution did not differ significantly from what would
be expected by chance, indicating that no relationship
between Ki67 staining and EGFR staining can be identified
in the cases examined.
In vitro
In cultures from nine high grade tumours, ranging in age
from 9 to 34 days, neither FN+ nor GFAP+ cells showed any
staining with EGFRl irrespective of whether they were in
explant or dispersed cell cultures. Heaps of abnormal FN+
FA cells and typical GFAP+ PF cells were both specifically
identified as EGFR1-. In the ganglioglioma GFAP+ cells and
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"cobblestone" sheets of F8RAg+ cells were also EGFR1-.
In one culture from a grade III tumour a single GFAP- cell
whose morphology was neither process-forming nor typically
flattened and adherent showed focal surface staining with
EGFR1.
Three cultures from a grade IV tumour contained small
numbers of FA cells with uniform surface staining with
EGFR1. One culture was examined after 24 days primary
culture and the other two 7 days after passage (24 and 28
days total in vitro). In the 24 day cultures the EGFR1+
cells were all GFAP+ (fig.4.24) but in the post-passage
preparation the EGFR1 reaction was distinctly focal
(fig.4.25). In the older preparation both GFAP+ and GFAP-
cells were EGFR+. In neither specimen were typical GFAP+
PF cells stained.
In six high grade tumours correlations were possible
between in vivo and in vitro staining. These are shown in
Table 4.6.
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Fig.4.24 After 24 days in vitro only a subpopulation of
GFAP+ cells (left) express EGFR (right). High
grade astrocytoma, polyclonal anti-GFAP,
monoclonal EGFR1, x520
Fig.4.25 A single GFAP+ cell (left) shows focal EGFR
expression (right) on its surface. High grade
astrocytoma, 28 days in vitro, first passage,
polyclonal anti-GFAP, monoclonal EGFR1, x520
- 215 -
 






Low - 4 -
Medium 1 1
High 114
*This group comprises both the low grade tumours
Kruskal-Wal1is one-way analysis of variance showed no
significant association between EGFR and Ki67 grades
(p=0.5)
Table 4.6 Correlations between in vivo and in vitro
expression of EGFR in 6 high grade astrocytomas.




















The expression of MHC Class II antigens (MHCII) by the
cells of tumours from sites other than the brain has been
described in lymphomas (Epenetos et al, 1985; Williamson
et al, 1986) melanomas (Ruiter et al, 1984; Van Duinen et
al, 1986), carcinoma of the breast (Perez et al, 1986; Zuk
et al, 1987) and colon (Lampert et al, 1985; Momburg et
al, 1986; Moore et al, 1986) and thymomas (Ring et al,
1986). In melanocytes the expression of MHCII has been
associated with malignant change and tumour progression,
being absent in most naevi but being found with
progressively increasing frequency in dysplastic naevi,
primary melanomas and metastatic lesions (Ruiter et al,
1984; Van Duinen et al, 1986). Studies of an experimental
tumour cell line (Jack et al, 1987) have shown an
association of MHCII expression with increased metastatic
efficiency and in thymomas there is a suggestion that
there is more expression in invasive lesions (Ring et al,
1986). However in breast (Zuk et al, 1987) and colon
carcinomas (Momburg et al, 1986) no such association with
tumour grade or behaviour has been found.
Although counts of MHCII+ cells were generally higher in
high grade tumours difficulties were encountered in
localising the expression to the surface of tumour cells
rather than of infiltrating macrophages. The marked
heterogeneity of expression that was found with a panel of
antibodies of differing haplotype specificities, and the
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fact that most tumours express some MHCII suggests that
there is unlikely to be a simple relationship between
MHCII expression and neoplastic progression in glial
cells. With the evidence that normal astrocytes have the
potential to express MHCII the significance of such
expression in tumours is more likely to be related to its
influence on any evoked immune reaction than as an
indicator of malignant change.
The staining of endothelial cells that was a feature in
one choroid plexus papilloma and two grade III
astrocytomas has been noted in B cell lymphomas (Epenetos
et al, 1985) and in melanomas (Ruiter et al, 1984), and in
the latter case this expression contrasted with the lack
of expression in adjacent normal vessels. Whether this
represents a phenomenon of induction in response to local
lymphokines, or an aberrant expression associated with
tumour-associated endothelial proliferation is not
apparent. The expression of such antigens by endothelial
cells would however indicate a potential for
MHC-restricted interactions with lymphocytes, the results
of which could be the production of factors acting to
further stimulate endothelial growth. The rarity of the
phenomenon suggests that such expression is not an
essential component of tumour angiogenesis in gliomas.
It was apparent from this study that macrophages are
present in astrocytic tumours in far larger numbers than
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an examination of routinely stained sections would
suggest. Similar findings have been recently described by
others (Hitchcock et al, 1988; Rossi et al, 1987; Rossi et
al, 1988) . Although the median values obtained with the
two macrophage markers were remarkably similar the wide
95% limits of agreement for the two methods suggest that
there are differences in the type of cell identified. The
tendency for Dako-macrophage to stain larger numbers of
cells in the same tumour is in keeping with the
observations of others (Rossi et al, 1987; Rossi et al,
1988) that there were variations in the staining with
different markers in some tumours. In vitro studies of
macrophage surface antigen expression have shown that the
state of activation is reflected in detectable differences
in surface antigens (Kreipe et al, 1986) . The differential
staining observed in some individual tumours, particularly
that of the foamy and non-foamy macrophages in the
oligodendroglioma, suggests that the antigen identified by
each antibody may similarly indicate a different state of
activation or function.
Although the mean difference between the values for the
two lymphocyte markers was small in absolute terms the 95%
limits of agreement were large in comparison with the
levels measured for each marker in most tumours. This
failure to find agreement between the two markers is
perhaps not surprising considering the different Clusters
of Differentiation that the two antigens identify (Bernard
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et al, 1984); it does however emphasise that the complex
heterogeneity of antigen expression in T cells may
complicate measures of the degree of lymphocyte
infiltration in tumours that utilise immunohistochemical
techniques.
The fact that the general levels of positive staining for
both lymphocytes and macrophages were higher in high grade
than low grade astrocytic lesions is compatible with
previously reported observations in this group of lesions
using conventionally stained material (Bertrand et al,
1960; Brooks et al, 1978). Hitchcock and Morris (1988)
compared high and low grade lesions and likewise found
higher percentages of cells staining with macrophage
markers and MHCII in high grade lesions, but the
differences were not statistically significant. Two
semi-quantitative studies of macrophage numbers and MHCII
expression in astrocytomas found generally higher levels
in the malignant lesions (Rossi et al, 1987) compared to
the lower grade tumours (Rossi et al, 1988). Low to
moderate numbers of macrophages were present in 38-86% of
tumours (depending on the antibody used) although no
statistical analyses were made of the differences between
grades. In a study of meningiomas a similar increase in
macrophage infiltration was noted in atypical lesions when
compared to benign tumours (Rossi et al, 1988a). A 12kD
factor chemotactic for macrophages has been isolated in
vitro from murine and human tumour cells (Botazzi et al,
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1983) and greater production of such a substance by more
malignant cells could be the basis for a higher level of
cellular response in more aggressive tumours. However the
complex interactions between lymphocytes infiltrating as
part of a primary immune response and macrophages
infiltrating in response to lymphokines make it unlikely
that a single process is operating. What is of interest
however is the fact that there is clear evidence for a
qualitatively similar cellular reaction in both low grade
and high grade tumours.
It has already been argued that the components of such a
reaction may influence the behaviour of non glial elements
in vivo and thus in vitro. Macrophage-produced TNF can
induce fibroblast proliferation, possibly by activation of
similar pathways to EGF although with a different binding
site (Vilcek et al, 1986) ; in vitro activation of
macrophages leads to the release of a different factor
capable of inducing fibroblasts, smooth muscle cells and
endothelium to proliferate when in a prior growth-arrested
state (Martin et al, 1981). It is therefore possible that
endothelial or other vascular elements in glial tumours of
different grades are subject to qualitatively similar
stimuli, but differ markedly in their exposure to that
part of the angiogenic stimulus that derives from tumour
cells. While the latter may be central to the
proliferation that characterises malignant gliomas the
former could so condition cells that they behave as
observed in vitro.
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The correlations between the percentages of cells stained
with DA6.231 and both T28 and Dako 150,90 suggests that
both macrophages and mature lymphocytes contribute to the
overall assessment of the number of DA6.231+ cells. Given
the same correlation in the glioma subgroup it also could
indicate that the lymphocyte response in these tumours is
in some way determined by the numbers of MHCII expressing
cells, be they macrophages or tumour cells. The first
possibility would certainly be in keeping with the
sequence of events that follows the development of an
immune reaction to foreign antigen; the second is
supported by similar observations in breast carcinomas
where numbers of T4 subset lymphocytes correlated with the
degree of MHCII expression by tumour cells (Zuk et al,
1987) .
The correlation between T28 + cells and Dako-150,95+ cells
in the gliomas is difficult to explain. The fact that it
was not found in the larger group suggests that it
reflects the specific circumstances of the immune reaction
to gliomas rather than a general association. Certainly it
would be in keeping with the suggestion that such a
reaction involves lymphocytes and macrophages in a
coordinated response to tumour antigen; since T28 + cells
include both helper and suppressor T cells clarification
would require more detailed analysis of T cell subsets, in
large enough numbers of tumours to make allowances for
patient age, tumour stage and therapy. The absence of any
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correlation between cell proliferation and any of the
other cell markers used suggests that there is, in the
tumours studied, nothing to support the view that tumour
growth is being enhanced by the presence of an immune
response.
The ranges of values for Ki67+ cells in the high grade
tumours studied correspond well with those reported by
Burger et al (1986) who found a range of 1.3 to 12.4%
positive cells in high grade lesions. Higher figures of
10-40% with a mean of 28% were reported by Giangspero et
al (1987) who considered the lower results to reflect loss
of the antigen detected by Ki67 following storage in
liquid nitrogen. The material studied by Burger and
colleagues had been stored for a maximum of three weeks
whereas in the present study storage times occasionally
exceeded three years. There was no relationship between
length of storage and Ki67 staining and given the
correspondence of the present study results with those of
Burger et al it would seem that if loss does occur it is
not progressive.
The significant difference in cell proliferation that was
apparent between high and low grade gliomas extends the
observations made by others (Burger et al, 1986;
Giangspero et al, 1987), and indicates that a more direct
measure of cell proliferation is apparently as efficient
as mitotic counts in distinguishing the two groups of
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tumours. Such a measure may therefore provide a more
sensitive tool in prognostication although this would
require prospective testing in a far larger series of
lesions. Certainly Burger found that the indices of two
fibrillary astrocytomas with nuclear atypia were higher
than those of two without this feature.
The relatively low frequency of Ki67 positivity in
endothelium that was observed in this study was also noted
in Burger's series (Burger et al, 1986) where only a few
positive cells were seen in glomeruli of proliferating
cells. The conclusion that inclusion of proliferating
endothelial cells is unlikely to introduce a significant
error is further reinforced by the findings that, despite
their appearance, less than 20% of vessels in malignant
gliomas contain demonstrably proliferating cells
(Nagashima et al, 1987) and have vascular labelling
indices that are always much lower than those of tumour
cells. These results are however at variance with the
study of Davenport et al (1987a) which assessed DNA
content of endothelial cells by in-situ photocytometry and
found relatively high percentages of cells to be in the
cell cycle. These differences may reflect a relative
insensitivity of the Ki67 technique, or a low specificity
of photocytometry, but do not invalidate the value of Ki67
in making comparisons between tumour types. The
proliferative index of the single metastasis in the
present series was similar to the median count for the
high grade gliomas, as would be expected, and with the
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exception of the oligodendroglioma the other tumours all
showed low indices in keeping with their known clinical
behaviour. The relatively high level for the
oligodendroglioma is of considerable interest given the
difficulty these lesions present when it comes to
predicting behaviour on the basis of morphology (Russell
et al, 1977) . Studies have shown that the application of
conventional markers of malignancy, such as mitotic count,
necrosis and vascular proliferation, can be of value in
predicting the behaviour of oligodendrogliomas (Burger et
al, 1987; Ludwig et al, 1986; Mork et al, 1986; Smith et
al, 1983; Wilkinson et al, 1987). The application of Ki67
staining to these tumours may therefore provide
information of value.
The finding of EGFR expression in a large proportion of
high grade astrocytic tumours confirms the findings of
others (Libermann et al, 1984; Wong et al, 1987) but
endothelial staining that has been reported to occur in
some meningiomas (Shiurba et al, 1988) was not seen in
this or other studies (Bigner et al, 1988). The absence of
any staining for EGFR in the low grade astrocytomas and
the ganglioglioma supports the suggestion (Bigner et al,
1988) that gene amplification is a late event in
neoplastic progression.
Although enhanced EGFR gene expression in tumours has been
found to be invariably associated with gene amplification
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(Libermann et al, 1985, 1985a; Wong et al, 1987), probably
largely in the form of double minutes (Bigner et al,
1987), this is a heterogeneous phenomenon at cellular
level and tumours which show amplification may still
contain up to 15 % of cells in which such amplification is
not present (Wong et al, 1987). While EGFR can be
demonstrated immunohistochemically in the majority of
tumours in which gene amplification has occurred, it can
also be found in almost as many tumours in which it has
not (Bigner et al, 1988). This may be because the EGFR1
antibody is a more sensitive way to detect increased gene
activity when compared to in vitro measures of
amplification, or indicate that there is
post-translational enhancement of receptor expression that
would not be detected by measuring gene copy numbers.
Whatever the explanation it indicates that histological
methods may not be measuring the same phenomenon as in
vitro techniques and any studies of the value of such
observations in prognosis must take account of these
discrepancies. Comparison of survival times in relation to
gene amplification between amplified and non-amplified
tumours showed that the former had slightly longer
survival times although the differences were not
significant (Bigner et al, 1988). With this combination of
uncertainty about the significance of gene amplification
and the likelihood that EGFR expression in tumour sections
is not a reliable measure of gene amplification the
failure to demonstrate a clear association between EGFR
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expression and proliferative index is not surprising. In
vitro studies have suggested that EGFR may directly
influence cell motility (Westermark et al, 1982) and so
may have a part to play in glial cell infiltration as well
as influencing tumour growth.
The few GFAP- cells that stained for EGFR remain
unidentified but their morphology and size were more in
keeping with their being lymphoid or monocytic rather than
neoplastic glial cells.
The numbers of cases in which correlations could be made
between in vitro and vivo findings was small, but it is
apparent that EGFR expression in vitro is a rare
phenomenon irrespective of in vivo expression, and
expression in vivo does not guarantee that such expression
will be seen in vitro in tissue derived from the same
tumour. This may be because gene expression is down
regulated under the conditions of culture, although
another amplified gene in malignant gliomas, gli, has been
shown to persist in vitro (Kinzler et al, 1987) possibly
indicating a conferred survival advantage. PA activity has
been found to be associated with down regulation of EGFR
in squamous carcinoma cells (Gross et al, 1983) and if
glial cells were the source of PA in cultures they might
be expected to show a reciprocal loss of EGFR. EGF binding
has been found to be reduced in both normal and
transformed cells when in a growth-arrested state
(Robinson et al, 1982) and this has been attributed to
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cell cycle dependent expression of the EGF receptor.
However the failure in the present study to demonstrate
EGFR in the cells that previous studies had shown not to
be growth-arrested makes it unlikely that this can be the
explanation of the paucity of EGFR expression. The fact
that indubitably glial cells in explants never expressed
EGFR, even, in one case, when derived from a strongly
staining tumour, makes it more likely that initial culture
conditions lead to reduced expression in a manner
unrelated to cell growth. The finding of GFAP+/EGFR1+
cells in older cultures, albeit in small numbers, does
indicate that expression is possible, and given the poor
survival of GFAP+ elements in such preparations may
indicate some conferred survival advantage although the
numbers of cells involved is too small for too much to be
made of this observation.
Although cell lines from glioblastomas have been found to
have enhanced expression of EGFR in vitro (Blin et al,
1983) this has not been the case with anything like the
frequency that would be expected from in-vivo analyses. In
one study only 1 out of 22 lines showed enhancement
(Filmus et al, 1985) and in another the levels of
expression were similar to those found in normal dividing
fibroblasts (Steck et al, 1986). These results contrast
with the persistence of EGFR expression that has been
observed in xenografts (Takahashi et al, 1987) and suggest
that EGFR enhancement in gliomas is not as readily
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maintained in vitro by gliomas as it is by squamous
carcinomas (Filmus et al, 1985) or that there is a
selection in vitro of cells that do not have gene
amplification, and may not even be glial. In any studies
that compare in vitro and in vivo expression of EGFR care
must clearly be taken to ensure that any cells expressing,
or failing to express, EGFR in vitro are critically
identified, and not assumed to be representative of those
cells that constitute the majority population in vivo.
Conclusions from studies of immune infiltrates, cell
proliferation and growth factor receptor expression.
Although there is clearly a heterogeneity of immune
response in astrocytic tumours, with a tendency for this
to be more marked in higher grade lesions, the point of
most interest in the context of this thesis is that the
reactions are qualitatively similar in high and low grade
tumours. Cell proliferation indices appear to be an
efficient way of discriminating between populations of
high and low grade tumours although here is no evidence
that the immune response has any direct enhancing, or
deleterious, effect on tumour growth.
Significant differences are apparent between the
expression of EGFR in high and low grade tumours,
although, as with cell proliferation indices, the overlap
precludes the use of EGFR staining in the diagnosis of
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malignancy in an individual case. The uncertainties
surrounding the meaning of immunohistochemically detected
EGFR may underly the failure to find any relationship
between its expression and cell proliferation despite an
association with grade.
It seems likely that vascular elements in high and low
grade tumours may be exposed in vivo to factors which,
while they might not alter their behaviour in vivo in low
grade tumours as grossly as in high grade tumours, may
influence their subsequent behaviour in vitro irrespective
of tumour type. One other factor that may contribute to
their behaviour in vitro is the effect of the carcinogenic
agent responsible for the original neoplastic change in
the glial cells.
Although some gliomas have been attributed to genetic
factors inferred from a familial pattern (Russell et al,
1977), there is a evidence to indicate that in common with
much human cancer (Doll et al, 1981) most are probably
determined by extrinsic agents. Population studies of
astrocytic tumours have shown that migrants from low
incidence areas acquire the higher levels of the
indigenous population in countries where incidence levels
are high (Gold, 1980) and collation studies have suggested
that there is a correlation between the incidence levels
of brain tumours and levels of atmospheric pollution
(Wellington et al, 1979).
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Glial tumours can be induced experimentally in animals
with viruses (Ogawa et al, 1969; Padgett et al, 1977) or
chemicals (Ishida et al, 1975; Seligman et al 1939) but
the situation in humans is far from clear. Viral DNA has
been identified in some human astrocytic tumours
(Ibelgaufts et al, 1982, 1982a), and there is strong
epidemiological evidence of an association between
industrial vinyl chloride exposure and the development of
malignant astrocytoma (Wagoner et al, 1981). Recent work
has suggested an association between brain tumour
development and exposure to electromagnetic radiation
(Thomas et al, 1987); however the groups with high
relative risks for astrocytic tumour development were
small, had been exposed in an apparently wide range of
occupations and no objective data was available on actual,
as opposed to presumed, exposure. Nevertheless all
astroglial neoplasms occur in parts of the brain where
blood-borne agents could gain access and such agents would
also, of necessity, have contact with elements of the
cerebral vessels.
When one considers the routes of access of environmental
carcinogens to the target cell marked contrasts are
apparent between the circumstances surrounding many common
epithelial tumours and gliomas. In the former the putative
agents, be they metabolites in urine in the case of
bladder cancer (Berry, 1982), inhaled combustion products
of tobacco in the case of the lung (Doll et al 1976), the
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bacterial metabolites of bile salts in the case of colon
cancer (Hill et al, 1975), or Human Papilloma Viruses in
the case of uterine cervix (Brescia et al, 1986), have
direct access from the environment without the need to
traverse other tissues. This contrasts with the situation
that obtains in the brain where any external agent must
pass through the blood vessel walls to gain access to
glial cells. Only if the active agent is produced locally
by enzymatic action after its precursor has gained access
would this not be the case.
As a result the carcinogen may effect some damage on the
endothelial or other mesenchymal elements that it
contacts, even if the damage is insufficient to result in
immediate abnormalities of cell behaviour. Such a partial
transformation has been observed in the effects of a
chemical carcinogen on experimental fibroblasts; cells
that appear morphologically to be homogeneously
transformed are found to comprise two populations, one
fully transformed and tumourigenic, and the other whose
abnormal growth pattern can be reversed by ascorbate and
which is incapable of tumour formation (Benedict et al,
1982). It is clear therefore that an agent capable of
inducing malignant change in cells may effect only partial
damage which may be manifest as an abnormality of growth
in vitro. Such dormant damage may then only become
manifest when a stimulus to proliferate is applied. In the
context of astrocytic tumours such manifestations could
include an enhanced survival in vitro in the form of cells
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whose phenotype was not glial, or an increased liability
to malignant progression in vitro or in vivo giving rise
to mixed glioblastoma/sarcoma in vivo (Morantz et al,
1976), sarcoma following transplantation of glial tumour
(Greene et al, 1968) or tumourigenic cell lines following
culture (Rutka et al 1987a). It is of interest that in a
study of a virally-induced glial tumour in rats (Groothuis
et al, 1980) the incidence of mixed sarcoma/glioma was 7%,
which is in the same order as that observed in human
series (Morantz et al, 1976); the authors were interested
in the possibility that mesenchymal elements might
ultimately become transformed as a consequence of their
constantly stimulated state and that such a transformation
might influence the eventual clinical outcome. In view of
the generally poor outlook for patients with malignant
gliomas this is unlikely to be a significant consideration
unless or until therapy is developed that specifically
influences the neoplastic glial elements but leaves the
residual non-neoplastic, but nevertheless damaged,
mesenchyme intact and liable to further progression.
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CHAPTER 5. FINAL DISCUSSION AND CONCLUSIONS
This thesis began with a consideration of the
intra-tumoural heterogeneity of neoplastic cells in
tumours in general and astrocytic neoplasms in particular.
Studies aimed at examining this phenomenon in vitro
yielded information on two apparently phenotypically
distinct populations of cells whose isolation seemed to
depend more on culture methods than on tumour type.
Although one population expressed GFAP and was clearly
glial the second expressed surface fibronectin (FN), and,
although appearing to be transformed on the basis of its
growth pattern, had characteristics that raised the
possibility of a non-glial origin. A detailed
consideration of the arguments for the latter cells being
glial or of vascular/mesenchymal origin left the matter
unresolved although most of the available evidence was at
least consistent with an origin from vascular rather than
parenchymal elements in the tumour.
In a search for in vivo correlates of the in vitro
phenotypes of the two main cell types no evidence was
found to support the view that the FN-expressing cells
were derived from a subpopulation of neoplastic cells
which were rare in vivo but able to thrive, to the
detriment of GFAP-containing cells, under appropriate
culture conditions. One phenotypic feature, namely the
expression of tissue plasminogen activator (t-PA), was
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found, with one exception, to be restricted to vascular
elements of astrocytic tumours.
In a further examination of the idea that vascular and
neoplastic elements in astroglial tumours are subject to
growth stimuli other than those derived from the
neoplastic cells themselves, the inter-relations between
tumour cell proliferation, immune cell infiltration,
growth factor receptor expression and tumour type were
studied. The results indicated that although there were
quantitative differences between high and low grade
tumours with regard to these features most tumours
contained an immune cell infiltrate which could be
contributing to a stimulus to angiogenesis. Nevertheless
the differences in vascular pattern between high and low
grade lesions suggest that such a contribution is likely
to be overshadowed by the difference in stimuli supplied
by high grade malignant cells and the cells of a low grade
tumour.
If the FN-expressing cells observed in cultures from both
high and low grade astrocytic tumours are derived from
mesenchymal rather than glial cells, what are the
implications for our understanding of the behaviour of
glial tumours in vivo and studies of such lesions in
vitro? It is clear that even if these cells are derived
from non-neoplastic components they are not entirely
normal in their behaviour, or in their genetic makeup
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(Kennedy et al, 1987). In serially transplanted human
gliomas cells of presumed vascular origin have shown
progression to a full neoplastic state (Greene et al,
1968) and may therefore have been damaged by the same
agent that induced neoplastic change in the astroglial
cells that comprise the parenchymal component of the
tumour. How widespread such a phenomenon is in tumours of
other sites is not known but, as has been argued earlier,
the phenomenon may reflect the route of access of the
carcinogen rather than any intrinsic feature of cerebral
vessels. Nevertheless the fact that exuberant vascular
proliferation and even sarcomatous change has been
observed in relation to metastatic tumours (Feigin et al,
1984) does raise the possibility of an intrinsic
instability. Of course in the latter circumstance the
coincidental prior exposure to an environmental
carcinogen, possibly the one that induced the primary
extracerebral cancer, with latent damage to endothelium of
the brain could not be excluded. In this context it may be
significant that vinyl chloride, an agent implicated in
the causation of malignant astrocytic tumours (Wagoner et
al, 1981), is also responsible for the development of
malignant tumours of vascular origin in the form of
angiosarcomas of the liver (Creech et al, 1974).
This problem could be further explored by studies that
examined the properties and behaviour of vascular elements
in tumours of other sites for features similar to those
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observed in the studies presented in this thesis. Such
work could compare the effect of supernatants from glial
tumour cultures (in which glial elements had been shown to
predominate) on endothelial cells from non-neoplastic
sources and from tissues other than the brain. Of
particular interest would be whether the response of
normal endothelial cells depended on their tissue of
origin. Perhaps in this way the relative importance could
be elucidated of prior damage, tumour type and organ of
origin in the process of tumour-associated vascular
proliferation.
The convenience of tissue culture and its suitability for
multiple analyses on a single tumour means that its
potential shortcomings must be recognised and account
taken of them. The influence of method of culture that was
observed in the present work is a clear indication that
where cell dispersion techniques are to be used the
resulting cultures must be proved to be glial, not simply
growing cells that are abnormal phenotypically, or even
genotypically. The question of what "gold-standard" marker
to use is not an easy one to answer. In general glial
markers such as GFAP, high affinity gamma amino butyric
acid (GABA) uptake or glutamyl synthetase expression
(Freshney et al, 1986) provide proof of a glial nature. In
their absence markers of malignancy are used on the
assumption that since, in gliomas, only glial cells are
neoplastic cells possessing "malignant" properties must be
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glial. It would appear however that t-PA expression, loss
of contact inhibition, and even angiogenic factor
production are not absolute indicators of the neoplastic
state, and while GFAP is highly specific when present
cells of indubitably glial origin may not express it.
From the work described in this thesis, primary explant
culture without repeated passage would seem to provide the
greatest chance of glial cells surviving and growing in a
mixture reflecting that of the original tumour; studies of
DNA content in cultures using such methods (Spaar et al,
1986) have suggested that stable representative
populations can be maintained for up to 3 weeks although
some cases show overgrowth of diploid cells which are
assumed to be of mesenchymal origin. This method however
is less reproducible than dispersed cell techniques, is
less easy to standardise, and also is less likely to give
rise to cells of proven glial nature that can be
propagated and repeatedly studied. Tec.hniques such as
dispersion and primary culture in conditions that only
allow fully independent cells to grow (Shapiro et al,
1985) will provide a greater guarantee that the cells
isolated will be glial and neoplastic, but they will
inevitably be a highly selected subgroup of the
heterogeneous population present in vivo and extrapolation
of, for instance, in vitro chemosensitivity tests would
require a long period of validity testing. Such methods do
however offer the best chance of examining the processes
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of neoplastic change and progression in gliomas at a
cellular level.
The nature of the interactions between presumed neoplastic
glial cells in explant cultures are far from clear; more
detailed studies of the ultrastructure of intercellular
contacts and their potential to serve a communication
function would be rewarding. It would be of interest to
know whether isolated FN+ FA cells show other transformed
properties such as diminished growth factor requirements
and growth in soft agax and whether PA activity from FN+
cells could be more specifically characterised as UK or
t-PA.
Even if the FN-expressing cells are derived from non-glial
elements they are nonetheless interesting. One implication
of the interpretations presented here is that the
development of a glial tumour, as opposed to a sarcoma of
cerebral mesenchyme, may be a reflection of differential
sensitivity of the two tissue elements to an environmental
carcinogen, not a absolute difference in response.
Furthermore the development of a fully neoplastic state is
associated with properties such as angiogenesis-factor
production that has implications for the induction of
further change in those tissue elements, such as vascular
mesenchyme, that have been damaged by the carcinogen but
not rendered neoplastic. The third component to consider
is the cellular immune reaction to the tumour which may be
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induced specifically by abnormal tissue antigens or
enhanced by tumour antigens whose function allows
tumour/lymphocyte/macrophage interactions which in turn
influence both neoplastic and non-neoplastic components of
the tumour.
It is clear that human astrocytic tumours are composed not
of a homogeneous population of neoplastic cells but are a
heterogeneous mixture of interacting glial, mesenchymal
and immune cells. Although the end product may be a mass
of tissue apparently lacking controls there may be complex
interactions and mechanisms determining such growth which,
if unravelled, might allow therapeutic control to be
imposed. Such tripartite interactions between tumour,
stroma, and the immune system probably operate, to varying
degrees, in most tumours, and may fruitfully be the
subject of further study in human astrocytic neoplasms.
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